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Introduction  
Cancer is a devastating disease that 1 in 3 people in their lifetime are faced with. In 
Europe, 3.7 million new cases and 1.9 million deaths are reported annually, which 
makes cancer the second most important cause of death and morbidity (1). Due to the 
aging of our population this incidence will increase in the coming decades. Although 
many advances in treatment of cancer have been made, novel therapeutic strategies 
and further understanding of the complexity of the disease and mechanisms of disease 
progression are highly needed to further increase the therapeutic effectiveness and 
cure of patients.  
Cancer originates from cells that have lost the control over cell proliferation and cell 
death. Solid tumours evolve into complex tissues that contain, in addition to cancer 
cells, other recruited cell types including cells of the immune system, the tumour blood- 
and lymphatic vasculature and fibroblasts. Together with extracellular matrix this cre-
ates the tumour microenvironment (TME). Cells of cancerous and non-cancerous origin 
in the TME constantly interact and thereby contribute to development of the tumour. 
The TME of solid tumours is characterized by poorly oxygenated regions (hypoxia) and 
regions that receive limited nutrients. Hypoxia occurs when oxygen demand exceeds 
delivery due to alterations of the metabolic and proliferative status of tumour cells or as 
a result of insufficient blood delivery due to an immature and chaotic tumour vascula-
ture. In general, two distinct patterns of hypoxia are considered. 1) Diffusion-limited, or 
chronic, hypoxia which is caused by limitations in oxygen diffusion from the tumour 
vasculature in the surrounding tissue or increased O2 consumption rates. Typically, 
cellular proliferation results in increased distance of cells to the nearest perfused vessel. 
Oxygen consumption by cells closer to the vessel results in reduced delivery and creates 
oxygen gradients in relation to distance from the vessel. During diffusion-limited or 
chronic hypoxia, oxygen levels vary at a relatively slow rate (hours to days). 2) Perfu-
sion-limited, or acute hypoxia is caused by temporal occlusion of vessels and leads to 
rapid fluctuations between oxygenation (minutes to hours)(2). Typically, normal tissues 
vary between 3.9% and 6.8% O2 (3). In cancer this is much more diverse. For example in 
breast (4), cervix (5), head and neck (6) and prostate carcinomas (7), oxygen levels vary 
between normal oxygenation to complete anoxia.  
Tumour hypoxia is a driver for selection of cells that have lost their apoptotic poten-
tial, as firstly described by Greaber et al. (8) who showed that p53 deficient cells take 
over the population under the pressure of hypoxia. From a clinical point of view, means 
of reducing the hypoxic fraction of tumours is highly desired since low oxygenation of 
tumours is associated with poor outcome in multiple cancer types, independent of 
treatment modality (9,10). In HNSCC, where a meta-analysis indicated that the degree 
of hypoxia is the most significant factor explaining variability in survival (11), the evi-
dence is strongest. The observed effect on local control is most likely caused by in sensi-
tivity of hypoxic cells to both chemo- and radiotherapy. Additionally there is an associa-
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tion between hypoxia and the occurrence of metastasis (12). It has been proposed that 
tumour hypoxia contributes to malignancy e.g. through activation of epithelial to mes-
enchymal transition (13-16), stimulation of blood vessel growth and formation of the 
pre-metastatic niche through secretion of microvesicles/exosomes/extracellular vesicles 
(hereafter indicated by EV) (17-25). Importantly, in head and neck squamous cell carci-
noma (HNSCC) evidence of the therapeutic benefit of hypoxia modification is strongest 
(26), indicating that hypoxia modification does not only influence local control, but also 
overall outcome.  
In short, tumour hypoxia leads to the expansion of cells with a more invasive, meta-
static and therapy resistant phenotype. Clinical studies show that hypoxia contributes to 
poor clinical outcome as it decreases loco-regional control, decreases disease free-
survival and overall survival in head and neck squamous cell carcinoma (HNSCC) (27) 
(28). Therefore it is essential to understand hypoxia and associated processes in order 
to selectively target these areas. 
Hypoxia responsive pathways  
In response to hypoxia, cells activate oxygen sensitive pathways to adapt and survive 
these severe conditions. The hypoxia inducible factor (HIF) pathway is the most investi-
gated hypoxia-responsive pathway. HIF are heterodimers composed of an oxygen-
regulated subunit (HIF1α, 2α and 3α, collectively referred to as HIFα) and a β-subunit 
(HIF1β/ARNT1, ARNT2 and ARNT3). When oxygen is present, HIF1α undergoes enzymatic 
hydroxylation by the O2 regulated prolyl-4-hydroxylases (PHDs) and will be degraded by 
the proteasome after binding by the von Hippel-Lindau (pVHL) tumour suppressor. In 
contrast, during hypoxia, PHD enzymes are inhibited and HIF1α hydroxylation leads to 
HIF1α stabilization leading to transcriptional activation of target genes after binding to 
hypoxia responsive elements (HRE) in the promoter regions. HIF activation is associated 
with enhanced angiogenesis by secretion of growth factors such as VEGF, altered me-
tabolism by the regulation of glycolytic genes to promote glycolysis, migration by activat-
ing the Wnt/β-catenin or PI3K/AKT pathway, invasion and metastasis (reviewed in (29)). 
During severe hypoxia (<0.2%O2), the folding of proteins in the endoplasmic reticulum 
(ER) is compromised and misfolded proteins accumulate in the ER (30). As a result, the 
unfolded protein Response (UPR) is activated. Activation of the UPR is initiated by three ER-
transmembrane stress sensors: Activating Transcription Factor 6 (ATF6), PKR)-like endo-
plasmic reticulum kinase (PERK) and Serine/threonine-protein kinase/endoribonuclease 
(IRE1). Typically these sensors are kept in an inactivated state through binding to heat 
shock protein family A (Hsp70) member 5 (HSPA5/ also known as BiP/GRP78). Due to the 
higher affinity of BiP to unfolded proteins, accumulation of unfolded proteins results in BiP-
dissociation from the sensor and thereby activating them. Activation of the UPR leads to 
decreased overall protein synthesis, translation of specific proteins, increased protein traf-
Dissertatie Tom Keulers Tab V.indd   8 02-01-19   16:07:07
1
Chapter 1 
8 
Introduction  
Cancer is a devastating disease that 1 in 3 people in their lifetime are faced with. In 
Europe, 3.7 million new cases and 1.9 million deaths are reported annually, which 
makes cancer the second most important cause of death and morbidity (1). Due to the 
aging of our population this incidence will increase in the coming decades. Although 
many advances in treatment of cancer have been made, novel therapeutic strategies 
and further understanding of the complexity of the disease and mechanisms of disease 
progression are highly needed to further increase the therapeutic effectiveness and 
cure of patients.  
Cancer originates from cells that have lost the control over cell proliferation and cell 
death. Solid tumours evolve into complex tissues that contain, in addition to cancer 
cells, other recruited cell types including cells of the immune system, the tumour blood- 
and lymphatic vasculature and fibroblasts. Together with extracellular matrix this cre-
ates the tumour microenvironment (TME). Cells of cancerous and non-cancerous origin 
in the TME constantly interact and thereby contribute to development of the tumour. 
The TME of solid tumours is characterized by poorly oxygenated regions (hypoxia) and 
regions that receive limited nutrients. Hypoxia occurs when oxygen demand exceeds 
delivery due to alterations of the metabolic and proliferative status of tumour cells or as 
a result of insufficient blood delivery due to an immature and chaotic tumour vascula-
ture. In general, two distinct patterns of hypoxia are considered. 1) Diffusion-limited, or 
chronic, hypoxia which is caused by limitations in oxygen diffusion from the tumour 
vasculature in the surrounding tissue or increased O2 consumption rates. Typically, 
cellular proliferation results in increased distance of cells to the nearest perfused vessel. 
Oxygen consumption by cells closer to the vessel results in reduced delivery and creates 
oxygen gradients in relation to distance from the vessel. During diffusion-limited or 
chronic hypoxia, oxygen levels vary at a relatively slow rate (hours to days). 2) Perfu-
sion-limited, or acute hypoxia is caused by temporal occlusion of vessels and leads to 
rapid fluctuations between oxygenation (minutes to hours)(2). Typically, normal tissues 
vary between 3.9% and 6.8% O2 (3). In cancer this is much more diverse. For example in 
breast (4), cervix (5), head and neck (6) and prostate carcinomas (7), oxygen levels vary 
between normal oxygenation to complete anoxia.  
Tumour hypoxia is a driver for selection of cells that have lost their apoptotic poten-
tial, as firstly described by Greaber et al. (8) who showed that p53 deficient cells take 
over the population under the pressure of hypoxia. From a clinical point of view, means 
of reducing the hypoxic fraction of tumours is highly desired since low oxygenation of 
tumours is associated with poor outcome in multiple cancer types, independent of 
treatment modality (9,10). In HNSCC, where a meta-analysis indicated that the degree 
of hypoxia is the most significant factor explaining variability in survival (11), the evi-
dence is strongest. The observed effect on local control is most likely caused by in sensi-
tivity of hypoxic cells to both chemo- and radiotherapy. Additionally there is an associa-
Introduction 
9 
tion between hypoxia and the occurrence of metastasis (12). It has been proposed that 
tumour hypoxia contributes to malignancy e.g. through activation of epithelial to mes-
enchymal transition (13-16), stimulation of blood vessel growth and formation of the 
pre-metastatic niche through secretion of microvesicles/exosomes/extracellular vesicles 
(hereafter indicated by EV) (17-25). Importantly, in head and neck squamous cell carci-
noma (HNSCC) evidence of the therapeutic benefit of hypoxia modification is strongest 
(26), indicating that hypoxia modification does not only influence local control, but also 
overall outcome.  
In short, tumour hypoxia leads to the expansion of cells with a more invasive, meta-
static and therapy resistant phenotype. Clinical studies show that hypoxia contributes to 
poor clinical outcome as it decreases loco-regional control, decreases disease free-
survival and overall survival in head and neck squamous cell carcinoma (HNSCC) (27) 
(28). Therefore it is essential to understand hypoxia and associated processes in order 
to selectively target these areas. 
Hypoxia responsive pathways  
In response to hypoxia, cells activate oxygen sensitive pathways to adapt and survive 
these severe conditions. The hypoxia inducible factor (HIF) pathway is the most investi-
gated hypoxia-responsive pathway. HIF are heterodimers composed of an oxygen-
regulated subunit (HIF1α, 2α and 3α, collectively referred to as HIFα) and a β-subunit 
(HIF1β/ARNT1, ARNT2 and ARNT3). When oxygen is present, HIF1α undergoes enzymatic 
hydroxylation by the O2 regulated prolyl-4-hydroxylases (PHDs) and will be degraded by 
the proteasome after binding by the von Hippel-Lindau (pVHL) tumour suppressor. In 
contrast, during hypoxia, PHD enzymes are inhibited and HIF1α hydroxylation leads to 
HIF1α stabilization leading to transcriptional activation of target genes after binding to 
hypoxia responsive elements (HRE) in the promoter regions. HIF activation is associated 
with enhanced angiogenesis by secretion of growth factors such as VEGF, altered me-
tabolism by the regulation of glycolytic genes to promote glycolysis, migration by activat-
ing the Wnt/β-catenin or PI3K/AKT pathway, invasion and metastasis (reviewed in (29)). 
During severe hypoxia (<0.2%O2), the folding of proteins in the endoplasmic reticulum 
(ER) is compromised and misfolded proteins accumulate in the ER (30). As a result, the 
unfolded protein Response (UPR) is activated. Activation of the UPR is initiated by three ER-
transmembrane stress sensors: Activating Transcription Factor 6 (ATF6), PKR)-like endo-
plasmic reticulum kinase (PERK) and Serine/threonine-protein kinase/endoribonuclease 
(IRE1). Typically these sensors are kept in an inactivated state through binding to heat 
shock protein family A (Hsp70) member 5 (HSPA5/ also known as BiP/GRP78). Due to the 
higher affinity of BiP to unfolded proteins, accumulation of unfolded proteins results in BiP-
dissociation from the sensor and thereby activating them. Activation of the UPR leads to 
decreased overall protein synthesis, translation of specific proteins, increased protein traf-
Dissertatie Tom Keulers Tab V.indd   9 02-01-19   16:07:07
Chapter 1 
10 
ficking through the ER and increased protein degradation by ER-associated degradation 
(ERAD) and autophagy.  
Autophagy is a cellular degradation- and recycle mechanism to maintain homeosta-
sis of the cell and achieves this by recycling damaged and aged cytoplasmic content, 
such as aggregated or misfolded proteins and organelles. In mice, autophagy enables 
survival to neonatal starvation by preventing energy depletion (31). Furthermore, de-
fective autophagy in brain causes accumulation of damaged mitochondria and protein 
aggregates and finally neuronal degeneration (32,33). Identically, in the liver autophagy-
defects cause protein accumulation, hepatocyte cell death and liver failure (34). These 
findings support the pro-survival role for autophagy by maintaining energy homeostasis 
and removal of toxic products and damaged organelles (35).  
Autophagy is continually active at a basal level, however during stress, like hypoxia or 
nutrient deprivation, autophagy is induced. Previously we showed that ATF4 (transcrip-
tion factor downstream of the PERK) activates transcription of the autophagy-associated 
proteins, including microtubule-associated protein light chain 3 beta (LC3B) and autoph-
agy related-5 (ATG5) (36) and GABARAPL1 (this thesis, chapter 3). In line, in tumours 
autophagy is mainly localized in hypoxic regions of tumours, sustaining the presence of 
hypoxic tumour regions (37-40), a feature associated with tumour progression (41). 
During autophagy, cytoplasmic content is recognized by substrate specific adaptor 
proteins that recruit LC3B to the site where the initial membrane, or phagophore, will 
be generated. LC3B is generated as a precursor protein which is immediately cleaved by 
autophagy related 4 cysteine peptidase (ATG4) to expose a C-terminal glycine for fur-
ther modification. This cytosolic form of LC3B is also referred to as LC3B-I. LC3B-I is then 
conjugated to phosphatidylethanolamine (PE) by an ubiquitination-like conjugation 
system where ATG7 acts as an ubiquitin-activating enzyme (E1). LC3B-I is transferred to 
the conjugating enzyme ATG3 (E2) were after it is conjugated to PE, forming the mem-
brane-bound LC3B-II that coats the inner and outer membrane of the double-
membrane, which allows the phagophore to grow. Efficient LC3B-PE formation requires 
the ATG12-ATG5-ATG16(L) complex. For their interaction, ATG12 is activated by the E1-
activating enzyme ATG7. Thereafter, ATG12 is transferred to ATG10 (E2-conjugating 
enzyme) and conjugated to ATG5. ATG5 interacts with ATG16(L) to form the complex, 
which can form a tetramer via ATG16 homodimerization (reviewed (42)). The complex 
fulfills multiple functions such as determination of the site for LC3/GABARAP family 
protein conjugation to PE. The phagophore expands until the content is completely 
enclosed by the autophagic vesicle, referred to as the autophagosome. Eventually, 
autophagosomes fuse with hydrolase and protease-containing lysosomes to degrade 
the content of the autophagosome, which is then effluxed into the cytosol, as amino 
acids, monosaccharides, fatty acids and nucleotides that are used to maintain biosyn-
thesis and energy homeostasis of the cell.  
LC3B turnover is used as a marker of autophagic structures and is used as a “golden 
standard” in assessing autophagy activation and rate of autophagy (autophagic flux) (43). 
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LC3B-II is localized on the intraluminal and cytoplasmic site and autophagosomes. After 
autophagosome/ lysosome fusion, cytoplasmic LC3B-II is delipidated by ATG4 and recy-
cled. Intraluminal LC3B-II is degraded by after lysosomal hydrolases during autolysosome 
formation. Therefore, LC3B-II turnover can be used to monitor autophagic activity (44). 
Autophagy is considered a doubled-edged sword. In normal cells autophagy has a 
cytoprotective role by degrading cytotoxic components, and thereby prevents disease. 
In the tumour microenvironment, autophagy plays a similar role. By activating autopha-
gy, cells survive nutrient depriving conditions, driving hypoxic tumour cells into a more 
aggressive, therapy resistant and metastatic phenotype. However, the stress tumour 
cells encounter (hypoxia, nutrient deprivation) are greater, making tumour cells more 
dependent on autophagy.  
The LC3/ GABARAP protein family 
The LC3/GABARAP protein family consists of the LC3 and GABARAP subfamilies and are 
characterized by high degrees of homology. LC3B is the most studied and characterized 
member of the protein family and is required for autophagosome formation. The LC3/ 
GABARAP protein family consisting of microtubule associated protein 1 light chain 3 
alpha (LC3A) (2 splice variants), LC3B, microtubule associated protein 1 light chain 3 
gamma (LC3C)), and GABA(A) receptor-associated protein (GABARAP), GABA(A) recep-
tor associated protein Like 1 (GABARAPL1) and GABA(A) receptor associated protein 
Like 2 (GABARAPL2) are implicated in autophagy. The LC3/ GABARAP protein family 
members share a high degree of homology, though they are unique in function and 
implicated in autophagy-independent mechanisms as well. An extensive review about 
autophagy (un-) related functions of all LC3/ GABARAP protein family members is pre-
sented in chapter 2. 
Initially, the GABARAP protein family members have been implicated in intracellular 
trafficking and transport of receptors to the plasma membrane (45-48). For example, 
GABA (A) receptor associated protein GABARAP derives its name from transport of the 
GABA(A) receptor (GABAAR) to the plasma membrane. Further research revealed that 
surface expression of other receptors like the angiotensin II (49), the epidermal growth 
factor receptor (EGFR) (50) and the human kappa opioid receptor is also mediated by 
GABARAP family proteins (48). However, retrograde transport is not limited to the 
transport of receptors alone. The GABARAP protein family, and especially GABARAPL1, 
is also implicated in (unconventional) secretion and the secretion of extracellular vesi-
cles (chapter 7 and 8). A comprehensive review about autophagy related proteins and 
secretion is presented in chapter 6 
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Like 2 (GABARAPL2) are implicated in autophagy. The LC3/ GABARAP protein family 
members share a high degree of homology, though they are unique in function and 
implicated in autophagy-independent mechanisms as well. An extensive review about 
autophagy (un-) related functions of all LC3/ GABARAP protein family members is pre-
sented in chapter 2. 
Initially, the GABARAP protein family members have been implicated in intracellular 
trafficking and transport of receptors to the plasma membrane (45-48). For example, 
GABA (A) receptor associated protein GABARAP derives its name from transport of the 
GABA(A) receptor (GABAAR) to the plasma membrane. Further research revealed that 
surface expression of other receptors like the angiotensin II (49), the epidermal growth 
factor receptor (EGFR) (50) and the human kappa opioid receptor is also mediated by 
GABARAP family proteins (48). However, retrograde transport is not limited to the 
transport of receptors alone. The GABARAP protein family, and especially GABARAPL1, 
is also implicated in (unconventional) secretion and the secretion of extracellular vesi-
cles (chapter 7 and 8). A comprehensive review about autophagy related proteins and 
secretion is presented in chapter 6 
Dissertatie Tom Keulers Tab V.indd   11 02-01-19   16:07:07
Chapter 1 
12 
Extracellular vesicles  
From yeast to mammals, cells secrete extracellular vesicles (EVs) as a vehicle of intercel-
lular communication. EVs are phospholipid bilayer enclosed vesicles that contain bioac-
tive molecules such as nucleic acids (DNA, RNAs, miRNAs), lipids and proteins (recep-
tors, enzymes, transcription factors and extracellular matrix proteins). EV is a generic 
name for vesicles originating from various cellular compartments including exosomes 
and microvesicles, but also apoptotic bodies are considered EVs. EVs are classified on 
their origin: Exosomes, as firstly described by Johnstone et al. (51), are generated during 
the maturation of early into late endosomes. During this process, intralumal vesicles 
(ILVs) are formed by inward budding of the endosomal membrane forming multivesicu-
lar bodies (MVB) (52). MVBs can either fuse with lysosomes for degradation or fuse with 
the plasma membrane, resulting in release of the ILVs (exosomes) into the extracellular 
environment. Microvesicles are a different class of EVs and are released directly by 
budding from the plasma membrane (53). Although there are no markers to distinguish 
exosomes and microvesicles after their release, they are all enriched in tetraspanins 
such as CD9, CD81, and CD63 (53).  
In addition to their role in normal physiology, such as their role in T-cell activation 
(54), EVs are implicated in several steps that stimulate cancer progression and cover 
most of the hallmarks of cancer described by Hannahan and Weinberg (55-57), includ-
ing angiogenesis (18,58), increased proliferation(59), increased migration and invasion 
(60), metastasis (61), immune evasion (62-64), pre-metastatic niche formation (61,65) 
and inflammation (66). 
For example, to meet the increasing demand of oxygen and nutrients of the tumour, 
blood vessel formation (angiogenesis) is essential. Several studies have shown that EVs 
contain pro-angiogenic cargo like pro-angiogenic mRNA’s (67-69) and growth factors 
such as vascular endothelial growth factor (VEGF) and platelet derived growth factor 
(PDGF) (70)(71). GBM tumour cells release pro-angiogenic EVs that are taken up by 
microvascular endothelial cells in the brain promoting tumour growth and stimulate 
tumour cell proliferation at distant sites (72). Another study performed with GBM cells, 
demonstrated that EVs derived from hypoxic GBM cells elicit pro-angiogenic responses 
in HUVEC cells in vitro and stimulate angiogenesis by inducing cytokine and growth 
factor secretion and thereby promote pericyte migration (73). Furthermore, EVs are 
shown to contribute to formation of the pre-metastatic niche (65,74). During the meta-
static cascade, tumour cells detach from the primary tumour and disseminate through-
out the body. Via the circulatory system circulating tumour cells invade the distant tis-
sue which provides a suitable microenvironment for colonization. Studies have shown 
that suitable microenvironments can be formed before the arrival of circulating tumour 
cells (75). EVs contribute to the formation of these predetermined regions, also re-
ferred to as pre-metastatic niches (75,76), for instance by destroying the vascular barri-
er though induction of vascular leakiness (77), extracellular matrix remodelling (78) or 
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reprogram bone marrow progenitors cells towards a pro-vasculogenic phenotype (79). 
Taken together, EVs are involved in a wide variety of cancer associated processes con-
tributing to tumour growth.  
Scope of this thesis 
The scope of this thesis is to gain insight in autophagy-associated proteins and their 
contribution to tumour development with particular focus on GABARAPL1, a member of 
the LC3/ GABARAP protein family; a group of proteins mainly involved in the recycle and 
degradation mechanism autophagy. The LC3/ GABARAP protein family is characterized 
by high degree of structural homology, suggesting that LC3/GABARAP family proteins 
exert similar functions. In chapter 2 we aimed to clarify the functional differences of the 
LC3/GABARAP protein family members in autophagy (un)-related functions based on 
available literature. In chapter 3 we demonstrate that the expression of the LC3/ GABA-
RAP protein family member GABARAPL1 is induced during hypoxia in several cancer cell 
lines in a PERK-dependent manner. Additionally we show that GABARAPL1 is required 
for increased membrane expression of the epidermal growth factor receptor (EGFR) 
during hypoxia. EGFR is often mutated or amplified in cancer and has a significant im-
pact on tumour development. In chapter 4 we elaborate on the autophagy-dependency 
of EGFRvIII+ cells during stress conditions and the effect of chloroquine treatment on 
patients with EGFRvIII expressing tumours. In chapter 5 we describe our findings that 
ATG12 expression is lost in a subset of HNSSC patients. Further we investigated the 
effects of the lost ATG12 expression on tumour growth, therapy efficacy and tumour 
control 
Autophagy is not exclusively required for the degradation of cellular content, but al-
so mediates unconventional forms of secretion. In chapter 6 we discuss the current 
knowledge of the physiological roles of autophagy-dependent secretion and the effects 
on the tumour microenvironment. Also autophagy-dependent receptor trafficking and 
its involvement in tumour development will be discussed. Further research on 
GABARAPL1 revealed that GABARAPL1 is required for the release of a subset of pro-
angiogenic extracellular vesicles released during hypoxia (chapter 7). This subset is 
marked by GABARAPL1 expression on the surface of the vesicle, what makes them ac-
cessible for targeting or detection purposes. In this regard, GABARAPL1+ EVs are detect-
able and elevated in the blood of cancer patients. Furthermore, in vitro tests demon-
strated that GABARAPL1+ EVs are targetable by antibodies, opening the window for 
biomarker or therapeutic development. EVs can contribute to metastasis formation by 
preparing the pre-metastatic niche. Therefore we explored the role of GABARAPL1+ EV 
in metastasis formation (chapter 8). Taken together, we show that autophagy is impli-
cated in key cellular mechanisms associated with cell survival and communication in the 
tumour micro-environment.  
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Abstract 
From yeast to mammals, autophagy is an important mechanism to sustain cellular ho-
meostasis through facilitating the degradation and recycling of aged and cytotoxic com-
ponents. During autophagy, cargo is captured in double membraned vesicles, the au-
tophagosomes, and degraded though lysosomal fusion. In yeast, autophagy initiation, 
cargo recognition, cargo engulfment and vesicle closure is Atg8 dependent. In higher 
eukaryotes, Atg8 has evolved into the LC3/GABARAP protein family consisting of 7 fami-
ly proteins (LC3A (two splice variants), LC3B, LC3C, GABARAP, GABARAPL1 and 
GABARAPL2). LC3B, the most studied family protein, is associated with autophagosome 
development and maturation, and is used to monitor autophagic activity. Given the high 
homology, the other LC3/GABARAP family proteins are often presumed to fulfill similar 
functions. Nevertheless, substantial evidence shows that the LC3/GABARAP family pro-
teins are unique in function and important in autophagy-independent mechanisms.  
In this review we discuss the current knowledge and function(s) of the 
LC3/GABARAP family proteins. We focus on processing of the individual family proteins 
end their role in autophagy initiation, cargo recognition, vesicle closure and trafficking, 
a complex and tightly regulated process that requires selective presentation and re-
cruitment of these family proteins. In addition, autophagy unrelated functions of the 
LC3/GABARAP protein family members are discussed. 
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Introduction  
Autophagy (from the Greek auto-, "self" and phagein, "to eat") is a catabolic process 
required to maintain cellular homeostasis through directing old/damaged organelles 
(e.g. mitochondria), protein aggregates and pathogens for lysosomal degradation. The 
products of lysosomal breakdown (e.g. amino acids, fatty acids) are recycled and trans-
ported across the lysosomal membrane into the cytoplasm. These metabolites can be 
re-used in protein and ATP production (reviewed in (1)). During metabolic stress or 
periods of insufficient nutrient supply, autophagy is rapidly upregulated to sustain ener-
gy production and provide building blocks for essential cellular functions. In line, cells 
deprived of glucose or amino acids, or exposed to hypoxia depend on autophagy for 
their survival (2,3). In short, autophagy acts as a pro-survival mechanism through main-
taining energy homeostasis and removal of toxic protein aggregates, pathogens and 
old/damaged organelles (4). Hence, defective autophagy in brain causes accumulation 
of damaged mitochondria and protein aggregates leading to neuronal degeneration (5). 
Similarly, autophagy-defects result in protein accumulation in the liver, causing hepa-
tomegaly, hepatocyte cell death and liver failure (6). 
Initiation of autophagy commences with the formation of an initial membrane struc-
ture, the phagophore (nucleation). As the phagophore elongates, it (non-)selectively 
sequesters cargo and closes into a double-membrane vesicle, the autophagosome. The 
autophagosome then fuses with a lysosome and exposes cargo to the lysosomal en-
zymes causing degradation of the content, a process well-conserved from yeast to hu-
mans. Research in yeast has provided insights into the role of essential proteins in au-
tophagy. This has led to the identification of at least 38 AuTophaGy-related proteins 
(Atg), of which many are functionally conserved in eukaryotes. In yeast, Atg8 is a limit-
ing protein in expansion of the phagophore (7). Atg8 levels correspond with autophago-
some size, as reduced Atg8 leads to the development of smaller autophagosomes with 
less favorable volume-to-surface ratios and attenuation of autophagy (7). In addition, 
Atg8 participates in cargo recruitment to the autophagosome by interacting with cargo 
binding proteins (e.g. Atg19) (8). For activation, Atg8 requires the covalent conjugation 
to phosphatidylethanolamine (PE) that enables its anchoring into the autophagosomal 
membranes, a process tightly orchestrated by Atg4, Atg7,Atg3 and the Atg12-Atg5-
Atg16L1 complex (9). 
In mammals, at least seven Atg8 orthologues exist; microtubule associated protein 1 
light chain 3 alpha MAP1LC3A (two splicing variants hereafter referred as LC3A-a and 
LC3A-b), -beta (MAP1LC3B (LC3B), -gamma (MAP1LC3C (LC3C), GABA type A receptor-
associated protein (GABARAP), GABARAP Like 1 (GABARAPL1/gec1) and GABARAP Like 2 
(GABARAPL2/GATE16). The most studied and best understood LC3/GABARAP family 
protein is LC3B. LC3B is essential for the execution of autophagy and therefore the 
widely accepted marker for autophagy activity assessment. The LC3/GABARAP family 
proteins are produced from separate transcripts, derived from their own genomic loca-
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tion (table 1). Nevertheless, they share a high sequence similarity and have a conserved 
carboxy-terminal glycine. In comparison to LC3B, LC3A-a, LC3A-b, LC3C, GABARAP, 
GABARAPL1 and GABARAPL2 display 92%, 94%, 71%, 59%, 60% and 65% similarity, 
respectively. Each LC3/GABARAP family protein is characterized by two amino-terminal 
α-helices and a carboxy-terminal ubiquitin core (10). LC3/GABARAP family proteins are 
often presumed to fulfil similar functions as LC3B. Functional differences and autophagy 
independent functions are frequently neglected and may lead to incomplete interpreta-
tion of data. Within this review we have provided an overview of the current knowledge 
on the function of the LC3/GABARAP family proteins.  
We have attempted to provide information on several questions raised: e.g. a) Are 
their functions limited to autophagy? b) Are they all crucial for the execution of autoph-
agy? c) What is their role in this process? d) Do they contribute to recruitment of selec-
tive targets for autophagy? If so, how is selectivity and recruitment organized? e) Is 
there functional redundancy? And f) how are LC3/GABARAP family proteins selectively 
recruited to the required site? In this manuscript, we address these questions by as-
sembling the current knowledge on processing, regulation, function and specificity of 
the LC3/GABARAP family proteins. By connecting the data described in literature, we 
highlight the underlying complexity in the mammalian autophagy machinery to permit a 
more complete interpretation of new experimental results in the future.  
Together, the provided data indicates that not all LC3/GABARAP family proteins are 
redundant in the autophagy process and each has a unique (autophagy independent) 
important function for cell homeostasis. 
Functions of LC3/GABARAP family proteins in autophagy (table 1) 
I. Initiation, elongation and closure of the autophagosome 
Whether the membrane for nucleation is formed de novo or is derived from an orga-
nelle is not fully understood yet. Membrane components can be derived from endo-
plasmic reticulum (ER), Golgi complex, endosomes, plasma membrane and ER-
mitochondria contact sites and may be driven by the distance of the source to the initi-
ating membrane (reviewed in (11)). Recently, it has become clear that the Unc51-like 
kinase 1 (ULK1) functions as a facilitator of phagophore formation. ULK1 is present in 
complexes consisting of ULK1, ATG13, FIP200 and ATG101 and can alter the complex`s 
activity through increased kinase activation (12) and is shown to be crucial during stress 
conditions (13). ULK1 phosphorylates beclin 1 (BECN1), a member of a second crucial 
autophagy-related complex and implicated in ER-derived phagophore formation (14). 
Part of this complex is a phosphoinositol 3 kinase (PI3K; Vps34) which phosphorylates 
phosphosphatidylinositol (PI) at position 3 to produce PI(3)P. PI(3)P serves as a docking 
site for effectors to further mediate phagophore maturation and elongation (15). Pull-
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down of ectopically expressed LC3/GABARAP family proteins revealed that GABARAP 
and GABARAPL1 display highest affinity to ULK1 and LC3B the lowest. This suggests that 
GABARAP subfamily proteins can, more efficiently than LC3B, serve as scaffolding pro-
teins by recruiting ULK1 and beclin 1 (complex) to the site of nucleation (16) (Fig 1A). 
Whether this indicates that phagophore development or cargo engulfment is depend-
ent on GABARAP proteins or that GABARAP proteins allow selective cargo engulfment 
remains unknown.  
After elongation autophagosome closure the autophagosomes is formed (Fig. 1C 
and D) and requires fusion events of both the inner and outer membrane leaflets (Fig. 
1D). In eukaryotic cells, specialized functions seem to be attributed to specific 
LC3/GABARAP family proteins. For example, cells deficient in the LC3 subfamily (LC3A, 
LC3B, LC3C) or GABARAP subfamily (GABARAP, GABARAPL1, GABARAPL2) display im-
paired autophagosome formation (17). Yet, knockdown of the LC3- or GABARAP sub-
family proteins leads to different autophagy impairment phenotypes, as deficiency in 
the LC3 subfamily (LC3A, LC3B and LC3C simultaneously) leads to generation of smaller 
autophagosomes whereas deficiency of GABARAP subfamily (GABARAP, GABARAPL1 
and GABARAPL2 simultaneously) leads to biogenesis of larger autophagosomes. Re-
expression of LC3B or GABARAPL2 is sufficient to rescue autophagy. Here, LC3B rescues 
phagophore elongation and GABARAPL2 mediates closure of the vesicle(17). These 
results are in line with observations in cell free systems where the amino-terminal α-
helices of GABARAPL2 and LC3B promote tethering and fusion of membranes. Although 
the fusion activity of GABARAPL2 and LC3B are similar, the fusion activity of LC3B is 
mediated by ionic interactions, whereas those of GABARAPL2 are mediated by hydro-
phobic interactions(18). Interestingly, GABARAP family proteins are present in an open 
and closed conformation. Herein, the open form has a protruding amino-terminal helix 
with hydrophobic residues that enables penetration into the adjacent membrane and 
interacts with the hydrophobic center of the lipid bilayer (19). In contrast, LC3B inter-
acts with the lipid head group (18). Together, these events can bring together (extend-
ing) membranes and lead to phagophore elongation (hemifusion, Fig. 1C) and closure 
(fusion, Fig. 1D). Whether the transition from elongation to closure is merely chance or 
is an orchestrated event when the cargo is engulfed remains unclear. These data sug-
gest little redundancy between LC3/GABARAP family protein function as functions ap-
pear to be inherent to their structural characteristics. 
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tion (table 1). Nevertheless, they share a high sequence similarity and have a conserved 
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Figure 1. Involvement of LC3/GABARAP family proteins in (non-)autophagy related processes.  
Autophagy initiation involves the formation of a phagophore. This nucleation phase (A) is commenced by two 
protein complexes, ULK1 complex and Beclin1 complex. Herein, the first can be localized to the phagophore 
by binding predominantly GABARAP/GABARAPL1. The ULK1 complex activation status influences the rate of 
autophagy by Beclin1 phosphorylation. The phagophore can engulf content either selectively or non-
selectively. Selectivity in cargo tethering to the phagophore (B) is established by the LC3/GABARAP family 
members that have different intrinsic properties that allows the binding linker proteins. Here mitophagy is 
illustrated by the protein BNIP3L/Nix at the mitochondrial membrane that can bind GABARAPL1 directly or be 
ubiquitinylated for SQSTM1 mediated recognition. Elongation (C) requires the delivery of membrane compo-
nents (orange) to the growing phagophore (purple). LC3B is the main family protein to effectuate elongation. 
Phagophore closure (D) generates a closed double membraned vesicle. Fusion of both membrane leaflets is 
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required for closure that is thought to be done by LC3B and GABARAPL2 in a cooperative fashion. Subsequent 
fusion of the autophagosome with a lysosome (E) is required to acquire the degradative enzymes and acidifi-
cation of the autophagosomal lumen for cargo degradation. This fusion event requires GABARAP and 
GABARAPL2 by their interaction with NSF and the calcium channel TRPML3, which both facilitate fusion. 
Moreover, all LC3/GABARAP proteins (notably LC3B the least) interact with PLEKHM1 that mediates bridging 
both vesicles. Besides autophagy, recent findings indicate the relevance of, in particular, GABARAP family 
proteins in receptor trafficking (F). These are involved as adaptor proteins connecting the receptors in golgi-
derived vesicles to tubulin fibers (also see table 1). 
II. Cargo targeting  
Initially, autophagy was considered a process of non-selective degradation. However, 
increasing evidence indicates that cargo can selectively be targeted for degradation. 
Selective autophagy has been described for aggregated proteins (aggrephagy), mito-
chondria (mitophagy), peroxisomes (pexophagy), ribosomes (ribophagy), endoplasmic 
reticulum (reticulophagy), lipid droplets (lipophagy) and pathogens (xenophagy); how-
ever much remains to be elucidated regarding the regulation and molecular mediators 
involved. For the engulfment of several specific substrates, LC3/GABARAP family pro-
teins play a pivotal role through interaction with autophagy adaptor proteins such as 
sequestosome 1 (SQSTM1/p62, hereafter referred to as SQSTM1), neighbor of BRCA1 
gene 1 (NBR1), calcium binding and coiled-coil domain 2 (NDP52/ CALCOCO2), 
BCL2/adenovirus E1B 19kDa interacting protein 3-like (NIX/BNIP3L), optineurin (OPTN), 
and WD repeat and FYVE domain containing (ALFY) (table 1). These are able to bind 
both the ubiquitinated substrate/cargo and LC3/GABARAP family proteins through their 
LC3 interacting regions (LIRs)(20) and facilitate cargo-tethering to the luminal side of 
the phagophore. The combination of LC3/GABARAP protein and adaptor protein is 
therefore essential in cargo selection, targeting and degradation.  
Aggrephagy: Protein aggregates and peroxisomes are degraded through autophagy. In 
this SQSTM1 plays an essential role (21). Although SQSTM1 displays no differences in 
LC3/GABARAP family protein affinity, only lipidated LC3B is able to recruit SQSTM1 to 
autophagosomes(22). Interestingly, ALFY (an autophagy receptor required for ag-
grephagy(23)), co-immunoprecipitates predominantly with GABARAP. The binding of 
ALFY to GABARAP is indispensable for the recruitment of LC3B-positive structures and 
the degradation of SQSTM1 structures (24). This suggests that GABARAP and LC3B func-
tion in a cooperative fashion during aggrephagy to establish a selective form of autoph-
agy. Recently, a new class of ubiquitin-atg8 receptors (CUET proteins) have been identi-
fied. The yeast CUE-ubiquitin-binding-domain protein Cue5 and its human homolog toll 
interacting protein (TOLLIP) mediate the clearance of polyQ protein aggregates. PolyQ 
proteins contain a polyQ tract, as a result of trinucleotide repeat, cytosine–adenine–
guanine (CAG) expansions, which encodes glutamine. Their aggregates are linked to 
neurodegenerative disorders like Huntington’s disease. TOLLIP contains two LIR motifs 
for interaction with LC3B The interaction with LC3 allows spatial organization of TOLLIP 
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recruitment and subsequent ubiquitination through CUE recruitment and degradation 
of the aggregate. Interactions with other members of the LC3/GABARAP proteins family 
remain matter of investigation (25).  
Xenophagy: In the elimination of intracellular pathogens, LC3C is uniquely required due 
to its strong preferential binding to the autophagy receptor, NDP52/CALCOCO2. Salmo-
nella Typhimurium, damages its surrounding vacuole membrane after invasion, leading 
to exposure of host glycans and microbial carbohydrates. The ‘vesicle damaging recep-
tor’ galectin 8 /LGALS8 recruits NDP52 and results in activation of bacterial 
autophagy(26). The binding of LC3C to NDP52 leads to the engulfment of the bacterium 
in the autophagosome. After entrapment, NDP52 is required for the maturation and 
degradation of Salmonella Typhimurium-containing autophagosomes through interac-
tion with, LC3A, LC3B and GABARAPL2 (27,28). The binding of LC3C and the other 
LC3/GABARAP family proteins is dependent on the presence of two distinct LIRs. Be-
cause of the essential role of “LC3C-LIR”, its role in xenophagy is non-redundant. In line, 
Galectin8, LC3C or NDP52 knockdown cells are defective in blocking proliferation of 
Salmonella (29), indicating a unique cooperation in xenophagy. Additionally, upon 
phosphorylation by TANK binding kinase 1 (TBK1) to enhance LC3 binding affinity, the 
autophagy receptor optineurin (OPTN) targets similar cytosolic bacteria as NDP52. 
OPTN mutants that are deficient in LC3 binding or silenced OPTN results in impaired 
degradation of ubiquitylated Salmonella enterica (30). In addition to Salmonella, P62 
and NDP52 also sequester intracytosolic Shigella and the membrane remnants to the 
autophagosome for degradation (31,32) 
Tax1 binding protein1 (TAX1BP1) is also involved in clearance of intracellular Salmonel-
la and also depends on ubiquitination of the substrate. TAX1BP1 not only binds to the LC3 
subfamily members LC3B and LC3C but also interacts with GABARAPL1 and GABARAPL2. 
In contrast to NDP52 and OPTN, there is no preference in binding affinity for LC3B of LC3C 
although it shares the same canonical LIR motif as OPTN and NDP52 (33).  
Furthermore, the TRIM family plays a role in antiviral defense by targeting viral cap-
sid proteins. Mandell et al found that the TRIM family, and especially tripartite motif 
containing5 (TRIM5α), interacts preferably with GABARAP and GABARAPL1, and to a 
lesser extend LC3A, LC3C and GABARAPL2. Although GST-pulldown assays show only a 
weak interaction with LC3B, co-immunoprecipitation studies and immunostainings 
show that LC3B may nonetheless be in complexes with TRIM5α. TRIM5α contains two 
LIR motifs. Mutation of these motifs results prevented the HIV capsid protein p24 from 
degradation (34). 
Glycophagy: Several myopathies are associated with defects in autophagic and lysoso-
mal degradation of glycogen, illustrating its importance in maintaining glycogen homeo-
stasis (35). In normal functioning, glycogen is hydrolyzed to glucose by lysosomal α-
glycosidase and is therefore an important source of energy. Starch-binding domain 
containing protein 1 (STBD1/genethonin 1) binds glycogen and anchors it to mem-
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branes, thereby affecting its cellular localization and its intracellular trafficking to lyso-
somes (36). STBD1 interacts with GABARAPL1 and to lesser extent GABARAP (37). Muta-
tions and deletions in STBD1’s motif to bind GABARAP subfamily proteins indicate that 
this motif is required for this GABARAPL1-mediated engulfment of glycogen into vesi-
cles (38). Although the interaction has been well established, the exact role of 
GABARAPL1 in glycophagy remains to be elucidated in functional assays. 
Mitophagy: Mitochondrial metabolism leads to the formation of by-products that lead 
to oxidative stress, DNA damage and mutations and increases in aged and dysfunctional 
mitochondria. Sustaining a healthy population of mitochondria is therefore critical to 
maintain cellular homeostasis and prevent accumulation of damaging agents. The turn-
over of mitochondria is autophagy-dependent and inhibition leads to accumulation of 
mitochondria and excessive exposure to reactive oxygen species (ROS) (39).Like other 
substrates, mitochondria can be ubiquitylated for degradation. Interestingly, there is 
some overlap in receptors involved in the recognition of other ubiquitylated substrates 
e.g. in xenophagy. After depolarization of the mitochondrial membrane, PINK accumu-
lates in the outer mitochondrial membrane and recruits NDP52 and OPTN, but not p62, 
to activate mitophagy independently of PARKIN. Interestingly, in knockout models of 
the 5 mitophagy receptors (TAX1BP1, optineurin, NBR1, p62 and NDP52), Lazarou et al 
found that LC3C is recruited by TAXBP1 during mitophagy and LC3B by OPTN and 
NDP52. Furthermore they observed that GABARAP family proteins are not recruited to 
mitochondria, suggesting that they are not actively involved in mitophagy (40).  
In contrast, Novak et al found that GABARAPL1 colocalizes with depolarized mito-
chondria during basal, starvation and apoptotic conditions (41-43). GABARAPL1 
deficiency attenuates autophagic flux and accumulates SQSTM1 including mitophagy 
and results in accumulation of damaged mitochondria (43). Whether GABARAPL1 is 
directy involved in mitophagy or influences mitophagy through modulation general 
autophagy activity remains matter of investigation. Nevertheless, the direct colocaliza-
tion of GABARAPL1 with mitochondria and its interaction with another important factor 
in mitophagy, BNIP3L/Nix suggests a direct role for GABARAPL1 in mitophagy (41) (Fig. 
1B).  
FUNDC1, an integral mitochondrial outer-membrane protein, acts as a specific re-
ceptor for mitophagy in an ubiquitin independent manner. In response to hypoxia 
FUNDC1 is able to bind LC3 proteins -A and -B and GABARAP and GABARAPL2 via its 
typical LIR domain ((YxxL). Upon hypoxia stimulation, Scr kinase is inactivated and the 
FUNDC1 LIR domain is dephosphorylated, resulting in an increased colocalization and 
interaction FUNDC1 and LC3B (44). Nix and its homolog Bnip3 also play a role in hypoxia 
induced mitophagy. Bnip3 and Nix, both members of the BCL2 family, are anchored in 
the outer mitochondrial membrane via their C terminal transmembrane domains, BNip3 
and Nix contain an identical LIR motif (WxxL). Phosphorylation of the ser17 and ser24 
specifically promotes LC3B and GABARAPL2 binding to Bnip3(45). 
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GABARAPL1 in glycophagy remains to be elucidated in functional assays. 
Mitophagy: Mitochondrial metabolism leads to the formation of by-products that lead 
to oxidative stress, DNA damage and mutations and increases in aged and dysfunctional 
mitochondria. Sustaining a healthy population of mitochondria is therefore critical to 
maintain cellular homeostasis and prevent accumulation of damaging agents. The turn-
over of mitochondria is autophagy-dependent and inhibition leads to accumulation of 
mitochondria and excessive exposure to reactive oxygen species (ROS) (39).Like other 
substrates, mitochondria can be ubiquitylated for degradation. Interestingly, there is 
some overlap in receptors involved in the recognition of other ubiquitylated substrates 
e.g. in xenophagy. After depolarization of the mitochondrial membrane, PINK accumu-
lates in the outer mitochondrial membrane and recruits NDP52 and OPTN, but not p62, 
to activate mitophagy independently of PARKIN. Interestingly, in knockout models of 
the 5 mitophagy receptors (TAX1BP1, optineurin, NBR1, p62 and NDP52), Lazarou et al 
found that LC3C is recruited by TAXBP1 during mitophagy and LC3B by OPTN and 
NDP52. Furthermore they observed that GABARAP family proteins are not recruited to 
mitochondria, suggesting that they are not actively involved in mitophagy (40).  
In contrast, Novak et al found that GABARAPL1 colocalizes with depolarized mito-
chondria during basal, starvation and apoptotic conditions (41-43). GABARAPL1 
deficiency attenuates autophagic flux and accumulates SQSTM1 including mitophagy 
and results in accumulation of damaged mitochondria (43). Whether GABARAPL1 is 
directy involved in mitophagy or influences mitophagy through modulation general 
autophagy activity remains matter of investigation. Nevertheless, the direct colocaliza-
tion of GABARAPL1 with mitochondria and its interaction with another important factor 
in mitophagy, BNIP3L/Nix suggests a direct role for GABARAPL1 in mitophagy (41) (Fig. 
1B).  
FUNDC1, an integral mitochondrial outer-membrane protein, acts as a specific re-
ceptor for mitophagy in an ubiquitin independent manner. In response to hypoxia 
FUNDC1 is able to bind LC3 proteins -A and -B and GABARAP and GABARAPL2 via its 
typical LIR domain ((YxxL). Upon hypoxia stimulation, Scr kinase is inactivated and the 
FUNDC1 LIR domain is dephosphorylated, resulting in an increased colocalization and 
interaction FUNDC1 and LC3B (44). Nix and its homolog Bnip3 also play a role in hypoxia 
induced mitophagy. Bnip3 and Nix, both members of the BCL2 family, are anchored in 
the outer mitochondrial membrane via their C terminal transmembrane domains, BNip3 
and Nix contain an identical LIR motif (WxxL). Phosphorylation of the ser17 and ser24 
specifically promotes LC3B and GABARAPL2 binding to Bnip3(45). 
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Ubiquitin-dependent cargo recognition can be executed by multiple different recep-
tors. Intriguingly, there seems to be an underlying layer of complexity when it comes to 
LC3/GABARAP proteins family member recruitment. For instance, during the clearance 
of cytosolic salmonella, TAX1BP1 recruits members of the LC3 and GABARAP protein 
subfamily. However, during mitophagy, TAX1BP1 selectively recruits LC3C and no 
GABARAP proteins. It remains matter of investigation of how selective autophagy recep-
tors recruit specific LC3/GABARAP proteins family members to targeted cargos in an 
ubiquitin (in-) dependent manner. 
III. Autophagosome-lysosome fusion 
The autophagosome can fuse with a lysosome directly to form the autolysosome or fuse 
with multiple components of the endocytic pathway including early and late endosomes 
or multivesicular bodies (MVBs) to generate amphisomes(46). Fusion of autophago-
somes or amphisomes with acidic lysosomes is required for content degradation. RAB7, 
a member of a family of small GTPases, is important in lysosome fusion (47) through 
interaction with homotypic fusion and protein sorting (HOPS) complex. HOPS functions 
as a guanine nucleotide exchange factor (GEF) to facilitate RAB7 activation and is a 
downstream effector of RAB7 to promote membrane tethering. For this, HOPS interacts 
with SNAP (soluble NSF (N-ethylmaleimide-sensitive factor)) attachment protein) recep-
tors (SNAREs) that can interact with other SNAREs through coiled-coil type interactions 
to facilitate membrane fusion. Full fusion of the autophagosome with the vacuole re-
quires NSF/SEC18 (48), which changes the SNARE’s conformation and allows binding to 
its interactor (49). Interestingly, GABARAPL2 and GABARAP are both able to interact 
with NSF (50,51). In addition, GABARAPL2 interacts with transient receptor potential 
cation channel, mucolipin subfamily, member 3 (TRPML3) (52). This is a Ca2+ permeable 
cation channel that is proposed to facilitate fusion events by promoting interbilayer 
contact (53). Thus, GABARAPL2 (and GABARAP) facilitate fusion by scaffolding NSF and 
TRPML3 at the location of fusion (Fig. 1E). 
In addition, pleckstrin homology domain-containing family M member 1 (PLEKHM1), 
a RAB7 effector which also binds components of the HOPS complex can function as a 
bridge between autophagosomes and lysosomal membranes. Pulldown analysis 
demonstrated that PLEKHM1 interacts with all LC3/GABARAP family proteins. Notably, 
the yield of LC3B was lowest (54) suggesting that autophagosome-lysosome fusion is 
more dependent on other LC3/GABARAP family proteins.  
In this section the different involvement and functions of the LC3/GABARAP family 
proteins in phagophore formation, elongation and closure, autophagosome-lysosome 
fusion and selective forms of autophagy have been highlighted. Although structurally 
these family proteins share high homology, each one seems to fulfill (a) unique func-
tion(s) in the execution of autophagy. 
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Ubiquitin-dependent cargo recognition can be executed by multiple different recep-
tors. Intriguingly, there seems to be an underlying layer of complexity when it comes to 
LC3/GABARAP proteins family member recruitment. For instance, during the clearance 
of cytosolic salmonella, TAX1BP1 recruits members of the LC3 and GABARAP protein 
subfamily. However, during mitophagy, TAX1BP1 selectively recruits LC3C and no 
GABARAP proteins. It remains matter of investigation of how selective autophagy recep-
tors recruit specific LC3/GABARAP proteins family members to targeted cargos in an 
ubiquitin (in-) dependent manner. 
III. Autophagosome-lysosome fusion 
The autophagosome can fuse with a lysosome directly to form the autolysosome or fuse 
with multiple components of the endocytic pathway including early and late endosomes 
or multivesicular bodies (MVBs) to generate amphisomes(46). Fusion of autophago-
somes or amphisomes with acidic lysosomes is required for content degradation. RAB7, 
a member of a family of small GTPases, is important in lysosome fusion (47) through 
interaction with homotypic fusion and protein sorting (HOPS) complex. HOPS functions 
as a guanine nucleotide exchange factor (GEF) to facilitate RAB7 activation and is a 
downstream effector of RAB7 to promote membrane tethering. For this, HOPS interacts 
with SNAP (soluble NSF (N-ethylmaleimide-sensitive factor)) attachment protein) recep-
tors (SNAREs) that can interact with other SNAREs through coiled-coil type interactions 
to facilitate membrane fusion. Full fusion of the autophagosome with the vacuole re-
quires NSF/SEC18 (48), which changes the SNARE’s conformation and allows binding to 
its interactor (49). Interestingly, GABARAPL2 and GABARAP are both able to interact 
with NSF (50,51). In addition, GABARAPL2 interacts with transient receptor potential 
cation channel, mucolipin subfamily, member 3 (TRPML3) (52). This is a Ca2+ permeable 
cation channel that is proposed to facilitate fusion events by promoting interbilayer 
contact (53). Thus, GABARAPL2 (and GABARAP) facilitate fusion by scaffolding NSF and 
TRPML3 at the location of fusion (Fig. 1E). 
In addition, pleckstrin homology domain-containing family M member 1 (PLEKHM1), 
a RAB7 effector which also binds components of the HOPS complex can function as a 
bridge between autophagosomes and lysosomal membranes. Pulldown analysis 
demonstrated that PLEKHM1 interacts with all LC3/GABARAP family proteins. Notably, 
the yield of LC3B was lowest (54) suggesting that autophagosome-lysosome fusion is 
more dependent on other LC3/GABARAP family proteins.  
In this section the different involvement and functions of the LC3/GABARAP family 
proteins in phagophore formation, elongation and closure, autophagosome-lysosome 
fusion and selective forms of autophagy have been highlighted. Although structurally 
these family proteins share high homology, each one seems to fulfill (a) unique func-
tion(s) in the execution of autophagy. 
 
29
 
Ta
bl
e 
1:
 S
um
m
ar
y 
of
 sp
ec
ia
liz
ed
 fu
nc
tio
ns
 o
f L
C3
/G
AB
AR
AP
 fa
m
ily
 p
ro
te
in
s i
n 
au
to
ph
ag
y 
Su
bf
am
ily
 
G
en
e 
Ch
ro
m
os
om
e 
lo
ca
tio
n 
G
en
e 
siz
e 
(k
b)
 
Pr
ot
ei
n 
 
Is
o 
fo
rm
s 
Co
m
po
ne
nt
 
M
ec
ha
ni
sm
 
Re
f 
LC
3 
M
AP
1L
C3
A 
20
q1
1.
22
 
1.
0 
LC
3A
-a
* 
LC
3A
-b
* 
2 
An
te
ro
gr
ad
e 
tr
af
fic
ki
ng
 
Fu
sio
n 
Xe
no
ph
ag
y 
M
ito
ph
ag
y 
 
In
te
ra
ct
io
n 
w
ith
 th
e 
RA
B7
 e
ffe
ct
or
 F
YC
O
1 
an
d 
PL
EK
H
M
1 
In
te
ra
ct
io
n 
w
ith
 T
RI
M
5α
 fo
r v
ira
l c
le
ar
an
ce
 
Re
cr
ui
tm
en
t b
y 
FU
N
DC
1 
(1
31
, 
13
2)
 
(3
4)
 
(4
4)
 
M
AP
1L
C3
B 
    
16
q2
4.
2 
    
10
.7
 
    
LC
3B
 
    
1  
El
on
ga
tio
n 
 Re
cr
ui
tm
en
t 
 Fu
sio
n 
An
te
ro
gr
ad
e 
tr
af
fic
ki
ng
 
 Ag
gr
ep
ha
gy
 
Xe
no
ph
ag
y 
M
ito
ph
ag
y 
Co
va
le
nt
 a
tt
ac
hm
en
t o
f P
E 
by
 th
e 
ub
iq
ui
tin
-li
ke
 
co
nj
ug
at
io
n 
sy
st
em
.  
Re
cr
ui
tm
en
t o
f p
62
/ S
Q
ST
M
1 
po
sit
iv
e 
st
ru
ct
ur
es
 to
 th
e 
au
to
ph
ag
os
om
e.
 
Ph
os
ph
or
yl
at
io
n 
by
 S
TK
3/
ST
K4
 
In
te
ra
ct
io
n 
w
ith
 th
e 
RA
B7
 e
ffe
ct
or
 F
YC
O
1 
an
d 
PL
EK
H
M
1 
In
te
ra
ct
io
n 
w
ith
 T
O
LL
IP
 
In
te
ra
ct
s w
ith
 c
ar
go
 re
ce
pt
or
 T
AX
1B
P1
 
Re
cr
ui
tm
en
t b
y 
op
tin
eu
rin
, N
DP
D5
2 
an
d 
FU
N
DC
1 
(1
5,
16
) 
 (2
2)
 
 (1
27
)  
(1
31
) 
(5
4)
 
(2
5)
 
(3
3)
 
(4
0,
44
) 
M
AP
1L
C3
B2
 
12
q2
4.
22
 
0.
8 
 
LC
3B
2 
1 
 
So
 fa
r, 
no
 fu
nc
tio
na
l r
ol
e 
in
 a
ut
op
ha
gy
 re
po
rt
ed
.  
(7
3)
 
M
AP
1L
C3
C 
1q
43
 
2.
8 
LC
3C
 
1 
Xe
no
ph
ag
y 
Fu
sio
n 
Xe
no
ph
ag
y 
 M
ito
ph
ag
y 
Bi
nd
in
g 
ub
iq
ui
tin
at
ed
 b
ac
te
ria
 re
ce
pt
or
 N
DP
52
 
In
te
ra
ct
io
n 
w
ith
 P
LE
KH
M
1 
In
te
ra
ct
s w
ith
 c
ar
go
 re
ce
pt
or
 T
AX
1B
P1
 
In
te
ra
ct
io
n 
w
ith
 T
RI
M
5α
 fo
r v
ira
l c
le
ar
an
ce
 
Re
cr
ui
tm
en
t b
y 
TA
X1
BP
1 
(2
6,
29
) 
(5
4)
  
(3
3)
 
(3
4)
 
(4
0)
 
G
AB
AR
AP
 
G
AB
AR
AP
 
17
p1
3.
1 
1.
5 
G
AB
AR
AP
 
1 
In
iti
at
io
n 
Fu
sio
n 
 An
te
ro
gr
ad
e 
tr
af
fic
ki
ng
 
  Ag
gr
ep
ha
gy
 
Xe
no
ph
ag
y 
 M
ito
ph
ag
y 
In
te
ra
ct
s w
ith
 U
LK
1,
 a
n 
im
po
rt
an
t m
ed
ia
to
r o
f 
nu
cl
ea
tio
n 
In
te
ra
ct
s w
ith
 N
SF
 a
nd
 P
LE
KH
M
1 
Ph
os
ph
or
yl
at
io
n 
by
 S
TK
3/
ST
K4
 
In
te
ra
ct
io
n 
w
ith
 th
e 
RA
B7
 e
ffe
ct
or
 F
YC
O
1 
Po
te
nt
ia
lly
 re
pr
og
ra
m
 e
nd
oc
yt
ic
 tr
af
fic
ki
ng
 e
ve
nt
s t
o 
fa
ci
lit
at
e 
au
to
ph
ag
y 
In
te
ra
ct
io
n 
w
ith
 A
LF
Y 
an
d 
N
BR
1 
In
te
ra
ct
s w
ith
 c
ar
go
 re
ce
pt
or
 T
AX
1B
P1
 
In
te
ra
ct
io
n 
w
ith
 T
RI
M
5α
 fo
r v
ira
l c
le
ar
an
ce
 
(1
6)
 
38
,3
9 
(5
0)
 (5
4)
 
(1
27
) 
 (1
31
) 
 (2
4,
13
3)
 
(3
3)
 
(3
4)
 
LC3/GABARAP family proteins: Autophagy (un)related functions 
Dissertatie Tom Keulers Tab V.indd   29 02-01-19   16:07:10
 
30
 
RA
C1
 s
ig
na
lin
g 
Re
cr
ui
tm
en
t b
y 
FU
N
DC
1 
In
te
ra
ct
io
n 
w
ith
 T
IA
M
1 
(4
4)
 
(1
34
) 
G
AB
AR
AP
L1
 
 
12
p1
3.
31
 
8.
7 
G
AB
AR
AP
L1
 
G
EC
1 
1 
In
iti
at
io
n 
 
  Fu
sio
n 
M
ito
ph
ag
y 
G
ly
co
ph
ag
y 
Xe
no
ph
ag
y 
In
te
ra
ct
io
n 
w
ith
 U
LK
1 
Po
te
nt
ia
lly
 re
pr
og
ra
m
 e
nd
oc
yt
ic
 tr
af
fic
ki
ng
 e
ve
nt
s t
o 
fa
ci
lit
at
e 
au
to
ph
ag
y 
In
te
ra
ct
io
n 
w
ith
 P
LE
KH
M
1 
In
te
ra
ct
io
n 
w
ith
 B
N
IP
3L
/N
ix
 
In
te
ra
ct
io
n 
w
ith
 S
TB
D1
 
In
te
ra
ct
io
n 
w
ith
 T
RI
M
5α
 fo
r v
ira
l c
le
ar
an
ce
 
(1
6)
 
   (4
1)
 
(3
8)
 
(3
4)
 
G
AB
AR
AP
L2
 
 
16
q2
2.
1 
10
.9
 
G
AB
AR
AP
L2
 
G
AT
E-
16
 
G
EF
2 
1 
Ve
sic
le
 c
lo
su
re
 
Fu
sio
n 
Tr
af
fic
ki
ng
  
 Xe
no
ph
ag
y 
 M
ito
ph
ag
y 
co
nj
ug
at
io
n 
to
 P
E 
In
te
ra
ct
io
n 
/s
ca
ffo
ld
in
g 
N
SF
 a
nd
 T
RP
M
L3
  
Ph
os
ph
or
yl
at
io
n 
by
 S
TK
3/
ST
K4
 a
nd
 P
LE
KH
M
1 
Po
te
nt
ia
lly
 re
pr
og
ra
m
 e
nd
oc
yt
ic
 tr
af
fic
ki
ng
 e
ve
nt
s t
o 
fa
ci
lit
at
e 
au
to
ph
ag
y 
In
te
ra
ct
s w
ith
 c
ar
go
 re
ce
pt
or
 T
AX
1B
P1
 
In
te
ra
ct
io
n 
w
ith
 T
RI
M
5α
 fo
r v
ira
l c
le
ar
an
ce
 
Re
cr
ui
tm
en
t b
y 
FU
N
DC
1 
(1
5,
16
) 
(5
0,
52
) 
(5
4,
12
7)
 
  (3
3)
 
(3
4)
 
(4
4)
 
* 
sp
lic
e 
va
ria
nt
s 
Chapter 2 LC3/GABARAP family proteins: Autophagy (un)related functions 
31 
Functions of LC3/GABARAP family proteins independent of autophagy? 
Although all LC3/GABARAP family proteins seem to fulfill (specific) roles within the exe-
cution of autophagy, some of the family proteins also fulfill functions that appear ca-
nonical autophagy-independent. Several LC3/GABARAP family proteins have been impli-
cated in receptor-trafficking, while others have been implicated in tumour-suppressive 
functions that appear autophagy independent.  
I. Intracellular trafficking 
Initially, the GABARAP protein family was described in intracellular transport of the 
GABA (A) receptor (GABAAR)(55). Further studies revealed that GABARAP also mediates 
membrane expression of the angiotensin II receptors (AGTR) (56,57), the human kappa 
opioid receptor (hKOPR) (58) and the transient receptor potential cation channel sub-
family V member 1 (TRPV1) (59).  
After assembly in the ER, GABAARs are transported to the golgi and are incorpo-
rated into transport vesicles (55). To facilitate receptor transport from the golgi to the 
plasma membrane, GABARAP interacts directly with the γ2 subunit of the GABAAR. 
Here, GABARAP possibly serves as a cargo-receptor required for GABAAR incorporation 
into the transport vesicle. Interestingly, GABARAP knockout mice show no defect in 
GABAAR trafficking, indicating that other molecules, such as GABARAPL1 can compen-
sate for the loss (60). 
Transport vesicles migrate along microtubules towards their destination. Antero-
grade transport, trafficking towards the plasma membrane, is facilitated by motor pro-
teins of the kinesin family. Kinesin family member 5A (KIF5A) and kinesin family member 
21B (KIF21B) control GABAAR surface expression via interaction with GABARAP (61,62). 
Yeast two hybrid screens also identified interactions with GABARAPL1 and GABARAPL2, 
however if these interactions are functional, remain elusive (61). In addition, Monas-
tyrska et al., proposed that vesicles exposing LC3/GABARAP protein family members on 
their surface, can be ‘docked’ on the microtubule by their highly positively charged N-
terminal region tubulin binding motif until further processing (63). Interestingly, this 
tubulin binding motif is conserved throughout the whole LC3/GABARAP protein family 
(64). Furthermore, the interaction of GABARAP with the endocytosis associated protein 
clathrin suggests that GABARAP may also be involved in the receptor internalization 
(65). Hence, Lainez et al. showed that internalization and recycling of the TRPV1 is pro-
moted by GABARAP, without altering the degradation rate of the receptor (59).  
When transport vesicles reach their destination, membrane fusion is required for 
further processing. Fusion of transport vesicles with target membranes is mediated by 
SNARE proteins. N-ethylmaleimide-sensitive factor (NSF) plays a role in the dissociation 
of SNARE complexes after membrane fusion, allowing them to be recycled for subse-
quent rounds of fusion. NSF also plays a role in the sorting of receptors into transport 
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Functions of LC3/GABARAP family proteins independent of autophagy? 
Although all LC3/GABARAP family proteins seem to fulfill (specific) roles within the exe-
cution of autophagy, some of the family proteins also fulfill functions that appear ca-
nonical autophagy-independent. Several LC3/GABARAP family proteins have been impli-
cated in receptor-trafficking, while others have been implicated in tumour-suppressive 
functions that appear autophagy independent.  
I. Intracellular trafficking 
Initially, the GABARAP protein family was described in intracellular transport of the 
GABA (A) receptor (GABAAR)(55). Further studies revealed that GABARAP also mediates 
membrane expression of the angiotensin II receptors (AGTR) (56,57), the human kappa 
opioid receptor (hKOPR) (58) and the transient receptor potential cation channel sub-
family V member 1 (TRPV1) (59).  
After assembly in the ER, GABAARs are transported to the golgi and are incorpo-
rated into transport vesicles (55). To facilitate receptor transport from the golgi to the 
plasma membrane, GABARAP interacts directly with the γ2 subunit of the GABAAR. 
Here, GABARAP possibly serves as a cargo-receptor required for GABAAR incorporation 
into the transport vesicle. Interestingly, GABARAP knockout mice show no defect in 
GABAAR trafficking, indicating that other molecules, such as GABARAPL1 can compen-
sate for the loss (60). 
Transport vesicles migrate along microtubules towards their destination. Antero-
grade transport, trafficking towards the plasma membrane, is facilitated by motor pro-
teins of the kinesin family. Kinesin family member 5A (KIF5A) and kinesin family member 
21B (KIF21B) control GABAAR surface expression via interaction with GABARAP (61,62). 
Yeast two hybrid screens also identified interactions with GABARAPL1 and GABARAPL2, 
however if these interactions are functional, remain elusive (61). In addition, Monas-
tyrska et al., proposed that vesicles exposing LC3/GABARAP protein family members on 
their surface, can be ‘docked’ on the microtubule by their highly positively charged N-
terminal region tubulin binding motif until further processing (63). Interestingly, this 
tubulin binding motif is conserved throughout the whole LC3/GABARAP protein family 
(64). Furthermore, the interaction of GABARAP with the endocytosis associated protein 
clathrin suggests that GABARAP may also be involved in the receptor internalization 
(65). Hence, Lainez et al. showed that internalization and recycling of the TRPV1 is pro-
moted by GABARAP, without altering the degradation rate of the receptor (59).  
When transport vesicles reach their destination, membrane fusion is required for 
further processing. Fusion of transport vesicles with target membranes is mediated by 
SNARE proteins. N-ethylmaleimide-sensitive factor (NSF) plays a role in the dissociation 
of SNARE complexes after membrane fusion, allowing them to be recycled for subse-
quent rounds of fusion. NSF also plays a role in the sorting of receptors into transport 
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vesicles and can bind GABARAP and the GABAAR (66). Interestingly, GABARAP is not 
found at GABAergic sites, but mainly in intracellular vesicles and at the end of golgi 
stacks where transport vesicles bud and fuse, suggesting its main role is transportation 
of these vesicles and not anchoring on the plasma membrane (66,67). Although, in-
creasing GABARAP expression leads to enhanced GABAAR expression at the plasma 
membrane (68), Gephyrin is required for GABAAR clustering (69). Since GABARAP is the 
only molecule that is able to bind both tubulin, gephyrin and the GABAAR, GABARAP 
may be the adaptor molecule between gephyrin and the GABAAR (70). Like all members 
of the LC3/GABARAP family, the C-terminal glycine of GABARAP can be conjugated to PE 
to establish its incorporation in the membrane. This modification is required for trans-
portation of the GABAAR (58), but is not required for trafficking of the Angiotensin II 
type A1 receptor (57). 
It addition to GABARAP, GABARAPL1 is required for anterograde transport of the 
kappa opioid receptor (KOR). Knockdown of either GABARAPL1 or GABARAP decreases 
the surface expression of kappa opioid receptor (58). Recently, we showed that the 
expression of GABARAPL1 during hypoxia is not restricted to the cytoplasm, but also 
localizes at the intraluminal side of the plasma membrane of cancer cells. At these sites, 
GABARAPL1 co-localizes with epidermal growth factor receptor (EGFR). GABARAPL1 
knockdown cells display reduced EGFR expression at the plasma membrane, whereas 
total EGFR levels are not altered (71). Similar results were also observed for carbonic 
anhydrase IX (CAIX), a hypoxia inducible factor-1 (HIF-1) transcriptional target (71), 
suggesting that GABARAPL1 plays a role in membrane expression of proteins during 
hypoxia.  
In contrast, GABARAPL2 is a membrane transport enhancer involved in intra-Golgi 
trafficking (72) (Fig. 1F). The Golgi complex is considered the central component of the 
secretory pathway required for lipid and protein modification, classification, packaging 
into specific carriers and delivery. GABARAPL2 stimulates the ATPase activity of NSF and 
is capable of interacting with GOS-28, a Golgi specific SNARE. The coupling between NSF 
activity and SNAREs activation allows GABARAPL2 to modulate intra-Golgi transport 
(51). 
As summarized above, the GABARAP family proteins facilitate receptor trafficking, 
actions that appear independent of autophagy. This illustrates the complexity of data 
interpretation in (genetic) models that change expression of these factors.  
II. Oncogene/Tumour suppressor 
LC3A is expressed in two isoforms, LC3A-a and -b (NP_115903 and NP_852610). They 
differ in amino-terminus sequence as a result of a different transcriptional start site. 
LC3A-a, but not LC3A-b, is turned over by lysosomes and whereas LC3A-a is ubiquitously 
expressed in most tissues, LC3A-b expression is low in general. Interestingly, LC3A-a 
expression, but not LC3B, is silenced in 45.5% of human cancer cell lines originating 
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from various tissues. Methylation of the CpG island proximal to the LC3A-a transcrip-
tional start site is observed in human cancer cell lines tested by COBRA (combined bisul-
fite restriction analysis), while no aberrant methylation was observed in LC3A-a express-
ing lines. Interestingly, LC3A-a re-expression in LC3A-a silenced cells decreases xeno-
graft growth, suggesting a role for LC3A-a in tumour progression (73). 
VHL (Von hippel Lindau) syndrome is an autosomal dominant disease cancer syn-
drome associated with loss of E3 ligase/tumour suppressor gene VHL which increases 
predisposition to many tumours including renal cancer. In the majority of spontaneous 
clear cell renal cell carcinomas (ccRCC) VHL is deleted (74). In renal tumours without 
loss of VHL, high levels of LC3C are observed. Knockdown of LC3C in these VHL express-
ing ccRCC cells increases the incidence of orthotopic tumour formation. Interestingly, in 
these models tumour progression is associated with increased LC3B-mediated autopha-
gy. While LC3B-mediated autophagy is required for tumour progression, LC3C acts as a 
tumour suppressor (75). This suggests that LC3C functions here independent of canoni-
cal (autophagosomal-lysosomal degradation) and LC3B-mediated autophagy to main-
tain homeostasis. Interestingly in colorectal cancer high LC3B expression is correlated 
with improved survival after surgery (76). This suggests that LC3B associated autophagy 
can promote or repress tumorigenic events dependent on the tumour site and potential 
other mechanisms at play.  
Recently, GABARAP has been indicated as a tumour suppressor gene. Compared to 
normal breast tissue, primary breast cancer tissues contain lower GABARAP mRNA and 
protein levels, this is in agreement with results observed in cell lines. Ectopic expression 
of GABARAP gene in low-expressing breast cancer cell lines reduced tumour growth rate 
(77). Moreover, tumour incidence induced by mutagenic and immunotoxic 7,12-
dimethylbenz(a)anthracene (DMBA) treatment was reduced in GABARAP knock out (KO) 
mice. Interestingly, injection of GABARAP proficient melanoma cells in GABARAP knock 
out mice led to reduced tumour growth, supporting the tumour suppressive role of 
GABARAP (78). This tumour suppressive feature of GABARAP could be mediated 
through direct effects on autophagy and/or in an indirect fashion by controlling recep-
tor trafficking such as EGFR (79) (71)). 
III. ER –associated degradation (ERAD) 
The ER requires a quality control system to ensure correct protein folding. Misfolded 
proteins are selected for degradation by processes collectively referred to as ER-
associated degradation (ERAD). At steady state, the effector proteins in ERAD (including 
EDEM1 and OS9) are removed rapidly from the ER to establish low ER residence, de-
fined as ERAD tuning. EDEM1 turnover is reduced in mouse embryonic fibroblasts lack-
ing ATG5 or treated with chloroquine. Gradient separated fractions showed that a small 
fraction of EDEM1 is associated with bulk ER; however, the majority of EDEM1 is pre-
sent in other fractions, fractions with LC3-I (80). This suggests that LC3 coated vesicles 
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vesicles and can bind GABARAP and the GABAAR (66). Interestingly, GABARAP is not 
found at GABAergic sites, but mainly in intracellular vesicles and at the end of golgi 
stacks where transport vesicles bud and fuse, suggesting its main role is transportation 
of these vesicles and not anchoring on the plasma membrane (66,67). Although, in-
creasing GABARAP expression leads to enhanced GABAAR expression at the plasma 
membrane (68), Gephyrin is required for GABAAR clustering (69). Since GABARAP is the 
only molecule that is able to bind both tubulin, gephyrin and the GABAAR, GABARAP 
may be the adaptor molecule between gephyrin and the GABAAR (70). Like all members 
of the LC3/GABARAP family, the C-terminal glycine of GABARAP can be conjugated to PE 
to establish its incorporation in the membrane. This modification is required for trans-
portation of the GABAAR (58), but is not required for trafficking of the Angiotensin II 
type A1 receptor (57). 
It addition to GABARAP, GABARAPL1 is required for anterograde transport of the 
kappa opioid receptor (KOR). Knockdown of either GABARAPL1 or GABARAP decreases 
the surface expression of kappa opioid receptor (58). Recently, we showed that the 
expression of GABARAPL1 during hypoxia is not restricted to the cytoplasm, but also 
localizes at the intraluminal side of the plasma membrane of cancer cells. At these sites, 
GABARAPL1 co-localizes with epidermal growth factor receptor (EGFR). GABARAPL1 
knockdown cells display reduced EGFR expression at the plasma membrane, whereas 
total EGFR levels are not altered (71). Similar results were also observed for carbonic 
anhydrase IX (CAIX), a hypoxia inducible factor-1 (HIF-1) transcriptional target (71), 
suggesting that GABARAPL1 plays a role in membrane expression of proteins during 
hypoxia.  
In contrast, GABARAPL2 is a membrane transport enhancer involved in intra-Golgi 
trafficking (72) (Fig. 1F). The Golgi complex is considered the central component of the 
secretory pathway required for lipid and protein modification, classification, packaging 
into specific carriers and delivery. GABARAPL2 stimulates the ATPase activity of NSF and 
is capable of interacting with GOS-28, a Golgi specific SNARE. The coupling between NSF 
activity and SNAREs activation allows GABARAPL2 to modulate intra-Golgi transport 
(51). 
As summarized above, the GABARAP family proteins facilitate receptor trafficking, 
actions that appear independent of autophagy. This illustrates the complexity of data 
interpretation in (genetic) models that change expression of these factors.  
II. Oncogene/Tumour suppressor 
LC3A is expressed in two isoforms, LC3A-a and -b (NP_115903 and NP_852610). They 
differ in amino-terminus sequence as a result of a different transcriptional start site. 
LC3A-a, but not LC3A-b, is turned over by lysosomes and whereas LC3A-a is ubiquitously 
expressed in most tissues, LC3A-b expression is low in general. Interestingly, LC3A-a 
expression, but not LC3B, is silenced in 45.5% of human cancer cell lines originating 
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from various tissues. Methylation of the CpG island proximal to the LC3A-a transcrip-
tional start site is observed in human cancer cell lines tested by COBRA (combined bisul-
fite restriction analysis), while no aberrant methylation was observed in LC3A-a express-
ing lines. Interestingly, LC3A-a re-expression in LC3A-a silenced cells decreases xeno-
graft growth, suggesting a role for LC3A-a in tumour progression (73). 
VHL (Von hippel Lindau) syndrome is an autosomal dominant disease cancer syn-
drome associated with loss of E3 ligase/tumour suppressor gene VHL which increases 
predisposition to many tumours including renal cancer. In the majority of spontaneous 
clear cell renal cell carcinomas (ccRCC) VHL is deleted (74). In renal tumours without 
loss of VHL, high levels of LC3C are observed. Knockdown of LC3C in these VHL express-
ing ccRCC cells increases the incidence of orthotopic tumour formation. Interestingly, in 
these models tumour progression is associated with increased LC3B-mediated autopha-
gy. While LC3B-mediated autophagy is required for tumour progression, LC3C acts as a 
tumour suppressor (75). This suggests that LC3C functions here independent of canoni-
cal (autophagosomal-lysosomal degradation) and LC3B-mediated autophagy to main-
tain homeostasis. Interestingly in colorectal cancer high LC3B expression is correlated 
with improved survival after surgery (76). This suggests that LC3B associated autophagy 
can promote or repress tumorigenic events dependent on the tumour site and potential 
other mechanisms at play.  
Recently, GABARAP has been indicated as a tumour suppressor gene. Compared to 
normal breast tissue, primary breast cancer tissues contain lower GABARAP mRNA and 
protein levels, this is in agreement with results observed in cell lines. Ectopic expression 
of GABARAP gene in low-expressing breast cancer cell lines reduced tumour growth rate 
(77). Moreover, tumour incidence induced by mutagenic and immunotoxic 7,12-
dimethylbenz(a)anthracene (DMBA) treatment was reduced in GABARAP knock out (KO) 
mice. Interestingly, injection of GABARAP proficient melanoma cells in GABARAP knock 
out mice led to reduced tumour growth, supporting the tumour suppressive role of 
GABARAP (78). This tumour suppressive feature of GABARAP could be mediated 
through direct effects on autophagy and/or in an indirect fashion by controlling recep-
tor trafficking such as EGFR (79) (71)). 
III. ER –associated degradation (ERAD) 
The ER requires a quality control system to ensure correct protein folding. Misfolded 
proteins are selected for degradation by processes collectively referred to as ER-
associated degradation (ERAD). At steady state, the effector proteins in ERAD (including 
EDEM1 and OS9) are removed rapidly from the ER to establish low ER residence, de-
fined as ERAD tuning. EDEM1 turnover is reduced in mouse embryonic fibroblasts lack-
ing ATG5 or treated with chloroquine. Gradient separated fractions showed that a small 
fraction of EDEM1 is associated with bulk ER; however, the majority of EDEM1 is pre-
sent in other fractions, fractions with LC3-I (80). This suggests that LC3 coated vesicles 
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that differ from autophagosomes (as LC3-I rather than LC3-II is associated) are required 
for the disposal of EDEM1 in the process of ERAD tuning. 
IV. LC3-associated phagocytosis 
During phagocytosis a cell engulfs particles (as cells or pathogens) to create an intracel-
lular vesicle known as a phagosome. Recently it was observed that these single mem-
brane vesicles can express LC3(81). The process is referred to as LC3-associated phago-
cytosis, or LAP. LC3 lipidation is required for its association with these phagosomes, and 
is dependent on an array of autophagy related proteins including ATG5, ATG7, Beclin1, 
ATG12, and ATG16L (81-83). However, other autophagy related proteins seem to be 
dispensable for LAP including ULK1/2, ATG13, FIP200 and ATG14(83). In addition, LAP 
specific proteins (dispensable for autophagy) are Rubicon (a Beclin1 interacting protein) 
and ROS-producing NADPH oxidase 2 (NOX2) (84). Recently, Martinez et al exploited 
this segregation in required proteins between autophagy and LAP by inducing LAP spe-
cific abrogation in immune cells and challenging mice with apoptotic cell injections. The 
phenotype that these mice presented included accumulation of lymphocytes, mono-
cytes, activated CD8+ cells, developed autoantibodies and kidney damage with in-
creased interferon gamma expression. This phenotype resembles aspects of systemic 
lupus erythematosus (SLE) patients and is the result of increased pro-inflammatory 
cytokine secretion. Therefore, LAP was suggested to be required to protect against 
certain autoimmune diseases (85). Nevertheless, phagosome maturation can occur 
independent of LC3(86), thus requirement of LC3 and other ATG proteins for phago-
some maturation is possibly condition dependent. Nevertheless, LAP facilitates antigen 
presentation on major histocompatibility complex (MHC) class II molecules (87).  
V. motility and growth 
Ras-related C3 botulinum toxin substrate 1 (RAC1) mediates cell motility and growth. 
RAC1 activity is controlled by the guanine exchange factor TIAM1. The recently discov-
ered CUL3 KBTBD6/KBTBD7 ubiquitin ligase complex controls TIAM1 abundance by 
ubiquitination and targeting for proteasomal degradation. Interestingly, ubiquitination 
of TIAM1 depends on binding to GABARAP, located on GABARAP positive vesicles, re-
sulting in restriction of RAC1 signaling to specific sites in the cell. For binding to GABA-
RAP, KBTBD6/7 contains a LIR motif to bind preferably to GABARAP proteins rather than 
the LC3 subfamily. Furthermore, the authors show that these GABARAP positive vesicles 
are not associated with autophagosome formation or degradation, suggesting a vesicle 
population distinct form autophagosomes (88).VI. Maintenance of ERES sites 
Endoplasmatic reticulum exit sites (ERES) are highly specialized sites that allow the 
export of proteins into COPII vesicles. In addition to their role in protein export, ERES 
are involved in the biogenesis of autophagosomes possibly through the delivery of 
membrane- and other components that are essential in the formation of autophago-
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somes or act as scaffold sites where the autophagosomes may be formed (reviewed in 
(89)). COPII consists of several protein including the cargo adapters SEC23 and SEC24 
(90). In conjunction with lipidated LC3C, Tectonin- β-propellor containing protein 2 
(TECPR2) associates with SEC24D and allows for efficient ER cargo export. Hence, either 
knockdown of TECPR2 or LC3C results in delayed delivery of cargo from the ER to the 
golgi (91). In addition, the maintenance of ERES via TECPR2 and LC3C is required to 
autophagosomes formation, failure to maintain ERES sites results in impaired autopha-
gosomes development (91).  
Given the high complexity and involvement of the LC3/GABARAP family proteins in 
these diverse cellular processes, it is likely that these family proteins may be involved in 
other momentarily unidentified processes. Nevertheless, substantial evidence has 
shown that the family proteins are also involved in autophagy unrelated processes. 
Experiments where these family proteins are knocked down should therefore interpret-
ed with caution. 
How the LC3/GABARAP family proteins may selectively be recruited 
The LC3/GABARAP protein family fulfills a variety of functions in intracellular trafficking 
and autophagy. As discussed above, most of these functions appear family protein spe-
cific. Interestingly, the functionality and activation of the LC3/GABARAP family proteins 
at first glance appears to be mediated by comparable enzymatic reactions (terminal 
glycine exposure, PE-conjugation). To achieve differences and effective recruitment of 
the required LC3/GABARAP family protein, the cell exploits affinity and specificity differ-
ences for ATG proteins which allow complex selection and recruitment of specific 
LC3/GABARAP family proteins. In this section, the complex recruitment and availability 
that is required for autophagy execution is discussed. 
I. LC3/GABARAP family protein activation 
LC3/GABARAP family proteins are present in cytoplasmic and membrane-bound 
isoforms; indicated as -I and -II (for LC3B; LC3B-I and –II) respectively. In yeast, covalent 
conjugation of a PE-group to Atg8 is required for membrane incorporation. In the Atg8 
conjugation reaction, Atg4, Atg7 and Atg3 are crucial(9). For the mammalian 
orthologues, similar mechanisms have been identified for LC3B, GABARAP, GABARAPL1 
and GABARAPL2 (92,93). Whether LC3A and LC3C require ATG4 processing and ATG7 
and ATG3 interactions for PE conjugation has not yet been demonstrated.  
A series of modifications is required for the efficient conjugation of PE and the cor-
rect localization of the LC3/GABARAP family proteins. Members of the ATG4 protease 
family cleave the pro-form to expose the conserved glycine (isoform-I). Subsequently, 
the E1 activating enzyme ATG7 catalyzes acyl adenylation of the carboxyl-terminus and 
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that differ from autophagosomes (as LC3-I rather than LC3-II is associated) are required 
for the disposal of EDEM1 in the process of ERAD tuning. 
IV. LC3-associated phagocytosis 
During phagocytosis a cell engulfs particles (as cells or pathogens) to create an intracel-
lular vesicle known as a phagosome. Recently it was observed that these single mem-
brane vesicles can express LC3(81). The process is referred to as LC3-associated phago-
cytosis, or LAP. LC3 lipidation is required for its association with these phagosomes, and 
is dependent on an array of autophagy related proteins including ATG5, ATG7, Beclin1, 
ATG12, and ATG16L (81-83). However, other autophagy related proteins seem to be 
dispensable for LAP including ULK1/2, ATG13, FIP200 and ATG14(83). In addition, LAP 
specific proteins (dispensable for autophagy) are Rubicon (a Beclin1 interacting protein) 
and ROS-producing NADPH oxidase 2 (NOX2) (84). Recently, Martinez et al exploited 
this segregation in required proteins between autophagy and LAP by inducing LAP spe-
cific abrogation in immune cells and challenging mice with apoptotic cell injections. The 
phenotype that these mice presented included accumulation of lymphocytes, mono-
cytes, activated CD8+ cells, developed autoantibodies and kidney damage with in-
creased interferon gamma expression. This phenotype resembles aspects of systemic 
lupus erythematosus (SLE) patients and is the result of increased pro-inflammatory 
cytokine secretion. Therefore, LAP was suggested to be required to protect against 
certain autoimmune diseases (85). Nevertheless, phagosome maturation can occur 
independent of LC3(86), thus requirement of LC3 and other ATG proteins for phago-
some maturation is possibly condition dependent. Nevertheless, LAP facilitates antigen 
presentation on major histocompatibility complex (MHC) class II molecules (87).  
V. motility and growth 
Ras-related C3 botulinum toxin substrate 1 (RAC1) mediates cell motility and growth. 
RAC1 activity is controlled by the guanine exchange factor TIAM1. The recently discov-
ered CUL3 KBTBD6/KBTBD7 ubiquitin ligase complex controls TIAM1 abundance by 
ubiquitination and targeting for proteasomal degradation. Interestingly, ubiquitination 
of TIAM1 depends on binding to GABARAP, located on GABARAP positive vesicles, re-
sulting in restriction of RAC1 signaling to specific sites in the cell. For binding to GABA-
RAP, KBTBD6/7 contains a LIR motif to bind preferably to GABARAP proteins rather than 
the LC3 subfamily. Furthermore, the authors show that these GABARAP positive vesicles 
are not associated with autophagosome formation or degradation, suggesting a vesicle 
population distinct form autophagosomes (88).VI. Maintenance of ERES sites 
Endoplasmatic reticulum exit sites (ERES) are highly specialized sites that allow the 
export of proteins into COPII vesicles. In addition to their role in protein export, ERES 
are involved in the biogenesis of autophagosomes possibly through the delivery of 
membrane- and other components that are essential in the formation of autophago-
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somes or act as scaffold sites where the autophagosomes may be formed (reviewed in 
(89)). COPII consists of several protein including the cargo adapters SEC23 and SEC24 
(90). In conjunction with lipidated LC3C, Tectonin- β-propellor containing protein 2 
(TECPR2) associates with SEC24D and allows for efficient ER cargo export. Hence, either 
knockdown of TECPR2 or LC3C results in delayed delivery of cargo from the ER to the 
golgi (91). In addition, the maintenance of ERES via TECPR2 and LC3C is required to 
autophagosomes formation, failure to maintain ERES sites results in impaired autopha-
gosomes development (91).  
Given the high complexity and involvement of the LC3/GABARAP family proteins in 
these diverse cellular processes, it is likely that these family proteins may be involved in 
other momentarily unidentified processes. Nevertheless, substantial evidence has 
shown that the family proteins are also involved in autophagy unrelated processes. 
Experiments where these family proteins are knocked down should therefore interpret-
ed with caution. 
How the LC3/GABARAP family proteins may selectively be recruited 
The LC3/GABARAP protein family fulfills a variety of functions in intracellular trafficking 
and autophagy. As discussed above, most of these functions appear family protein spe-
cific. Interestingly, the functionality and activation of the LC3/GABARAP family proteins 
at first glance appears to be mediated by comparable enzymatic reactions (terminal 
glycine exposure, PE-conjugation). To achieve differences and effective recruitment of 
the required LC3/GABARAP family protein, the cell exploits affinity and specificity differ-
ences for ATG proteins which allow complex selection and recruitment of specific 
LC3/GABARAP family proteins. In this section, the complex recruitment and availability 
that is required for autophagy execution is discussed. 
I. LC3/GABARAP family protein activation 
LC3/GABARAP family proteins are present in cytoplasmic and membrane-bound 
isoforms; indicated as -I and -II (for LC3B; LC3B-I and –II) respectively. In yeast, covalent 
conjugation of a PE-group to Atg8 is required for membrane incorporation. In the Atg8 
conjugation reaction, Atg4, Atg7 and Atg3 are crucial(9). For the mammalian 
orthologues, similar mechanisms have been identified for LC3B, GABARAP, GABARAPL1 
and GABARAPL2 (92,93). Whether LC3A and LC3C require ATG4 processing and ATG7 
and ATG3 interactions for PE conjugation has not yet been demonstrated.  
A series of modifications is required for the efficient conjugation of PE and the cor-
rect localization of the LC3/GABARAP family proteins. Members of the ATG4 protease 
family cleave the pro-form to expose the conserved glycine (isoform-I). Subsequently, 
the E1 activating enzyme ATG7 catalyzes acyl adenylation of the carboxyl-terminus and 
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is then transferred to the E2 conjugating enzyme, ATG3 and, in turn, mediates the cova-
lent conjugation to PE (isoform–II)(94). Although each of the LC3/GABARAP family pro-
teins undergoes this type of conjugation, differences in efficiency and specificity exist. 
For example, conjugation is most efficient for GABARAPL1, followed by GABARAPL2 and 
least efficient in LC3B (95). This interpretation is based on the ratio I/II in cell-free assays 
exposing isoform-I to ATP, ATG7, ATG3 and liposomes that are devoid of additional 
regulatory mechanisms or post-translational modifications. Nevertheless, this setup 
provides assessment of the systems potential for individual LC3/GABARAP family pro-
tein conjugation. These differences indicate that the ratio in LC3/GABARAP family pro-
teins presentation to the ATG7-ATG3 process has a major impact on the generation of 
membrane associated (-II) forms.  
In addition to LC3/GABARAP family protein conjugation, autophagy relies on another 
conjugation reaction to create the ATG12-ATG5-ATG16(L) complex. For their interac-
tion, ATG12 is activated by the E1 activating enzyme ATG7. Hereafter, ATG12 is trans-
ferred to ATG10 (E2 conjugating enzyme) and conjugated to ATG5. ATG5 interacts with 
ATG16(L) to form the complex, which can form a tetramer via ATG16 homodimerization 
(reviewed in (96)). The complex fulfils multiple functions. First, it is involved in determi-
nation of the site for LC3/GABARAP family protein conjugation to PE by ATG3. In yeast, 
the Atg12-Atg5 conjugate promotes the transfer of Atg8 from Atg3 to the substrate, PE, 
by stimulating the activity of Atg3 (8). Also in mammalian cells, localization ATG12-
ATG5-ATG16L determines the site of LC3B conjugation (97). The direct interaction of 
ATG12 and ATG3 (98) further indicates that ATG12 recruits ATG3 to determine localiza-
tion of LC3/GABARAP family protein membrane incorporation. Nevertheless, the 
ATG12-ATG5 conjugate, but not ATG12 alone, is able to facilitate this LC3/GABARAP 
family protein PE–conjugation (98). Second, the ATG12-ATG5 conjugate interacts with 
TECPR1 (a lysosomal resident protein) which is crucial for autophagosome-lysosome 
fusion (99). Third, the yeast Atg12-Atg5-Atg16 complex and Atg8 cooperate into a self-
organizing system to form a protein mesh (scaffold) causing stabilization of the mem-
brane (100). This interaction is mediated through a non-canonical Atg8 binding motif in 
Atg12, antiparallel arrangement of two Atg16 dimers and the ability of Atg5 to bind 
membranes and interact with Atg16(L) (100). Interestingly, in mammalian cells 
GABARAPL1 is observed at the plasma membrane (101) and could indicate a role for 
GABARAPL1 in membrane stabilization. It is however still unclear whether the ATG12-
ATG5-ATG16 complex is capable of interacting with other LC3/GABARAP family proteins 
than LC3B.  
The LC3/GABARAP family proteins fulfil unique functions, but appear to be regulated 
by similar mechanisms. Interestingly, the machinery displays differential conjugation 
efficiency that can be of importance to orchestrate the functional complexity among 
the LC3/GABARAP family proteins.  
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I.i. ATG4 cysteine protease family – four isoforms varying in homologue 
selectivity 
Directly after production, pro-LC3B is cleaved at glycine 120 generating isoform I. This 
priming is comparable for all LC3/GABARAP family proteins and is ATG4 dependent. 
ATG4 is a class of cysteine proteases with four isoforms in humans; ATG4A, -B, -C and -
D. Most information is available on ATG4B which is capable of cleaving LC3B (42,102-
104), GABARAP (102-104), GABARAPL1 (42,104) and GABARAPL2 (42,102,103). ATG4A 
displays different substrate specificity and cleaves GABARAPL2 most efficient, followed 
by GABARAP, and LC3B the least (102,104). Interestingly, overexpression of dominant 
negative ATG4A mutant (ATG4AC77A) increases the number of unclosed autophagic 
membranes (17) and is in line with the role for GABARAPL2 in vesicle closure (17,18). 
Interestingly, ATG4C and ATG4D contain a caspase 3 cleavage domain (DEVD) and, 
compared to full-length ATG4D, its cleaved form has higher priming and delipidating 
activity, predominantly directed to GABARAPL1. ATG4D silencing sensitizes HeLa cells to 
starvation-induced cell death, suggesting that ATG4D-dependent autophagy contributes 
to cellular survival. Interestingly, cleaved ATG4D is recruited to mitochondria (42) and 
may mediate recruitment of GABARAPL1 for (dysfunctional) mitochondria clearance 
(43). Together, this implicates that specific LC3/GABARAP family protein activation and 
recruitment can be regulated at the post-translational level through activation or ex-
pression of ATG4 isoforms.  
I.ii. ATG3 and ATG12-ATG5-ATG16(L) dynamics in LC3/GABARAP family protein 
recruitment  
As LC3/GABARAP family proteins display different functions, recruitment and activation 
at the site of requirement is therefore important. Directing specific family proteins to 
the ‘flat’ membrane or the highly curved extending tips of the phagophore is crucial for 
elongation and closure. In addition, as LC3/GABARAP family proteins are required for 
specific types of autophagy, selective recruitment is essential. For example, autophago-
somes directed for lysosomal degradation or receptor trafficking from Golgi to the 
plasma membrane (GABARAP and GABARAPL1-mediated anterograde transport 
(57,105)), requires association with distinct LC3/GABARAP family proteins. This is, at 
least in part, dependent on ATG3 and ATG12-ATG5-ATG16(L) complex cooperation. 
Recently, the amino-terminal amphipathic helix in ATG3 has been annotated to sense 
the membrane curvature (95) and enables ATG3 to associate with highly curved mem-
branes such as the tips of the growing phagophore. Remarkably, the PE-conjugation of 
GABARAP family proteins by ATG3 increases with the degree of membrane curvature. 
This allows incorporation of GABARAP family proteins at the phagophore tips and locali-
zation of GABARAPL2 at the site of closure (17). This is also illustrated in low-diameter, 
highly curved liposomes (50-200nm). Here the efficiency in PE-conjugation of 
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starvation-induced cell death, suggesting that ATG4D-dependent autophagy contributes 
to cellular survival. Interestingly, cleaved ATG4D is recruited to mitochondria (42) and 
may mediate recruitment of GABARAPL1 for (dysfunctional) mitochondria clearance 
(43). Together, this implicates that specific LC3/GABARAP family protein activation and 
recruitment can be regulated at the post-translational level through activation or ex-
pression of ATG4 isoforms.  
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As LC3/GABARAP family proteins display different functions, recruitment and activation 
at the site of requirement is therefore important. Directing specific family proteins to 
the ‘flat’ membrane or the highly curved extending tips of the phagophore is crucial for 
elongation and closure. In addition, as LC3/GABARAP family proteins are required for 
specific types of autophagy, selective recruitment is essential. For example, autophago-
somes directed for lysosomal degradation or receptor trafficking from Golgi to the 
plasma membrane (GABARAP and GABARAPL1-mediated anterograde transport 
(57,105)), requires association with distinct LC3/GABARAP family proteins. This is, at 
least in part, dependent on ATG3 and ATG12-ATG5-ATG16(L) complex cooperation. 
Recently, the amino-terminal amphipathic helix in ATG3 has been annotated to sense 
the membrane curvature (95) and enables ATG3 to associate with highly curved mem-
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GABARAP family proteins by ATG3 increases with the degree of membrane curvature. 
This allows incorporation of GABARAP family proteins at the phagophore tips and locali-
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GABARAPL1, GABARAPL2 and LC3B is different (95). GABARAPL1 protein content is 
almost completely PE-conjugated at <100nm diameter membranes, whereas this is less 
effective for GABARAPL2 and LC3B (95). Since classical mammalian autophagosomes are 
approximately 500-1500nm in size (106), this suggests that GABARAPL1 can be efficient-
ly incorporated in membranes of smaller-sized vesicles (95). The conjugation of 
GABARAPL1 is highly efficient even in absence of the ATG12-ATG5-ATG16(L) complex, 
suggesting that for small vesicles the absence of the ATG12-ATG5-ATG16(L) complex 
would promote incorporation of GABARAPL1 over other family proteins. 
Together, increasing evidence is emerging that the cell is able to orchestrate 
LC3/GABARAP family protein recruitment through the cooperation of ATG3 and the 
ATG12-ATG5-ATG16(L) complex. Yet, although in yeast an Atg8 binding motif has been 
identified in Atg12 (100), it remains unclear if this motif exists in mammalian ATG12 
and, when exists, has different affinity towards the other LC3/GABARAP family proteins. 
Potentially, the requirement of this complex for PE-conjugation of LC3B, but not for 
GABARAPL1 provides the cell with sufficient tools to specifically incorporate the desired 
LC3/GABARAP family protein into the vesicle.  
II. Transcriptional regulation of LC3/GABARAP family proteins  
Recent reports indicate that transcriptional mechanisms play important roles in the 
regulation of autophagic activity (107). The diversity of transcription factors that are 
capable of regulating the expression of LC3/GABARAP family proteins may reflect the 
requirement for specific family protein expression in e.g. cargo selection or autophagic 
rate and may depend on environmental factors (metabolic condition, pathogen expo-
sure etc) or may reflect tissue specific effects (table 2). 
GATA1/FOXO: The zinc finger DNA binding protein family of GATA (globin transcription 
factor) transcription factors regulate transcription during development and cell differ-
entiation. GATA binding protein 1 (GATA1) plays an important role in erythropoiesis by 
controlling the growth and division (proliferation) of immature red blood cells. During 
erythropoiesis, GATA1 mediates expression of LC3A, LC3B, GABARAP, GABARAPL1 and 
GABARAPL2 (108). These effects are, at least in part, mediated through a member of 
the evolutionary conserved forkhead box O (FOXO) family of transcription factors, 
FOXO3. During erythropoiesis depletion of FOXO3 reduces the transcriptional effect of 
GATA1 and decreases upregulation of LC3B, GABARAPL1 and GABARAPL2 (108). In skel-
etal muscle, FOXO3 is also capable of regulating LC3B and GABARAPL1 expression, 
whereas in cardiomyocytes, neurons and hepatocytes FOXO1 is also able to fulfill a 
similar function (109-113).  
UPR/ATF4/CHOP: Transcriptional upregulation of LC3/GABARAP family proteins may 
allow sustained autophagy activity through replenishment of the, during autophagy, 
degraded protein. For example, the high lysosomal turnover of LC3B during hypoxia-
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induced autophagy in the absence of transcriptional replenishment results in LC3B de-
pletion. Activation of the unfolded protein response (UPR) and production of activating 
transcription factor 4 (ATF4) (3) results in LC3B transcription and supports prolonged 
autophagy(3). In addition, ATF4 controls expression of LC3A, GABARAPL1 and 
GABARAPL2 in skeletal muscle-, cancer- and embryonic cells respectively (101,114,115). 
ATF4 induces expression of another transcription factor, CHOP/GADD153/DDIT3/C/EBP-
homologues protein, which in turn controls GABARAP expression in embryonic cells 
(114).  
Other regulatory mechanisms: Several other transcription factors have been shown to 
be able to regulate expression of LC3/GABARAP family proteins. Most identified factors 
are capable of increasing expression of the target gene, but also repressive factors have 
been identified, indicating the importance of gene expression regulation in autophagy. 
Transcription factor EB (TFEB), a member of the basic helix-loop-helix Leu zipper family 
has been identified as a key regulating transcription factor for autophagy related genes 
(107), including LC3B and LC3A (116,117). The extent of gene induction is controlled by 
the repressive transcription factor zinc-finger protein with KRAB and SCAN domain 3 
(ZKSCAN3) (118). During starvation TFEB and ZKSCAN3 are regulated oppositely. Reduc-
tion of ZKSCAN expression results in increased LC3B and GABARAPL2 mRNA expression 
(118). Whether the repressive effect of ZKSCAN3 on autophagy related genes is exclu-
sively counteracting TFEB-mediated transcription, or that ZKSCAN3 opposes the general 
transcription of a set of autophagy-related genes, independent of transcription factor, 
remains elusive.  
LC3B is the most studied and therefore best understood member of the 
LC3/GABARAP family. So far, 8 transcription factors have been identified that are capable 
of regulating its (basal) expression. In addition to the transcription factors mentioned, 
LC3B expression is controlled by CCAAT/enhancer binding protein (119), E2F1(120), c-jun 
(121,122) and sterol regulatory element binding protein 2 (SREBP2) (123). The diversity 
of stimulatory factors driving LC3B expression potentially emphasizes the essential role 
for LC3B in the execution of autophagy. Also for GABARAPL1 many (6) transcription fac-
tors have been identified. GABARAPL1 is induced in response to the transcription factors 
ATF4(101), GATA1(108), C/EBPβ(119), FOXO1 (109,112), FOXO3 (108,111,112), and Es-
trogen receptor activation (124). Furthermore, GABARAP expression is controlled by 
GATA1 (108), CHOP (114), p38α (125) and p73 (126) transcriptional activity. 
To date no specific transcription factors have been found that regulate LC3C tran-
scription. In clear cell renal cell carcinomas (ccRCC) expression of the tumour suppres-
sor, von Hippel Lindau (VHL) protein, is frequently lost. Loss in VHL, amongst other ef-
fects, results in stabilization of hypoxia inducible factor (HIF) proteins. Interestingly, the 
loss of VHL results in repression of LC3C mRNA and protein expression. HIF2α knock-
down results in elevated expression of LC3C in VHL-deficient cells, illustrating the regu-
lation of LC3C expression by VHL-activity through controlling HIF2α stability (75).  
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Table 2: LC3/GABARAP family proteins transcription factors 
LC3/GABARAP family 
member 
Transcription 
factor/mechanism 
Cell type/mechanism Reference 
LC3A ATF4 
TFEB  
GATA1 
Skeletal muscle 
Lung cancer (A549 specifically) 
Erythropoiesis 
(115) 
(116) 
(108) 
LC3B ATF4 
 
C/EBPβ 
E2F1 
FOXO1 
FOXO3 
GATA1 
c-Jun 
 
SREBP2 
TFEB 
ZKSCAN3 (repressive) 
Colorectal cancer, glioblastoma, 
breast cancer 
Liver (circadian rhythm) 
Osteosarcoma 
Neurons, hepatocytes 
Skeletal muscle, erythropoiesis 
Erythropoiesis 
Nasopharyngeal-, hepatocellular 
carcinoma 
Human Embryonic kidney 
Cervical cancer 
Various cancer cell lines 
(3) 
 
(119) 
(120) 
(109,113) 
(108,110) 
(108) 
(121,122) 
(123) 
(117) 
(118) 
LC3C HIF2α (repressive) Clear cell renal cell carcinoma (75) 
GABARAP CHOP 
p38α 
GATA1 
p73 
Mouse embryonic fibroblasts 
Colorectal cancer 
Erythropoiesis 
Rhabdomyosacoma 
(114) 
(125) 
(108) 
(126) 
GABARAPL1 ATF4 
C/EBPβ  
Estrogen-regulated 
FOXO1 
FOXO3 
 
GATA1 
Colorectal cancer, glioblastoma 
Liver (circadian rhythm) 
Glandular Epithelial Cells 
Cardiomyocytes, hepatocytes 
Cardiomyocytes, skeletal muscle, 
Erythropoiesis 
Erythropoiesis 
(101) 
(119) 
(124) 
(109,112) 
(108,111,112) 
(108) 
GABARAPL2 ATF4 
GATA1 
ZKSCAN3 (repressive) 
Mouse embryonic fibroblasts 
Erythropoiesis 
Bladder carcinoma 
(114) 
(108) 
(118) 
III. Post-translational modification  
The best understood post-translational modification of the LC3/GABARAP family protein 
is the conjugation to PE. This event determines the availability for the family protein to 
actively participate in autophagy or its related processes. Other post-translational modi-
fications of LC3/GABARAP family proteins are still poorly understood.  
Phosphorylation: LC3B phosphorylation by Serine/threonine-protein kinase 3 (STK3) and 
Serine/threonine-protein kinase 4 (STK4) is important in lysosomal fusion. Failure to 
phosphorylate LC3B-Thr50 results in failure of fusion of autophagosomes with lyso-
somes and inhibition of autophagic flux (127). Interestingly, Thr50 is conserved in LC3A-
a and –b and LC3C, but is absent in the GABARAP family proteins (Fig. 2). In addition, 
Protein Kinase A (PKA) phosphorylates murine LC3B at serine 12 which restrains LC3B 
conjugation and autophagosome association. During nutrient depleted conditions PKA 
activity decreases, leading to rapid activation and availability of LC3B for the execution 
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of autophagy (128). Thus, PKA suppresses autophagy and allows existence of a phos-
phorylated, unconjugated LC3B pool. This pool is then readily available for rapid induc-
tion of autophagy. In humans, the 12th amino acid of LC3B is a threonine. Yet, PKA is 
capable of phosphorylating both serine and threonine residues (129). In LC3A-a, LC3C 
and GABARAPL2 a serine is observed at position 12 (Fig. 2). While this suggests that the 
post-translational phosphorylation status of LC3B can regulate the size of the protein 
pool available for conjugation, it remains unknown, however plausible, if these events 
regulate other LC3/GABARAP family proteins.  
Acetylation: LC3B cycles between nucleus and cytoplasm a process which is regulated 
by acetylation of LC3B at Lys49 and Lys51 which prevents LC3B from entering the cyto-
plasm and interaction with ATG7 for further processing. Nutrient deprivation results in 
deacetylation of nuclear LC3B by sirtuin 1 (SIRT1) leading to an increased cytoplasmic 
translocation and available substrate for ATG7 (130). Interestingly, both lysine residues 
at 49 and 51 are present in all LC3/GABARAP family proteins, suggesting a common 
regulatory mechanism for availability. These insights suggest that post-translational 
modifications are an important system for regulation LC3B availability and rapid induc-
tion of autophagy. If this type of regulation is important for the other LC3/GABARAP 
family proteins remains to be investigated.  
 
 
Figure 2. LC3/GABARAP family protein alignment.  
The alignment of human LC3/GABARAP displays 27 conserved amino acids in for all proteins (*). This includes 
the glycine (grey) for PE –conjugation. Potential phosphorylation (yellow) and acetylation (green) events are 
indicated.  
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Table 2: LC3/GABARAP family proteins transcription factors 
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Functional variance by differential (affinity in) binding partners between 
LC3/GABARAP family proteins 
Besides similarities, functional differences are attributed to LC3/GABARAP family pro-
teins. Important in establishing these differences are the interactions with binding part-
ners. Interestingly, extensive proteomics analysis of binding partners of LC3/GABARAP 
family proteins has demonstrated that there is overlap in interactome; however, more 
importantly, that there are clear differences in binding partners. These data are gener-
ated based on pull-down assays and will be vital in identifying differences in affinity, 
specificity in function and biological relevance (37).  
The difference in interactome for the LC3/GABARAP family proteins may depend on 
differential properties of the LC3/GABARAP family proteins. The structure of the 
LC3/GABARAP family proteins comprises a carboxyl-terminus ubiquitin-like (UBL) core (a 
conserved ubiquitin fold) and two amino-terminal helices. Binding of the LIR to the 
LC3/GABARAP family protein occurs at the interface of the amino-terminal arm and the 
UBL core. The surface of helix 1 of LC3 is basic compared to the acidic nature of 
GABARAPL2 and GABARAP. The surface of helix 2 is acidic, neutral and basic for respec-
tively LC3, GABARAPL2 and GABARAP. The difference in helices 1 and 2 electrostatic 
surface potential in LC3/GABARAP family proteins together with differences in the LIR in 
autophagy receptors contributes to variation in binding partners (10). This is also illus-
trated by the total number of interacting proteins, of which approximately one-third are 
specific for LC3 subfamily, one-third specific for GABARAP subfamily and one-third is 
associated with both (37). An interesting example in this context is LC3C. According to 
proteomic analysis, LC3C has the least overlapping interactors. Properties of LC3C and 
its unique interacting partner NDP52 have established its indispensable function in 
xenophagy.  
This emphasizes that subtle differences between proteins allow specific interactions 
and illustrates the complexity of their functions.  
Closing remarks 
There are at least seven orthologues of yeast Atg8 known in humans. Despite the high 
structural similarities between the LC3/GABARAP family proteins, the existing differ-
ences in LIR, amino terminal helices and conformation that makes each family protein 
unique in binding partners and function. Valuable data on e.g. pull-down assays which 
contribute to mapping the autophagy interaction network (37) have provided important 
insights in the interactome. Their roles in autophagy and specific sequestration of cargo 
are diverse. How the cell orchestrates this complex recruitment to fulfill these specific 
functions is highlighted in this review. Differences in conjugation (stress-induced regula-
tion; dependent on vesicle curvature), binding partners and expression (via differential 
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transcriptional regulation) and post-translational regulation ((de)phosphorylation and 
(de)acetylation events), contribute to the systems complexity. Increasing evidence indi-
cates that the LC3/GABARAP proteins display functions that are unrelated to canonical 
autophagy. This has important implications for functional experiments using knockdown 
models or factors that influence expression of the family proteins. Unravelling the role 
of the individual LC3/GABARAP family proteins is important to distinguish specialized 
functions attributed to each specific family protein for autophagy (un)related functions.  
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Abstract 
Background and purpose The epidermal growth factor receptor (EGFR) is overexpressed, 
amplified or mutated in various human epithelial tumours and hypoxia is a common 
feature of solid tumours. Both EGFR and hypoxia are associated with therapy resistance 
and poor treatment outcome. To survive hypoxia, cells adapt by activation of hypoxia 
responsive pathways and expression of hypoxia-induced plasma membrane proteins. 
We observed that GABAA receptor associated protein like1 (GABARAPL1) and plasma 
membrane expression of EGFR were increased during hypoxia. Here we explored the 
role of the GABARAPL1 in EGFR membrane expression during hypoxia.  
Material and methods Quantitative qPCR, immunoblot analysis, flow cytometry and 
cytochemistry were used to assess this interplay.  
Results GABARAPL1 mRNA and protein levels are increased during hypoxia in vitro and 
correlate with tumour hypoxia in a panel of primary HNSCC xenografts. High 
GABARAPL1 mRNA is associated with poor outcome of HNSCC patients. During hypoxia, 
EGFR membrane expression is increased and GABARAPL1 and EGFR colocalize at the 
plasma membrane. GABARAPL1 knockdown inhibits EGFR membrane expression during 
hypoxia.  
Conclusion GABARAPL1 is required for increased membrane expression of EGFR during 
hypoxia, suggesting a role for GABARAPL1 in the trafficking of these membrane pro-
teins. 
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Introduction 
Solid tumours are characterized by the presence of abnormal and immature vasculature 
that leads to extreme homogeneities in oxygenation. Oxygenation in these regions var-
ies from normal (approx. 5% O2) to severe hypoxia and even anoxia [1, 2]. Tumour cells 
within hypoxic regions contribute to increased invasion [3], metastatic spread [4] and 
therapy resistance [5].  
For survival, cancer cells adapt to hypoxia by activation of several signalling path-
ways including the hypoxia inducible factor (HIF) pathway and the unfolded protein 
response (UPR). During normoxic conditions, the HIF-1α protein is ubiquitylated and 
rapidly degraded. HIF1α is stabilized during hypoxia and modifies the microenvironment 
by upregulating expression of several proteins. For example, through increasing vascular 
endothelial growth factor (VEGF) expression and induction of angiogenesis [6]. Other 
HIF1 transcriptional targets are carbonic anhydrase 9 (CA9) and Glucose Transporter 1 
(GLUT1). These proteins are respectively involved in deacidification and increased glu-
cose uptake during hypoxia [7].  
The UPR is activated during hypoxia as a consequence of increased misfolded or un-
folded proteins [8]. The UPR constitutes of three parallel signalling cascades initiated by 
PERK (PKR-like ER kinase), IRE1 (inositol-requiring protein 1) and ATF6 (activating tran-
scription factor 6). PERK is a kinase that phosphorylates eIF2α to inhibit translation 
initiation. The blockade in overall protein translation allows selective translation of the 
transcription factor, ATF4 [9], and subsequently CHOP [10]. The UPR is important for 
inhibition of mRNA translation [11], promote ER homeostasis [12], increasing the cell’s 
antioxidant capacity [13] and induce expression of several autophagy-related genes [14] 
[15] during hypoxia.  
Epidermal growth factor receptor (EGFR) signalling is increased in many cancer 
types due to overexpression, amplification or mutation. Activation of the receptor leads 
to a cascade of signalling pathways that control growth, migration and differentiation 
and acquisition of an EMT-like phenotype [16]. EGFR is upregulated during hypoxia [17] 
and combined targeting of EGFR and hypoxia modification is expected to increase tu-
mour responsiveness to radiotherapy [18]. 
After production, membrane proteins, including EGFR, require active transportation 
to the plasma membrane. GABARAPL1 is a member of the GABARAP protein family, 
which consists of 3 members, GABARAP, GABARAPL1 and gate-16/GABARAPL2. Alt-
hough their function is largely unknown, they are implicated in several vesicular mecha-
nisms as autophagy and receptor trafficking. For example, GABARAPL1 promotes cell 
surface expression of the Kappa Opioid Receptor (KOR) by facilitating its trafficking 
along the secretory pathway. Accordingly, knockdown of GABARAPL1 decreases the 
surface expression of KOR [19]. Binding of GABARAPL1 to the KOR is based on hydro-
phobic interactions, and the N-terminal region of GABARAPL1 is important for binding 
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hough their function is largely unknown, they are implicated in several vesicular mecha-
nisms as autophagy and receptor trafficking. For example, GABARAPL1 promotes cell 
surface expression of the Kappa Opioid Receptor (KOR) by facilitating its trafficking 
along the secretory pathway. Accordingly, knockdown of GABARAPL1 decreases the 
surface expression of KOR [19]. Binding of GABARAPL1 to the KOR is based on hydro-
phobic interactions, and the N-terminal region of GABARAPL1 is important for binding 
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to tubulin and surface expression of the KOR [20]. In addition, the tubulin binding region 
is important for GABAA receptor clustering [21]. 
We observed that EGFR membrane expression and GABARAPL1 production are in-
creased during hypoxia. We therefore hypothesized that GABARAPL1 mediates in-
creased EGFR membrane-expression.  
Material and methods 
Cell culture Colorectal adenocarcinoma (HT29, HCT116), mammary adenocarcinoma 
(MCF7), glioblastoma astrocytoma (U87, U373) cells and large cell lung cancer (H460) 
were maintained as described by ATCC. Doxycycline-inducible (1µg/ml) shRNA targeting 
GABARAPL1 [TTACCTTACTTCATACTTGCCC] or scrambled control [CGAGGGCGACTTAAC-
CTTAGG] was achieved through lentiviral pTripZ (Thermo Scientific) expression as de-
scribed previously [14]. Knockdown of UPR components (siRNAs) and HIF1α (shRNA 
expression) was done as described previously [15]. Hypoxia exposure was done using a 
MACS VA500 workstation (Don Whitley Scientific) that allows maintaining a stable O2 
concentration over time due to continuous gas influx.  
Immunoblot Cells were lysed and processed as described previously [11]. Proteins were 
probed with antibodies against GABARAPL1 (Proteintech group, 11010-1-AP), EGFR 
(SC03, Santa Cruz), eIF4E, p-ERK (Cell signaling) and Beta-Actin (MP Biomedicals). Bound 
antibodies were visualized using HRP-linked antibodies (Cell Signaling). 
Membrane isolation Cells were exposed to anoxia (O2< 0.02 %), trypsinized and resus-
pended in hypotonic swelling buffer (10mM Tris, 1mM β-mercaptoethanol, 100 µm 
EDTA and HEPES, pH 7,3) for 1h on ice. Cell ghosts were ultracentrifuged at 145000xg 
for 30 minutes and analysed by western blot.  
Clinical study GABARAPL1 mRNA expression was determined by quantitative PCR in 86 
head and neck cancer patients [22]) and used to median-dichotomize the patient co-
hort. Differences between patient characteristics (Suppl table1) were assessed with a 
χ2-test or student’s t-test. Differences in recurrence-free survival were determined 
using Kaplan-Meier survival analysis and Log-Rank (Mantel-Cox) test. 
Immunofluorescence Cells were fixed with 4% paraformaldehyde, permeabilized, 
blocked and probed with anti-GABARAPL1 (Aviva Systems Biology, ARP55398_P050) and 
anti-EGFR (Oregon Green-labeled Cetuximab). Anti-GABARAPL1 was visualized using 
goat anti-rabbit Alexa-555 (Invitrogen, A-21428).  
Quantitative real-time PCR mRNA was isolated with NucleoSpin RNA II kit (Bioke) and 
reverse transcribed using I-script (BIO-RAD). Expression was normalized to 18S. Primers 
used are listed in Supplementary table 2.  
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Flow cytometry single cells were labelled with anti-EGFR (Cetuximab-oregon green) or 
anti-CA9-hiLyte-488(Novus Biologicals) and anti-GLUT1-APC(BD biosciences) Membrane 
expression was determined by flow cytometry..  
Click-it chemistry: After 16 hours of anoxia exposure, azide-labeled methionine (L-AHA) 
was allowed to incorporate for 8 hours. Subsequently, cells were trypsinised and la-
belled by click-it chemistry according to the manual (Thermo Fisher) and analysed by 
flow cytometry. 
Statistics Data were analysed using GraphPad Prism. Student’s t test was used for single 
comparisons. Multiple testing was done using a repeated measures ANOVA with a Bon-
ferroni post-hoc test. P-values < 0.05 were considered statistically significant. 
Results 
GABARAPL1 expression is increased during hypoxia 
Previously, microarray analysis on HT29, MCF7 and DU145 cancer cell lines during hy-
poxia (O2<0.02%) were performed [23]. In all three cell lines, hypoxia increased 
GABARAPL1 mRNA expression (Suppl. Fig. 1A). These results were validated on inde-
pendent experiments by qPCR analysis of HT29, MCF7, DU145, U87 (Fig. 1A), U373 
(fig1B) and HCT116 (fig1C) cells. GABARAPL1 induction is dependent on severity of hy-
poxia as moderate hypoxia (0.2% O2) is less capable of inducing GABARAPL1 expression 
in HT29 and U373 cells (Suppl. Fig 1B) after 24 hours exposure. In line with RNA expres-
sion, GABARAPL1 protein expression levels are induced during anoxia (O2<0.02%) in U87 
and HT29 cells, but not in U373 (Fig. 1D). 
Cells adapt to hypoxia through activation of multiple pathways, including HIF and 
UPR signalling. We therefore investigated the contribution of these pathways to hypox-
ia-induced GABARAPL1 expression. Knockdown of HIF1α did not change the extent of 
GABARAPL1 upregulation in HT29 and U373 cells during hypoxia (Fig. 1C). Next, we 
investigated the three parallel arms of the UPR; PERK, ATF6 and IRE1. Knockdown of 
PERK, but not ATF6 or IRE1 abrogated hypoxia-induced GABARAPL1 mRNA expression 
(Fig. 1D). Downstream of PERK, targeting ATF4 or CHOP revealed that ATF4 is required 
for GABARAPL1 mRNA upregulation during hypoxia. Together, this indicates that tran-
scriptional upregulation of GABARAPL1 during hypoxia is mediated by PERK/ATF4 signal-
ling.  
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Figure 1. Increased GABARAPL1 expression is PERK/ATF4 dependent. 
(A) Transcriptional regulation of GABARAPL1 in HT29, MCF7, Du145 and U87 cancer cells during anoxia (O2 
<0.02%). (B) HIF1α knockdown (shHIF1α) in HT29 and U373 cells does not affect GABARAPL1 mRNA expres-
sion. (C) Transcriptional upregulation of GABARAPL1 during hypoxia is dependent on PERK/ATF4 signaling. A-C, 
n=3, mean±SEM. (D) GABARAPL1 protein expression in induced during anoxia (O2<0.02%) 
GABARAPL1 mRNA expression correlates with tumour hypoxia and poor clinical 
outcome 
As GABARAPL1 is upregulated during hypoxia, we assessed whether GABARAPL1 mRNA 
expression could serve as surrogate marker for tumour hypoxia. In a panel of 14 primary 
human head and neck squamous cell carcinoma (HNSCC) xenografts [24], GABARAPL1 
mRNA expression and hypoxia (pimonidazole) were determined. The hypoxic fraction 
[25] correlated with GABARAPL1 mRNA expression (Fig. 2A; Pearson r=0.63; p<0.05), 
suggesting that GABARAPL1 mRNA can be used as a surrogate marker for tumour hy-
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poxia in HNSCC. In agreement with the PERK/ATF4-dependence, GABARAPL1 mRNA 
expression correlates with another UPR-dependent hypoxia regulated gene, LC3b 
[15](Fig. 2B; Pearson r=0.54; p<0.05). 
 
 
Figure 2. GABARAPL1 mRNA expression correlates with tumour hypoxia and poor clinical outcome. 
(A) In 14 HNSCC xenografts, GABARAPL1 mRNA expression was determined and correlated with (hypoxic 
fraction) (pimonidazole) and (B) LC3b mRNA. (C) high GABARAPL1 mRNA expression is associated with in-
creased local (p=0.10) and (D) locoregional recurrences (p=0.03) in a cohort of 86 HNSCC patients. 
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Tumour hypoxia is a negative prognostic and predictive factor of patient outcome as it 
decreases the efficacy of radio- and chemotherapy. This has been particularly well es-
tablished in HNSCC [26, 27].  
We therefore questioned if GABARAPL1 expression has prognostic value in a cohort of 
86 HNSCC patients after chemoradiation [22]. Local (p=0.19) and locoregional (p=0.038) 
control was worse in patients with high GABARAPL1 expressing tumours (Fig. 2C and 2D)  
GABARAPL1 is required for increased EGFR membrane expression during hypoxia 
Recent reports indicate that EGFR expression is increased during hypoxia [17]. To inves-
tigate if GABARAPL1 mediates EGFR membrane expression, cellular localization was 
assessed using confocal microscopy. In U87 cells, GABARAPL1 is present in a typical 
vesicle-like pattern. During anoxia, GABARAPL1 is also observed at the cellular perime-
ter and colocalizes with EGFR at the plasma membrane (fig 3A). In accordance, both 
EGFR and GABARAPL1 are enriched in the membrane fraction of anoxia exposed HT29 
cells (Fig. 3B). 
To determine if GABARAPL1 is involved EGFR membrane-expression, doxycycline-
inducible GABARAPL1 knockdown cells were engineered (Fig 3C). EGFR expression at 
the plasma membrane of control and GABARAPL1 knockdown in HT29, U373, MDA-
MB231 and U87 cells after exposure to hypoxia (O2 0.2%) and anoxia (O2< 0.02 %) was 
determined by flow cytometry.  
EGFR membrane expression is induced in all control (SCR) cell lines during hypoxia 
and anoxia (Fig 3D). This increased EGFR membrane expression was inhibited after 
GABARAPL1 knockdown (Fig 3D) 
To determine if the reduced EGFR membrane expression is the result of a reduced 
total EGFR expression, EGFR mRNA and total protein expression was determined. Dur-
ing hypoxic and anoxic conditions, EGFR mRNA and total protein levels are not altered 
or even increased in GABARAPL1 knockdown cells (Fig 3F). Notably, EGFR mRNA of 
U373 and MDA-MB-231 GABARAPL1 knockdown cells during normoxic conditions was 
increased (FIG 3E).  
To determine if GABARAPL1 is required uniquely for EGFR trafficking during hypoxia, 
overall membrane protein expression in SCR control and GABARAPL1 knockdown cells 
was determined using click-it chemistry. GABARAPL1 knockdown reduces membrane 
protein expression in both HT29 (23%) and MCF7 (43%), indicating a role in protein 
trafficking broader than EGFR (Fig 3G). In line, CA9 plasma membrane expression was 
decreased after GABARAPL1 knockdown in 4 cell lines tested (Suppl fig 2A). Reduced 
CA9 membrane expression was not caused by reduced production in GABARAPL1 
knockdown cells as indicated by total protein expression (Fig 3F) and qPCR (Suppl. Fig 
2C). Interestingly, in contrast to EGFR and CA9, GLUT1 membrane expression is not 
affected by GABARAPL1 knockdown, despite increased CA9 and GLUT mRNA expression 
in MDA-MD-231 GABARAPL1 knockdown cells (Suppl Fig 2C and 2D). 
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Figure 3. GABARAPL1 is required for increased EGFR membrane expression during hypoxia.  
(A) Immunofluoresent staining of GABARAPL1(red) and EGFR(green) in U87 cells. (B) immunoblot of total and 
membrane fraction of anoxic HT29 cells. (C) GABARAPL1 knockdown cell lines. (D) FACS analysis of EGFR 
membrane expression during hypoxic (O2 0.2 %), and anoxic (O2 <0.02 %), conditions n=4 mean±SEM (E) EGFR 
mRNA expression. n=3 mean±SEM (F) Immunoblot of total EGFR and CA9 levels (G) Membrane expression of 
proteins assessed by Click-it chemistry. 
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Discussion 
EGFR expression and tumour hypoxia are negative prognostic factors associated with 
poor treatment outcome. In this study we explored the role of GABARAPL1, which we 
identified as a hypoxia induced protein required for the trafficking of EGFR to the plas-
ma membrane during hypoxia.  
Here we show that the GABARAP family member GABARAPL1 is induced during hy-
poxia on both mRNA and protein levels. Interestingly, other GABARAP family members, 
GABARAP and GABARAPL2, are not induced during hypoxia, suggesting a differential 
role for gabarapl1 during these conditions (data not shown). Several proteins, including 
EGFR can be upregulated during hypoxia [17] and require transportation to the mem-
brane. Since the GABARAP family is implicated in several processes like anterograde 
trafficking of several receptors like the Kappa Opioid Receptor [19], angiotensin [28, 
29]and GABAA receptor[30] we questioned the role of GABARAPL1 in EGFR trafficking. 
EGFR and other growth factor receptors are often amplified or mutated in cancer and 
may promote hypoxia tolerance [16, 31]. In this report we show that the membrane 
expression of EGFR is elevated during hypoxia and that this effect is GABARAPL1 de-
pendent. It is therefore tempting to speculate that the observed relation between high 
GABARAPL1 and outcome is partly mediated through facilitating enhanced EGFR-
signalling.  
Hypoxia induced membrane expression of EGFR in most of the cell lines tested. Alt-
hough consistent, this was less pronounced in the parental cell lines compared to the 
genetically modified cell lines (Suppl Fig 3). In the pTRIPZ lentiviral system, parallel to 
shRNA expression, red fluorescent protein is expressed. This may lead to increased 
misfolding of proteins and/or ROS formation and may contribute to increased EGFR 
upregulation during hypoxia in the transgenic cells. 
For efficient membrane expression and further downstream signalling, clustering of 
receptors, including EGFR is essential. Chen et al showed that the tubulin-binding motif 
of GABARAP is required for clustering of the GABAA receptor [32]. Also GABARAPL1 
contains this binding motif, which is located in the first 22 amino acids [33]. GABARAPL1 
acts as a linker between microtubules and the KOR to facilitate anterograde trafficking 
[34]. GABARAPL1 may act similarly in EGFR receptor clustering and/ or trafficking. 
Together our data support the specific expression and/or translocation of proteins 
during hypoxia that allow cells to adapt to conditions of low oxygenation. GABARAPL1 in 
this respect seems to fulfil a specific role in trafficking of EGFR and CA9.  
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genetically modified cell lines (Suppl Fig 3). In the pTRIPZ lentiviral system, parallel to 
shRNA expression, red fluorescent protein is expressed. This may lead to increased 
misfolding of proteins and/or ROS formation and may contribute to increased EGFR 
upregulation during hypoxia in the transgenic cells. 
For efficient membrane expression and further downstream signalling, clustering of 
receptors, including EGFR is essential. Chen et al showed that the tubulin-binding motif 
of GABARAP is required for clustering of the GABAA receptor [32]. Also GABARAPL1 
contains this binding motif, which is located in the first 22 amino acids [33]. GABARAPL1 
acts as a linker between microtubules and the KOR to facilitate anterograde trafficking 
[34]. GABARAPL1 may act similarly in EGFR receptor clustering and/ or trafficking. 
Together our data support the specific expression and/or translocation of proteins 
during hypoxia that allow cells to adapt to conditions of low oxygenation. GABARAPL1 in 
this respect seems to fulfil a specific role in trafficking of EGFR and CA9.  
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Supplementary Figure 1 
A) Micro array analysis shows an increased GABARAPL1 expression during hypoxia (O2 <0.02%) 
B) GABARAPL1 mRNA expression during hypoxia (O2 0.2%) as assessed by qPCR n=3 mean±SEM 
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Supplementary figure 2 
(A B) Membrane expression levels of CA9(A) and GLUT1(B) as determined by FACS in GABARAPL1 knockdown 
cells during hypoxia (O.2% O2) and anoxia (<0.02% O2). Shown graph is a representative example n=3. B) n=3 
mean ±SEM (C D) relative mRNA expression of CA9(C) and GLUT1(D) in GABARAPL1 knockdown cells during 
anoxia(<0.02% O2) n=4 mean±SEM 
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Supplementary figure 3 
Relative EGFR expression in parental cell lines as determined by FACS n=3 mean± SEM 
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Abstract  
Expression of EGFRvIII is frequently observed in glioblastoma and is associated with 
increased cellular proliferation, enhanced tolerance to metabolic stresses, accelerated 
tumour growth, therapy resistance and poor prognosis. We observed that expression of 
EGFRvIII elevates the activation of macroautophagy/autophagy during starvation and 
hypoxia and explored the underlying mechanism and consequence. Autophagy was 
inhibited (genetically or pharmacologically) and its consequence for tolerance to meta-
bolic stress and its therapeutic potential in (EGFRvIII+) glioblastoma was assessed in 
cellular systems, (patient derived) tumour xenografts and glioblastoma patients. Au-
tophagy inhibition abrogated the enhanced proliferation and survival advantage of 
EGFRvIII+ cells during stress conditions, decreased tumour hypoxia and delayed tumour 
growth in EGFRvIII+ tumours. These effects can be attributed to the supporting role of 
autophagy in meeting the high metabolic demand of EGFRvIII+ cells. As hypoxic tumour 
cells greatly contribute to therapy resistance, autophagy inhibition revokes the radiore-
sistant phenotype of EGFRvIII+ tumours in (patient derived) xenograft tumours. In line 
with these findings, retrospective analysis of glioblastoma patients indicated that chlo-
roquine treatment improves survival of all glioblastoma patients, but patients with EG-
FRvIII+ glioblastoma benefited most. Our findings disclose the unique autophagy de-
pendency of EGFRvIII+ glioblastoma as a therapeutic opportunity. Chloroquine treat-
ment may therefore be considered as an additional treatment strategy for glioblastoma 
patients and can reverse the worse prognosis of patients with EGFRvIII+ glioblastoma.  
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Introduction 
EGFR (epidermal growth factor receptor) is a transmembrane glycoprotein and 1 of 4 
members of the ERBB family of tyrosine kinase receptors. Binding of one of its natural 
ligands results in homo- or heterodimerization of the receptor, autophosphorylation 
and subsequent activation of signal transduction pathways. These pathways are in-
volved in regulating cellular proliferation, differentiation, and survival.(1,2) Although 
present in normal cells, EGFR is overexpressed in a variety of tumours and has been 
associated with poor prognosis and decreased survival (3). EGFR activation also plays a 
role in resistance to chemotherapy and radiation treatment in tumour cells (4,5).  
In cancer, EGFR is often mutated, leading to enhanced or sustained receptor signal-
ing. One of the most common variants of EGFR is an exon 2–7 deletion mutant, EGFRvIII 
(also termed ΔEGFR or de2-7EGFR) (6-9). This deletion results in a truncated receptor 
that lacks 267 amino acids in the extracellular binding domain. This deletion leads to 
important functional changes; the receptor is unable to bind its ligands, but becomes 
constitutively active, resulting in uncontrolled pro-oncogenic effects and thereby pro-
motes neoplastic transformation and tumourigenicity (10-13). EGFRvIII expression is 
observed in several malignancies, including glioblastoma (GBM), non-small lung cell 
carcinoma, breast cancer, prostate cancer and head and neck cancer (6,8,9) and is asso-
ciated with poor prognosis (14). In GBM patients with amplification of the EGFR gene, 
the overall prevalence of EGFRvIII is 50–60% (15) and has been reported to contribute 
to tumour stem cell maintenance (16-18). Expression of EGFRvIII greatly enhances GBM 
tumourigenicity in vivo (19,20) and stimulates cell invasion in vitro and in vivo (21,22).  
The tumour microenvironment is characterized by extreme heterogeneities in nutri-
ent supply and oxygenation that arise primarily due to a poorly developed and/or func-
tioning vascular network. Gradients of oxygenation exist around individual perfused 
vessels and range from normal values (~5% O2) near the vessel wall to anoxia in peri-
necrotic regions. Transient changes in blood flow also lead to strong temporal changes 
in oxygenation within specific tumour regions (23). The percentage of viable hypoxic 
tumour cells within individual tumours with otherwise similar clinical features varies 
tremendously among patients (24) and is clinically important because high levels of 
tumour hypoxia correlate with poor prognosis and a more aggressive phenotype (24-
26). The source of the variability in hypoxia among different tumours is likely due to the 
acquisition of changes that drive increased hypoxia tolerance (27). Strikingly, EGFRvIII 
expression in vivo is rapidly lost when tumour cells are cultured in vitro under nutrient-
rich conditions (28). This observation suggests that in the tumour microenvironment, 
which is characterized by heterogeneities in nutrient supply and oxygenation, EGFRvIII-
expressing tumour cells have a survival advantage, a finding supported by pre-clinical 
evidence (12,13). 
To survive starvation and hypoxia, cells respond by upregulation of autophagy 
(Greek for “self-eating”) (29,30). A number of recent studies have demonstrated that 
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tumour growth, therapy resistance and poor prognosis. We observed that expression of 
EGFRvIII elevates the activation of macroautophagy/autophagy during starvation and 
hypoxia and explored the underlying mechanism and consequence. Autophagy was 
inhibited (genetically or pharmacologically) and its consequence for tolerance to meta-
bolic stress and its therapeutic potential in (EGFRvIII+) glioblastoma was assessed in 
cellular systems, (patient derived) tumour xenografts and glioblastoma patients. Au-
tophagy inhibition abrogated the enhanced proliferation and survival advantage of 
EGFRvIII+ cells during stress conditions, decreased tumour hypoxia and delayed tumour 
growth in EGFRvIII+ tumours. These effects can be attributed to the supporting role of 
autophagy in meeting the high metabolic demand of EGFRvIII+ cells. As hypoxic tumour 
cells greatly contribute to therapy resistance, autophagy inhibition revokes the radiore-
sistant phenotype of EGFRvIII+ tumours in (patient derived) xenograft tumours. In line 
with these findings, retrospective analysis of glioblastoma patients indicated that chlo-
roquine treatment improves survival of all glioblastoma patients, but patients with EG-
FRvIII+ glioblastoma benefited most. Our findings disclose the unique autophagy de-
pendency of EGFRvIII+ glioblastoma as a therapeutic opportunity. Chloroquine treat-
ment may therefore be considered as an additional treatment strategy for glioblastoma 
patients and can reverse the worse prognosis of patients with EGFRvIII+ glioblastoma.  
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Introduction 
EGFR (epidermal growth factor receptor) is a transmembrane glycoprotein and 1 of 4 
members of the ERBB family of tyrosine kinase receptors. Binding of one of its natural 
ligands results in homo- or heterodimerization of the receptor, autophosphorylation 
and subsequent activation of signal transduction pathways. These pathways are in-
volved in regulating cellular proliferation, differentiation, and survival.(1,2) Although 
present in normal cells, EGFR is overexpressed in a variety of tumours and has been 
associated with poor prognosis and decreased survival (3). EGFR activation also plays a 
role in resistance to chemotherapy and radiation treatment in tumour cells (4,5).  
In cancer, EGFR is often mutated, leading to enhanced or sustained receptor signal-
ing. One of the most common variants of EGFR is an exon 2–7 deletion mutant, EGFRvIII 
(also termed ΔEGFR or de2-7EGFR) (6-9). This deletion results in a truncated receptor 
that lacks 267 amino acids in the extracellular binding domain. This deletion leads to 
important functional changes; the receptor is unable to bind its ligands, but becomes 
constitutively active, resulting in uncontrolled pro-oncogenic effects and thereby pro-
motes neoplastic transformation and tumourigenicity (10-13). EGFRvIII expression is 
observed in several malignancies, including glioblastoma (GBM), non-small lung cell 
carcinoma, breast cancer, prostate cancer and head and neck cancer (6,8,9) and is asso-
ciated with poor prognosis (14). In GBM patients with amplification of the EGFR gene, 
the overall prevalence of EGFRvIII is 50–60% (15) and has been reported to contribute 
to tumour stem cell maintenance (16-18). Expression of EGFRvIII greatly enhances GBM 
tumourigenicity in vivo (19,20) and stimulates cell invasion in vitro and in vivo (21,22).  
The tumour microenvironment is characterized by extreme heterogeneities in nutri-
ent supply and oxygenation that arise primarily due to a poorly developed and/or func-
tioning vascular network. Gradients of oxygenation exist around individual perfused 
vessels and range from normal values (~5% O2) near the vessel wall to anoxia in peri-
necrotic regions. Transient changes in blood flow also lead to strong temporal changes 
in oxygenation within specific tumour regions (23). The percentage of viable hypoxic 
tumour cells within individual tumours with otherwise similar clinical features varies 
tremendously among patients (24) and is clinically important because high levels of 
tumour hypoxia correlate with poor prognosis and a more aggressive phenotype (24-
26). The source of the variability in hypoxia among different tumours is likely due to the 
acquisition of changes that drive increased hypoxia tolerance (27). Strikingly, EGFRvIII 
expression in vivo is rapidly lost when tumour cells are cultured in vitro under nutrient-
rich conditions (28). This observation suggests that in the tumour microenvironment, 
which is characterized by heterogeneities in nutrient supply and oxygenation, EGFRvIII-
expressing tumour cells have a survival advantage, a finding supported by pre-clinical 
evidence (12,13). 
To survive starvation and hypoxia, cells respond by upregulation of autophagy 
(Greek for “self-eating”) (29,30). A number of recent studies have demonstrated that 
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human tumour cell lines induce autophagy when exposed in vitro to hypoxia and/or 
metabolic stress, (31-33) which mediates both selective and bulk degradation of pro-
teins, cytoplasmic content, and organelles, and enables a cell to recycle constituents 
and provide itself with the necessary nutrients to maintain energy levels, protein syn-
thesis and essential metabolic processes (34).  
Based on our observations that EGFRvIII expression results in increased autophagy 
activation in metabolically challenged cells, we hypothesized that the increased survival 
and growth of EGFRvIII-expressing cells and tumours during stressful conditions is sup-
ported by autophagy. Targeting autophagy could therefore be a potential tool to lower 
tolerance to metabolic stresses and increase cell killing of EGFRvIII-expressing GBM 
cells. 
Materials and Methods 
In vivo experiments 
Animal facilities and experiments were in accordance with local institutional guidelines 
and approved by the local animal welfare committee. Experiments were performed as 
described previously (33). Briefly, tumours were grown in NMRI-nu (nu/nu) female mice 
(Charles River). Cells in matrigel (BD Biosciences, 354234) were injected subcutaneously 
(1.5x106 cells). For the generation of primary human xenografts, a small piece of biopsy 
(approx. 1 mm3) was implanted for the generation of the first generation tumour 
(growth until 1 cm3). This tumour was cut into multiple pieces, implanted in recipient 
mice and experiments were subsequently performed on these 2nd generation tumours. 
Tumour size was assessed by caliper measurement in 3 orthogonal diameters. Mice 
treated with CQ (Sigma Aldrich, C6628) received 60 mg/kg CQ for 7 consecutive days. 
For radiation treatment, tumours were positioned in the irradiation field using a cus-
tom-built jig and irradiated with a single dose of 10 Gy (15 MeV e-) using a linear accel-
erator (Varian, Palo Alto, CA, USA)(35) Number of animals used are listed in the respec-
tive figure legend. 
Patient studies 
The retrospective analyses and the establishment of patient derived xenografts were 
approved by the respective local medical ethics committees. All patients with a primary 
GBM, treated in Maastricht with radiotherapy between 2007 and 2012 with sufficient 
histological tissue available and who had completed the planned treatment with te-
mozolomide (75mg/m2/day) and radiotherapy (60Gy), were included in the analysis (Fig. 
6B and table 1). The effect of CQ on prognosis in EGFRvIII-expressing GBM was evaluat-
ed on 43 GBM patients (of which sufficient tumour tissue was still available) that were 
included in a randomized, placebo controlled phase II trial (Fig. 6C and table 2) (36).  
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Reagents and cell lines 
Unless specified otherwise, all reagents were obtained from Sigma Chemical Co. (the 
Netherlands) and all electrophoresis reagents were from Bio-Rad (the Netherlands). 
MEM-α medium was obtained from Invitrogen (10370070). Glutamax-I (35050038) and 
pyruvate (11360039) were obtained from Life Technologies, DMEM (BE12-604F) and 
fetal bovine serum (FBS) were from GE-Healthcare. Glucose determination kits were 
purchased from Biosentec (010). Cell lines were obtained from and maintained as de-
scribed by ATCC (HTB-14 (U87) and HTB-17 (U373)), negative for mycoplasma contami-
nation (Lonza Mycoalerts, LT07-318). The cells’ origin was authenticated by STR analysis 
(Identicell). Cell lines that endogenously express EGFRvIII (DKMG and BS153) were kind-
ly provided by Malte Kriegs and Nina Struve (Hamburg, Germany) and maintained as 
described previously (37). For doxycycline (Sigma, D9891) inducible knockdown of Lc3b, 
shRNA [TTTCTCACTCTCATACACCTCT] (Sigma Aldrich, TRCN0000152696) was expressed 
from Tet-pLKO-puro (addgene, 21915; depositor Dmitri Wiederschain (38)) as described 
previously (39). ATG7 knockdown was induced using pTRIPZ lentiviral delivery of 
shATG7 [ATACAGTGTTCCAATAGCTGGG] (Dharmacon). Dominant negative ULK1K46I was 
used as described previously (40). Differences in autophagic flux were confirmed using 
mCherry-EGFP-LC3 expression from a pBabe-puro vector (addgene, 22418; depositor J. 
Debnath) (41).  
Western blotting 
Cells were lysed and processed as described previously (7) and proteins were separated 
through SDS-PAGE. After transfer, proteins were probed with antibodies against EGFR, 
EGFRvIII runs at lower height (Santa Cruz Biotechnology, sc-03), MAP1LC3B (Cell Signal-
ing Technology, 2775S), ACTB/actin (MP Biomedicals, 08961001), p-EGFRvIII (Cell Signal-
ing Technology, 3777), p-MAPK/ERK (Cell Signaling, 4370) or tubulin (Cell Signaling 
Technology, 2146). Bound antibodies were visualized using HRP-linked anti-rabbit (Cell 
Signaling Technology, 7074S) or anti-mouse (Cell Signaling Technology, 7076S) antibod-
ies. 
Immunofluorescence and immunohistochemistry 
For immunofluorescence, cells were grown on glass coverslips (VWR, 470019-016). 
After exposure, cells were washed and fixed in 4% paraformaldehyde (Sigma Aldrich, 
p6148). After permeabilization, cells were probed with anti-MAP1LC3B (Cell Signaling 
Technology, 2775S) followed by anti-rabbit Alexa Fluor 488 (Invitrogen, A11006). For 
EGFRvIII expression determination in tumours, formalin-fixed paraffin-embedded tissue 
slides were probed with antibodies directed against EGFRvIII (clone L8A4, kindly provid-
ed by Dr. Bigner [Duke University Medical Center, Durham, NC]). 
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For assessment of microenvironmental changes in the xenograft studies, frozen, ac-
etone-fixed sections were stained by using anti-pimonidazole (Hypoxyprobe Inc, HP4-
100kit), 9F1 (rat monoclonal antibody to mouse endothelium, Department of Pathology, 
Radboud University Medical Center) or anti-BrdU (Sigma-Aldrich, B8434; as described 
previously (33)). For quantitative analysis, the slides were scanned with a computerized 
digital image processing system by using a high-resolution intensified solid-state camera 
on a fluorescence microscope (Axioskop; Zeiss, the Netherlands) with a computer-
controlled motorized stepping stage (33).  
Proliferation assessment 
Cells were seeded in a 24-well culture plate (Greiner Bio One, 662160) and incubated 
under normal, serum starved or hypoxic conditions (0.2% O2). CQ was used at a concen-
tration of 5 µg/ml (Sigma Aldrich, C6628). Cellular density was determined using Cristal 
violet staining. 
Clonogenic survival assay 
Eight h after counting and seeding, cells were exposed to serum-free medium or hypox-
ia (O2 < 0.02%, Don Whitley, VA500) as described previously.(42) After exposure the 
medium was replaced with normal medium and cells were incubated under standard 
culture conditions until colonies formed (10 days). Colonies were visualized using 0.4% 
methylene blue in 70% ethanol staining. Only colonies consisting of ≥50 cells were 
counted. 
Statistics 
Statistical analyses were performed using graphpad software. When comparing 2 condi-
tions unpaired t-tests were used. For multiple comparisons, one way-ANOVA with Bon-
ferroni corrections were used. p-values <0.05 were considered statistically significant. 
Results 
EGFRvIII-expressing cells are highly dependent on autophagy during starvation 
EGFR is often overexpressed or mutated in diverse cancer types and especially in glio-
blastoma. One of the most commonly found mutations in EGFR is the constitutive active 
deletion variant EGFRvIII, which contributes to increased intrinsic radioresistance but 
also increases tolerance to microenvironmental factors that contribute to therapy re-
sistance (e.g., hypoxia) (24-26,43,44). The tumour microenvironment is characterized by 
the presence of regions that are low in oxygen (hypoxia) and nutrient supply. Previously 
we and others have shown that cells deprived of nutrients or oxygen rapidly activate 
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autophagy (31-33,45). Considering the high proliferation rate and nutritional demand of 
EGFRvIII-expressing cells, (46) we explored autophagic activity in EGFRvIII-expressing 
cells. Immunohistochemical analysis during serum-starved conditions revealed more 
and larger autophagosomes in the EGFRvIII-expressing cells compared to the control 
cells (Fig. 1A), suggesting changes in autophagic activity.  
The gold standard in autophagy activity determination, is the measurement of au-
tophagic flux. In short, during autophagy LC3B is partially degraded. Blocking lysosomal 
function prevents this degradation and the accumulation of this protein during these 
conditions reflects autophagic activity (flux). To achieve lysosomal inhibition, cells were 
exposed to nutrient deprivation in the absence and presence of the lysosomotropic 
drug, chloroquine (CQ, 5µg/ml). A faster and more pronounced induction of autophagy, 
as indicated by the accumulation of LC3B-II, was observed in the EGFRvIII-expressing 
U373 (Fig. 1B) and U-87 MG cells (Fig. 1C). Exposure to afatinib, an irreversible tyrosine 
kinase inhibitor, decreases autophagic flux in EGFRvIII-expressing cells in a dose-
dependent manner, indicating that the increased autophagic flux in EGFRvIII-expressing 
cells during starvation was EGFRvIII-activity dependent (Fig. S1A).  
To determine if the higher autophagic flux contributed to growth advantages of EG-
FRvIII-expressing cells, cellular proliferation during normal and starvation conditions 
was determined. CQ addition had no significant effect on proliferation of either control 
or EGFRvIII-expressing cells during normal culture conditions (Fig. 1D), indicating that 
the used concentration was non-toxic at this dose. During starvation, EGFRvIII-
expressing cells proliferated faster compared to control cells (Fig. 1E, p<0.05). This 
growth advantage was abrogated by the addition of CQ to the culture medium. To as-
sess whether autophagy inhibition alters survival of EGFRvIII-expressing cells, clonogen-
ic survival after serum deprivation was determined. Serum deprivation did not signifi-
cantly change clonogenic survival of control or EGFRvIII-expressing cells (Fig. 1F). How-
ever, CQ addition resulted in increased cell death of EGFRvIII-expressing cells (p<0.05 
Control +CQ versus EGFRvIII + CQ at t=4). Although CQ has been widely used as an in-
hibitor of autophagy, its effects are not solely restricted to the inhibition of autophagy. 
To confirm if the observed effects were dependent on autophagy, we engineered cells 
expressing a doxycycline-inducible shRNA directed against LC3B. In agreement with an 
autophagy dependence, targeting LC3B sensitized cells to serum deprivation. In line 
with our pharmacological data, this effect was most pronounced in EGFRvIII-expressing 
cells (Fig. 1G, p<0.05). 
Taken together, these data indicate that EGFRvIII-expressing cells activate autopha-
gy to a higher extent and are highly dependent on autophagy for survival in response to 
serum deprivation.  
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Figure 1. EGFRvIII-expressing cells display increased autophagy activation and dependence during serum-
starved conditions.  
(A) EGFRvIII-expressing cells display more and larger autophagosomes during starvation as assessed by immu-
nofluorescence (nuclei [DAPI] in blue, LC3B in green). Scale bars: 10 µm. Immunoblot analysis of control and 
EGFRvIII-expressing cells reveal elevated autophagic flux during serum-starved conditions in EGFRvIII-
expressing U373 (B) and U87-MG (C) cells. Proliferation curves under normal (D) and serum-starved (E) condi-
tions show that CQ (5 µg/ml) does not influence growth under normal conditions, but can abrogate the 
growth advantage of EGFRvIII-expressing cells during starvation. n=3, mean ± SEM. Clonogenic survival as-
sessment after serum starvation with or without addition of CQ (F) or expression of a shRNA targeting LC3B 
(G) indicate that the elevated survival advantage of EGFRvIII-expressing cells is autophagy dependent. n=3, 
mean ± SEM. SCR, scrambled control.  
EGFRvIII-expressing cells depend more on autophagy during hypoxia 
To assess if the enhanced autophagic response was restricted to serum deprivation or 
also applies to other types of metabolic stress present within the tumour microenvi-
ronment, we assessed the autophagic response and dependency on autophagy during 
hypoxic conditions. Similar to serum deprivation, EGFRvIII+ cells displayed an enhanced 
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autophagic flux compared to the control cells as indicated by faster LC3B-II accumula-
tion in the presence of CQ (5 µg/ml) in U373 (Fig. 2A) and U-87 MG cells (Fig. 2B). This 
was further confirmed using tandem mCherry-EGFP-LC3B expression in U373 cells. 
Although no clear differences could be observed during normal culture conditions (not 
shown), after 16 h hypoxia exposure, EGFRvIII+ cells displayed mostly red foci whereas 
EGFRvIII- cells also displayed green/yellow foci (Fig. 2C). These data indicate faster pro-
cessing of autophagosomes in EGFRvIII+ cells and support the flux analysis results seen 
by immunoblot.  
To assess the dependency on autophagy for the survival of EGFRvIII-expressing cells, 
clonogenic survival after hypoxia exposure was determined in the presence of CQ (Fig. 
2D) or after expressing a short hairpin that targets LC3B (Fig. 2E), or ATG7 (Fig. 2F) or 
after overexpression of dominant negative ULK1K46I (Fig. 2G). As reported previously, 
(12) EGFRvIII-expressing cells displayed a survival advantage in comparison to control 
cells, yet EGFRvIII-expressing cells were sensitized to hypoxia (O2<0.02%) more than 
control cells in the presence of CQ or after targeting autophagy genetically (Fig. 2C and 
D, both p<0.05 at t=3 and/or -4; Fig. 2F and G, p<0.05).  
In addition to analysis of cells that ectopically express EGFRvIII, we explored the au-
tophagy dependence of glioblastoma cells that endogenously express EGFRvIII. EG-
FRvIII-enriched populations were obtained after cell sorting (37). This way BS153 and 
DKMG isogenic cell populations have been obtained that lack EGFRvIII expression or are 
highly enriched for EGFRvIII expression (Fig. 2H). Also endogenous EGFRvIII+ cells dis-
played enhanced autophagic flux during hypoxia in BS153 (Fig. 2I) and DKMG (Fig. 2J) 
isogenic cell lines. This was further confirmed using mCherry-EGFP-LC3B expression in 
these cells. EGFRvIII+ cells displayed mostly mCherry-positive foci whereas EGFRvIII- also 
displayed yellow/green foci, suggesting a more rapid turnover of autophagosomes in 
EGFRvIII+ BS153 (Fig. 2K) and DKMG (Fig. 2L) cells. Due to their migratory character both 
BS153 and DKMG cells failed to form colonies. Therefore, the sensitivity of these cells to 
CQ (5 µg/ml) addition during hypoxia was assessed by chrystal violet staining after ex-
posure to hypoxia. During ambient air incubation, this concentration of CQ did not in-
fluence cell proliferation (Fig. S1B and C). As observed in ectopically expressing EGFRvIII+ 
cells, endogenously expressing EGFRvIII+ cells displayed a survival advantage during 
hypoxia in BS153 (Fig. 2M) and DKMG (Fig. 2N) cells. This survival advantage was fully 
abrogated in the presence of CQ. These data indicate that cells are highly dependent on 
autophagy for survival during hypoxia after ectopic, but also endogenous, expression of 
EGFRvIII. 
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Figure 1. EGFRvIII-expressing cells display increased autophagy activation and dependence during serum-
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EGFRvIII-expressing cells reveal elevated autophagic flux during serum-starved conditions in EGFRvIII-
expressing U373 (B) and U87-MG (C) cells. Proliferation curves under normal (D) and serum-starved (E) condi-
tions show that CQ (5 µg/ml) does not influence growth under normal conditions, but can abrogate the 
growth advantage of EGFRvIII-expressing cells during starvation. n=3, mean ± SEM. Clonogenic survival as-
sessment after serum starvation with or without addition of CQ (F) or expression of a shRNA targeting LC3B 
(G) indicate that the elevated survival advantage of EGFRvIII-expressing cells is autophagy dependent. n=3, 
mean ± SEM. SCR, scrambled control.  
EGFRvIII-expressing cells depend more on autophagy during hypoxia 
To assess if the enhanced autophagic response was restricted to serum deprivation or 
also applies to other types of metabolic stress present within the tumour microenvi-
ronment, we assessed the autophagic response and dependency on autophagy during 
hypoxic conditions. Similar to serum deprivation, EGFRvIII+ cells displayed an enhanced 
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autophagic flux compared to the control cells as indicated by faster LC3B-II accumula-
tion in the presence of CQ (5 µg/ml) in U373 (Fig. 2A) and U-87 MG cells (Fig. 2B). This 
was further confirmed using tandem mCherry-EGFP-LC3B expression in U373 cells. 
Although no clear differences could be observed during normal culture conditions (not 
shown), after 16 h hypoxia exposure, EGFRvIII+ cells displayed mostly red foci whereas 
EGFRvIII- cells also displayed green/yellow foci (Fig. 2C). These data indicate faster pro-
cessing of autophagosomes in EGFRvIII+ cells and support the flux analysis results seen 
by immunoblot.  
To assess the dependency on autophagy for the survival of EGFRvIII-expressing cells, 
clonogenic survival after hypoxia exposure was determined in the presence of CQ (Fig. 
2D) or after expressing a short hairpin that targets LC3B (Fig. 2E), or ATG7 (Fig. 2F) or 
after overexpression of dominant negative ULK1K46I (Fig. 2G). As reported previously, 
(12) EGFRvIII-expressing cells displayed a survival advantage in comparison to control 
cells, yet EGFRvIII-expressing cells were sensitized to hypoxia (O2<0.02%) more than 
control cells in the presence of CQ or after targeting autophagy genetically (Fig. 2C and 
D, both p<0.05 at t=3 and/or -4; Fig. 2F and G, p<0.05).  
In addition to analysis of cells that ectopically express EGFRvIII, we explored the au-
tophagy dependence of glioblastoma cells that endogenously express EGFRvIII. EG-
FRvIII-enriched populations were obtained after cell sorting (37). This way BS153 and 
DKMG isogenic cell populations have been obtained that lack EGFRvIII expression or are 
highly enriched for EGFRvIII expression (Fig. 2H). Also endogenous EGFRvIII+ cells dis-
played enhanced autophagic flux during hypoxia in BS153 (Fig. 2I) and DKMG (Fig. 2J) 
isogenic cell lines. This was further confirmed using mCherry-EGFP-LC3B expression in 
these cells. EGFRvIII+ cells displayed mostly mCherry-positive foci whereas EGFRvIII- also 
displayed yellow/green foci, suggesting a more rapid turnover of autophagosomes in 
EGFRvIII+ BS153 (Fig. 2K) and DKMG (Fig. 2L) cells. Due to their migratory character both 
BS153 and DKMG cells failed to form colonies. Therefore, the sensitivity of these cells to 
CQ (5 µg/ml) addition during hypoxia was assessed by chrystal violet staining after ex-
posure to hypoxia. During ambient air incubation, this concentration of CQ did not in-
fluence cell proliferation (Fig. S1B and C). As observed in ectopically expressing EGFRvIII+ 
cells, endogenously expressing EGFRvIII+ cells displayed a survival advantage during 
hypoxia in BS153 (Fig. 2M) and DKMG (Fig. 2N) cells. This survival advantage was fully 
abrogated in the presence of CQ. These data indicate that cells are highly dependent on 
autophagy for survival during hypoxia after ectopic, but also endogenous, expression of 
EGFRvIII. 
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Figure 2. Inhibition of the elevated autophagic response in EGFRvIII-expressing cells abrogates their survival 
advantage during hypoxia. Immunoblot analysis indicates elevated autophagy activation in EGFRvIII-
expressing U373  
(A) and U87 (B) cells during hypoxia. (C) Tandem GFP-mCherry-LC3B expression indicates elevated autophagic 
flux in EGFRvIII+ cells during hypoxia (24 h O2<0.02%). Scale bars: 2 µm. Autophagy inhibition either through 
CQ addition (5 µg/ml) (D) or shRNA expression directed against LC3B (E) abrogates the survival advantage of 
EGFRvIII-expressing cells as assessed by clonogenic survival assay. n=3, mean ± SEM (F) Targeting Atg7 
through expression of a shRNA (G) or ULK1 through expression of dominant negative ULK1K46I results in loss of 
survival advantage of EGFRvIII+ cells as determined by clonogenic survival assay after 48 h hypoxia (O2<0.02%). 
n=3, mean ± SEM (H) EGFR and EGFRvIII expression of BS153 and DKMG cell populations. Autophagic flux 
determination in (I) BS153 and (J) DKMG cells during hypoxia. Tandem GFP-mCherry-LC3B expression indi-
cates elevated autophagic flux in EGFRvIII+ (K) BS153 and (L) DKMG cells during hypoxia (24 h O2<0.02%). Scale 
bars: 2 µm. Autophagy inhibition through CQ addition (5µg/ml) abrogates the survival advantage of EGFRvIII+ 
(M) BS153 and (N) DKMG cells as assessed by crystal violet staining after hypoxia exposure. n=3, mean ± SEM.  
EGFRvIII-expressing xenografts depend on autophagy for accelerated regrowth 
after therapy 
To investigate the higher dependency of EGFRvIII-expressing cells on autophagy during 
metabolic stresses in vivo, control and EGFRvIII-expressing tumour xenografts were 
grown in nude mice (Fig. 3A) and treated with CQ (60 mg/kg daily). In line with previous 
results, (12) EGFRvIII tumours displayed accelerated growth compared to control tu-
mours (Fig. 3A). Interestingly, 7-day CQ treatment resulted in decreased growth (Fig. 
3B; 20% increase in doubling time for control tumours and 30% increase for EGFRvIII 
expressing tumours, both p<0.05). EGFRvIII expression was validated by immunohisto-
chemistry (Fig. 3C). 
CQ treatment changes the tumour microenvironment by decreasing the hypoxic 
fraction through reduced hypoxia tolerance (33) and increased perfusion (47). Our in 
vitro data suggest that EGFRvIII-expressing cells were more dependent on autophagy 
for survival during hypoxia (Fig. 2). In line with the observed increased intrinsic toler-
ance of EGFRvIII-expressing cells to hypoxia (Fig. 2 and ref. (12)), EGFRvIII-expressing 
tumours displayed a higher hypoxic fraction compared to control tumours as deter-
mined by pimonidazole immunohistochemistry (Fig. 3D). In both control tumours and 
EGFRvIII-expressing tumours CQ treatment resulted in a decrease in tumour hypoxia 
(Fig. 3D; p<0.05 in control, p<0.01 for EGFRvIII tumours), although this effect was most 
pronounced in EGFRvIII-expressing tumours.  
As expected, cellular proliferation, as determined by BrdU incorporation, was higher 
in EGFRvIII-expressing tumours compared to control tumours (Fig. S2A), but was unaf-
fected by CQ treatment, indicating that hypoxic cells contribute very little to prolifera-
tion in the tumour. In control tumours, CQ treatment increased vessel density (p<0.05) 
and may have contributed to the reduction in tumour hypoxia (Fig. S2B). In contrast, 
EGFRvIII tumours showed a high vessel density when untreated, but there CQ treatment 
reduced, although to a limited extent (18%), the vessel density (p<0.05). These results 
suggest that the effect of CQ on vessel function and abundance is phenotype depend-
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survival advantage of EGFRvIII+ cells as determined by clonogenic survival assay after 48 h hypoxia (O2<0.02%). 
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bars: 2 µm. Autophagy inhibition through CQ addition (5µg/ml) abrogates the survival advantage of EGFRvIII+ 
(M) BS153 and (N) DKMG cells as assessed by crystal violet staining after hypoxia exposure. n=3, mean ± SEM.  
EGFRvIII-expressing xenografts depend on autophagy for accelerated regrowth 
after therapy 
To investigate the higher dependency of EGFRvIII-expressing cells on autophagy during 
metabolic stresses in vivo, control and EGFRvIII-expressing tumour xenografts were 
grown in nude mice (Fig. 3A) and treated with CQ (60 mg/kg daily). In line with previous 
results, (12) EGFRvIII tumours displayed accelerated growth compared to control tu-
mours (Fig. 3A). Interestingly, 7-day CQ treatment resulted in decreased growth (Fig. 
3B; 20% increase in doubling time for control tumours and 30% increase for EGFRvIII 
expressing tumours, both p<0.05). EGFRvIII expression was validated by immunohisto-
chemistry (Fig. 3C). 
CQ treatment changes the tumour microenvironment by decreasing the hypoxic 
fraction through reduced hypoxia tolerance (33) and increased perfusion (47). Our in 
vitro data suggest that EGFRvIII-expressing cells were more dependent on autophagy 
for survival during hypoxia (Fig. 2). In line with the observed increased intrinsic toler-
ance of EGFRvIII-expressing cells to hypoxia (Fig. 2 and ref. (12)), EGFRvIII-expressing 
tumours displayed a higher hypoxic fraction compared to control tumours as deter-
mined by pimonidazole immunohistochemistry (Fig. 3D). In both control tumours and 
EGFRvIII-expressing tumours CQ treatment resulted in a decrease in tumour hypoxia 
(Fig. 3D; p<0.05 in control, p<0.01 for EGFRvIII tumours), although this effect was most 
pronounced in EGFRvIII-expressing tumours.  
As expected, cellular proliferation, as determined by BrdU incorporation, was higher 
in EGFRvIII-expressing tumours compared to control tumours (Fig. S2A), but was unaf-
fected by CQ treatment, indicating that hypoxic cells contribute very little to prolifera-
tion in the tumour. In control tumours, CQ treatment increased vessel density (p<0.05) 
and may have contributed to the reduction in tumour hypoxia (Fig. S2B). In contrast, 
EGFRvIII tumours showed a high vessel density when untreated, but there CQ treatment 
reduced, although to a limited extent (18%), the vessel density (p<0.05). These results 
suggest that the effect of CQ on vessel function and abundance is phenotype depend-
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ent. No differences in perfused vessels in either of the tumours were observed (Fig. 
S2C). In contrast, the necrotic fraction increased significantly after CQ treatment in 
EGFRvIII-expressing tumours (2.3 fold, p=0.01), but not in control tumours (Fig. 3E), 
suggesting that CQ treatment leads to cell death of EGFRvIII-expressing cells in vivo. 
 
 
Figure 3. CQ treatment reduces tumour growth and tumour hypoxia and increases tumour necrosis in EG-
FRvIII-expressing tumours.  
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(A) Growth curves of control U373 xenografts (open circles, n=6) or treated from day -7 to 0 with CQ (60 
mg/kg) (filled circles, n=5) and EGFRvIII-expressing U373 xenografts (open squares, n=7) treated with CQ 
(filled squares, n=7). (B) Doubling times of the corresponding tumours. (C) Immunohistochemical staining for 
EGFRvIII on control (upper panel) and EGFRvIII-expressing xenografts (lower panel). Scale bars: 2 mm. (D) (Left 
panel) Micrographs of pimonidazole-DAPI staining prior to and after 7 days CQ treatment on EGFRvIII-
expressing tumours. (Right panel) Quantification of the tumour hypoxic fraction (control n=6, control + CQ 
n=6, EGFRvIII n=5, EGFRvIII + CQ n=5). (E) (Left panel) Micrographs of hematoxylin and eosin staining prior to 
and after 7 days CQ treatment on EGFRvIII-expressing tumours. (Right panel) Quantification of tumour necro-
sis (control n=6, control + CQ n=6, EGFRvIII n=5, EGFRvIII + CQ n=5). 
 
Hypoxic cells contribute to radiotherapy resistance; we therefore determined whether 
the decrease in hypoxia after CQ administration could sensitize EGFRvIII-expressing 
tumours to irradiation. Control and EGFRvIII tumour bearing mice were treated with CQ 
for 7 days prior to irradiation and tumour regrowth was monitored. As expected, 
growth of control tumours was significantly delayed after a single, tumour specific, dose 
of 10 Gy and could be further delayed by CQ pre-treatment (Fig. 4A). EGFRvIII-
expressing tumours respond faster to irradiation, often an indication of a different type 
of cell death(48) but also regrow faster. Yet the effect of CQ pre-treatment on EGFRvIII-
expressing tumours postponed regrowth even further (Fig. 4A). To illustrate the differ-
ences in radiation sensitivity of the individual tumours, the data are replotted in Fig. 4B 
as Kaplan–Meier plots. Tumour irradiation extended the median survival of mice with 
control tumours from 20 to 31 days, and CQ pre-treatment increased median survival 
further to 40 days. The effect of CQ addition in EGFRvIII-expressing tumours was much 
larger as irradiation extended survival from 15 to 25 days, but in combination with CQ 
pre-treatment this survival was extended to 48 days (Fig. 4B). This effect was even more 
pronounced after a larger irradiation dose (15 Gy), showing an additional increase from 
61 to 108 days after CQ treatment prior to irradiation (Fig. S3).  
Expression of EGFRvIII on GBM cells is rapidly lost when cultured in vitro, suggesting 
a survival and/or selection advantage for EGFRvIII-expressing cells in the tumour micro-
environment. For this reason most studies on EGFRvIII are performed in established 
GBM cell lines in which EGFRvIII is ectopically expressed. These cells and xenografts 
might behave different than the original tumours as these cells are clearly not depend-
ent on EGFRvIII signalling for survival or growth, and expression levels of EGFRvIII may 
be much higher than endogenous levels. We have therefore generated primary tumour 
xenografts directly derived from a cancer patient (patient derived xenograft; PDX), with 
an EGFRvIII-positive GBM. These primary tumour xenografts are thought to better re-
semble and reflect the original tumour and its response to therapy. After growth as a 
xenograft, EGFRvIII expression was retained over generations, as determined by EG-
FRvIII-specific immunohistochemistry (Fig. 4C) and a substantial hypoxic fraction was 
observed (Fig. 4D, mean ± Stdev 0.15 ± 0.04, n=6). Similar to the ectopically EGFRvIII-
expressing tumours, CQ administration reduced tumour growth (18 to 28 days doubling 
time p<0.05) in endogenously expressing EGFRvIII-positive PDX (Fig. 4E), which resulted 
in an increase in median survival from 32 to 40 days (Fig. 4F). Tumour irradiation in-
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(A) Growth curves of control U373 xenografts (open circles, n=6) or treated from day -7 to 0 with CQ (60 
mg/kg) (filled circles, n=5) and EGFRvIII-expressing U373 xenografts (open squares, n=7) treated with CQ 
(filled squares, n=7). (B) Doubling times of the corresponding tumours. (C) Immunohistochemical staining for 
EGFRvIII on control (upper panel) and EGFRvIII-expressing xenografts (lower panel). Scale bars: 2 mm. (D) (Left 
panel) Micrographs of pimonidazole-DAPI staining prior to and after 7 days CQ treatment on EGFRvIII-
expressing tumours. (Right panel) Quantification of the tumour hypoxic fraction (control n=6, control + CQ 
n=6, EGFRvIII n=5, EGFRvIII + CQ n=5). (E) (Left panel) Micrographs of hematoxylin and eosin staining prior to 
and after 7 days CQ treatment on EGFRvIII-expressing tumours. (Right panel) Quantification of tumour necro-
sis (control n=6, control + CQ n=6, EGFRvIII n=5, EGFRvIII + CQ n=5). 
 
Hypoxic cells contribute to radiotherapy resistance; we therefore determined whether 
the decrease in hypoxia after CQ administration could sensitize EGFRvIII-expressing 
tumours to irradiation. Control and EGFRvIII tumour bearing mice were treated with CQ 
for 7 days prior to irradiation and tumour regrowth was monitored. As expected, 
growth of control tumours was significantly delayed after a single, tumour specific, dose 
of 10 Gy and could be further delayed by CQ pre-treatment (Fig. 4A). EGFRvIII-
expressing tumours respond faster to irradiation, often an indication of a different type 
of cell death(48) but also regrow faster. Yet the effect of CQ pre-treatment on EGFRvIII-
expressing tumours postponed regrowth even further (Fig. 4A). To illustrate the differ-
ences in radiation sensitivity of the individual tumours, the data are replotted in Fig. 4B 
as Kaplan–Meier plots. Tumour irradiation extended the median survival of mice with 
control tumours from 20 to 31 days, and CQ pre-treatment increased median survival 
further to 40 days. The effect of CQ addition in EGFRvIII-expressing tumours was much 
larger as irradiation extended survival from 15 to 25 days, but in combination with CQ 
pre-treatment this survival was extended to 48 days (Fig. 4B). This effect was even more 
pronounced after a larger irradiation dose (15 Gy), showing an additional increase from 
61 to 108 days after CQ treatment prior to irradiation (Fig. S3).  
Expression of EGFRvIII on GBM cells is rapidly lost when cultured in vitro, suggesting 
a survival and/or selection advantage for EGFRvIII-expressing cells in the tumour micro-
environment. For this reason most studies on EGFRvIII are performed in established 
GBM cell lines in which EGFRvIII is ectopically expressed. These cells and xenografts 
might behave different than the original tumours as these cells are clearly not depend-
ent on EGFRvIII signalling for survival or growth, and expression levels of EGFRvIII may 
be much higher than endogenous levels. We have therefore generated primary tumour 
xenografts directly derived from a cancer patient (patient derived xenograft; PDX), with 
an EGFRvIII-positive GBM. These primary tumour xenografts are thought to better re-
semble and reflect the original tumour and its response to therapy. After growth as a 
xenograft, EGFRvIII expression was retained over generations, as determined by EG-
FRvIII-specific immunohistochemistry (Fig. 4C) and a substantial hypoxic fraction was 
observed (Fig. 4D, mean ± Stdev 0.15 ± 0.04, n=6). Similar to the ectopically EGFRvIII-
expressing tumours, CQ administration reduced tumour growth (18 to 28 days doubling 
time p<0.05) in endogenously expressing EGFRvIII-positive PDX (Fig. 4E), which resulted 
in an increase in median survival from 32 to 40 days (Fig. 4F). Tumour irradiation in-
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creased median survival to 66 days and could be increased by CQ administration to 102 
days post treatment. Together, these data indicate that autophagy is a therapeutic 
vulnerability of EGFRvIII-expressing GBM that can be exploited by CQ administration.  
 
 
Figure 4. CQ treatment sensitizes EGFRvIII-expressing tumours to irradiation.  
(A) Growth curves of U373 xenografts: untreated (dashed lines; control [blue, n=6], EGFRvIII[(red, n=7]), 
treated with a single, tumour-specific dose of 10 Gy at t=0 (interrupted line; control [blue, n=8], EGFRvIII [red, 
n=7]) or irradiated after 7 days CQ (60 mg/kg) pre-treatment from t = -7 to t = 0 and irradiated with a single, 
tumour-specific dose of 10 Gy at t = 0 (solid lines; control [blue, n=9], EGFRvIII [red n=11]). (B) Kaplan-Meier 
representations of the time to reach 4x the treated volume (from t = 0). Immunohistochemical staining for (C) 
EGFRvIII (scale bar: 50 μm) and (D) pimonidazole of PDX (scale bar: 2 mm), indicating EGFRvIII positivity and a 
substantial hypoxic fraction. (E) Growth curves of the PDX untreated (black closed circles, n=5), treated with 
CQ (60 mg/kg) for 7 days from t = -7 to t = 0 (open circles, n=5), treated with a single, tumour-specific dose, of 
10 Gy at t = 0 (gray closed circles, n=4) and treated with CQ (60 mg/kg) for 7 days from t = -7 to t = 0 followed 
by a single, tumour-specific dose, of 10 Gy at t = 0 (gray open circles, n=5). (F) Kaplan-Meier representations 
of the time to reach 4x the treated volume (from t = 0).  
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EGFRvIII-expressing cells are dependent on autophagy due to a high metabolic 
demand 
As EGFRvIII-expressing cells appear to be more dependent on autophagy for their sur-
vival during metabolic stress, we hypothesized that autophagy supports the high meta-
bolic demand of EGFRvIII-expressing cells.(46) We therefore assessed glucose abun-
dance in the medium of control and EGFRvIII-expressing cells. Although glucose con-
sumption was higher under normal culture conditions in EGFRvIII-expressing cells, the 
addition of CQ (5 µg/ml) did not change glucose consumption under ambient oxygen 
conditions (Fig. 5A, p<0.05 at t=24). As expected, glucose consumption increased during 
hypoxia (Fig. 5A). Interestingly, CQ addition did not change glucose consumption of 
control cells, but increased glucose consumption by EGFRvIII-expressing cells (Fig. 5A). 
Comparable to CQ, inhibition of autophagy through targeting LC3B, increased glucose 
consumption in EGFRvIII-expressing cells (Fig. 5B) during hypoxia, but also increased 
glucose consumption in control cells. This illustrates that besides autophagy, CQ and 
LC3B may also be involved or influence other processes. 
The increased glucose metabolism after inhibition of autophagy during hypoxia in 
EGFRvIII cells, suggests that autophagy is used as an alternative mechanism required in 
support of the high metabolic demand and energy production. We therefore ques-
tioned whether the elevated autophagic flux in EGFRvIII cells during hypoxia is required 
to meet this demand. We therefore assessed autophagic flux after provision of additive 
external resources (glucose and pyruvate) for metabolic processing. In control cells, no 
changes in flux were observed after addition of glucose and/or pyruvate (Fig. 5C). In 
contrast, in EGFRvIII-expressing cells, addition of pyruvate, but not glucose, rescued the 
elevated autophagic flux. We hypothesized that failure to meet the high metabolic 
demand, for example through autophagy inhibition, results in cell death of EGFRvIII-
expressing cells. To test this, we exposed control and EGFRvIII-expressing cells to hypox-
ia for 48 h in the presence or absence of CQ (Fig. 5D) or short hairpins targeting LC3B 
(Fig. 5E), supplemented the culture medium with additional pyruvate and assessed 
clonogenic survival. Interestingly, the addition of pyruvate rescued cell death in autoph-
agy-deficient EGFRvIII-expressing cells (p<0.01 in Fig. 5D and E), but not in control cells. 
This illustrates the therapeutic potential of targeting the high metabolic demand of 
EGFRvIII-expressing cells and tumours through inhibition of autophagy.  
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CQ (60 mg/kg) for 7 days from t = -7 to t = 0 (open circles, n=5), treated with a single, tumour-specific dose, of 
10 Gy at t = 0 (gray closed circles, n=4) and treated with CQ (60 mg/kg) for 7 days from t = -7 to t = 0 followed 
by a single, tumour-specific dose, of 10 Gy at t = 0 (gray open circles, n=5). (F) Kaplan-Meier representations 
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EGFRvIII-expressing cells are dependent on autophagy due to a high metabolic 
demand 
As EGFRvIII-expressing cells appear to be more dependent on autophagy for their sur-
vival during metabolic stress, we hypothesized that autophagy supports the high meta-
bolic demand of EGFRvIII-expressing cells.(46) We therefore assessed glucose abun-
dance in the medium of control and EGFRvIII-expressing cells. Although glucose con-
sumption was higher under normal culture conditions in EGFRvIII-expressing cells, the 
addition of CQ (5 µg/ml) did not change glucose consumption under ambient oxygen 
conditions (Fig. 5A, p<0.05 at t=24). As expected, glucose consumption increased during 
hypoxia (Fig. 5A). Interestingly, CQ addition did not change glucose consumption of 
control cells, but increased glucose consumption by EGFRvIII-expressing cells (Fig. 5A). 
Comparable to CQ, inhibition of autophagy through targeting LC3B, increased glucose 
consumption in EGFRvIII-expressing cells (Fig. 5B) during hypoxia, but also increased 
glucose consumption in control cells. This illustrates that besides autophagy, CQ and 
LC3B may also be involved or influence other processes. 
The increased glucose metabolism after inhibition of autophagy during hypoxia in 
EGFRvIII cells, suggests that autophagy is used as an alternative mechanism required in 
support of the high metabolic demand and energy production. We therefore ques-
tioned whether the elevated autophagic flux in EGFRvIII cells during hypoxia is required 
to meet this demand. We therefore assessed autophagic flux after provision of additive 
external resources (glucose and pyruvate) for metabolic processing. In control cells, no 
changes in flux were observed after addition of glucose and/or pyruvate (Fig. 5C). In 
contrast, in EGFRvIII-expressing cells, addition of pyruvate, but not glucose, rescued the 
elevated autophagic flux. We hypothesized that failure to meet the high metabolic 
demand, for example through autophagy inhibition, results in cell death of EGFRvIII-
expressing cells. To test this, we exposed control and EGFRvIII-expressing cells to hypox-
ia for 48 h in the presence or absence of CQ (Fig. 5D) or short hairpins targeting LC3B 
(Fig. 5E), supplemented the culture medium with additional pyruvate and assessed 
clonogenic survival. Interestingly, the addition of pyruvate rescued cell death in autoph-
agy-deficient EGFRvIII-expressing cells (p<0.01 in Fig. 5D and E), but not in control cells. 
This illustrates the therapeutic potential of targeting the high metabolic demand of 
EGFRvIII-expressing cells and tumours through inhibition of autophagy.  
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Figure 5. EGFRvIII-expressing cells require autophagy to meet high metabolic demand.  
(A) Glucose utilization by control and EGFRvIII-expressing U373 cells under ambient (left) or hypoxic 
(O2<0.02%) (right) conditions with or without addition of CQ (5 µg/ml). n=3, mean ± SEM. (B) Glucose con-
sumption after expression of a control shRNA or a shRNA targeting LC3B. n=3, mean ± SEM (C) Autophagic flux 
determination in control and EGFRvIII-expressing cells after 8-h hypoxia exposure with additional glucose or 
methyl pyruvate supplementation (5 mM). (D) Clonogenic survival after 48 h hypoxia (O2<0.02%) exposure in 
the presence of CQ, methyl pyruvate or CQ and pyruvate. (O2<0.02%) n=3, mean ± SEM. (E) Clonogenic sur-
vival after 48-h hypoxia (O2<0.02%) exposure in control and LC3B-depleted cells with pyruvate supplemented 
n=3, mean ± SEM.  
Patients with EGFRvIII-positive GBM benefit from CQ treatment 
Several reports have been published on the prognostic role of EGFRvIII in GBM patients. 
Although most reports indicate worse survival for EGFRvIII+ GBM patients, others have 
indicated a different outcome. This difference may depend on the method of EGFRvIII 
detection either through PCR or immunohistochemistry or on the heterogeneity of the 
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patient populations and therapeutic interventions included. We therefore selected 57 
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encouraging as CQ treatment improved median survival from 5 to 10 months in patients 
with EGFRvIII-negative GBM (Fig. 6C, p=0.0002). Strikingly median survival of patients 
with EGFRvIII-positive GBM increased from 3 to 15 months (p=0.0006), confirming our 
pre-clinical findings and the therapeutic potential of CQ in the treatment of EGFRvIII-
expressing tumours.  
Table 1. Characteristics of GBM patients treated with TMZ and radiotherapy (60 Gy) 
EGFRvIII status EGFRvIII- EGFRvIII+ 
 
27 (47%) 30 (53%) 
Male 15/27 19/30 
Female 12/27 11/30 
Karnofsky performance (pre-surgery)  
 
60 - 70 0 (0%) 2 (7%) 
80 – 90 8 (30%) 19 (63%) 
100 19 (70%) 9 (30%) 
TMZ (75 mg/m2/day) 27/27 (100%) 30/30 (100%) 
Radiotherapy (60 Gy) 27/27 (100%) 30/30 (100%)  
Table 2. Characteristics of GBM patients 
 
no CQ treatment  CQ treatment 
EGFRvIII status vIII- vIII+ vIII-  vIII+ 
Male 5/8 3/7  10/13 (77%) 6/15 (40%) 
Female 3/8 4/7 3/13 (23%) 9/15 (60% 
Karnofsky performance (pre-surgery)  
 
  
 
< 70 0 (0%) 1 (14%) 0 (0%) 1 (7%) 
70 – 80 7 (87%) 6 (86%) 7 (54%) 7 (47%) 
90 -100 1 (13%) 0 (0%) 6 (46%) 7 (47%) 
Karnofsky performance (post-surgery)       
< 70 1 (13%) 2 (29%) 0 (0%) 0 (0%) 
70 – 80 1 (13%) 1 (14%) 1 (8%) 3 (20%) 
90 -100 6 (74%) 4 (57%) 12 (92%) 12 (80%) 
2nd surgery 4/8 (50%) 2/7 (29%) 2/13 (15%) 2/15 (13%) 
Radiotherapy 3/8 (38%) 2/7 (29%) 8/13 (62%) 6/15 (40%) 
Discussion 
Our data confirmed that the expression of EGFRvIII indicates a poor prognosis for GBM 
patients due to increased therapy resistance, increased proliferation and accelerated 
tumour growth. Furthermore, EGFRvIII-expressing cells are more resistant to metabolic 
stresses and result in an increased hypoxic fraction of the tumour. As tumour hypoxia is 
a major limiting factor in successful cancer treatment,(27) targeting hypoxia in EGFRvIII-
EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability 
85 
expressing tumours may therefore be essential in acquiring improved tumour control 
and ultimately tumour cure. Here we reveal that expression of EGFRvIII leads to in-
creased autophagic flux during metabolic stresses such as hypoxia and starvation. In line 
with previous reports, EGFRvIII-expressing cells proliferate faster and display increased 
survival during these stresses (10-13). We show that these advantages can be abrogat-
ed through inhibition of autophagy either through genetic or pharmacological targeting. 
In vivo, EGFRvIII tumours display increased tumour growth and faster tumour regrowth 
after radiotherapy, effects that are likely to contribute to the poor outcome of EGFRvIII+ 
GBM patients. Importantly, CQ treatment inhibits the accelerated growth and regrowth 
of EGFRvIII tumours. As observed previously, (33) CQ treatment results in reduced tu-
mour hypoxia in tumour xenografts, yet we observed that the largest reduction occurs 
in EGFRvIII-expressing tumours. Strikingly, CQ treatment results in a drastic increase in 
necrosis of EGFRvIII tumours, but not in control tumours. In addition to lowering the 
intrinsic tolerance to hypoxia, CQ may induce vessel normalization and increase perfu-
sion, resulting in decreased tumour hypoxia (47). In our experiments, vessel density 
increased in control tumours but not in EGFRvIII-expressing tumours (Fig. S2). Our data 
indicates that EGFRvIII expression changes the tumour cell dependence on autophagy 
to tolerate low oxygen levels. In the absence of autophagy, these cells will die leading to 
increased tumour necrosis. These results are in line with the enhanced cell death after 
autophagy inhibition in EGFRvIII-expressing cells, in vitro (Fig. 2C and D).  
During autophagy, recycled products are transported across the autolysosomal 
membrane into the cytoplasm. These metabolites can be reused in protein and ATP 
production (34). In our studies we observed that EGFRvIII+ tumours cells displayed in-
creased activation and dependence on autophagy during hypoxia, effects that can be 
rescued by adding pyruvate to the culture medium. As EGFRvIII+ cells consume more 
glucose (Fig. 5), autophagy may be essential in supporting metabolic processes in EG-
FRvIII+ cells. EGFRvIII may induce the increased glucose uptake and consumption 
through enhanced RRAS signalling. Similar to our observations, oncogenic RRAS pro-
motes glucose uptake and utilization in glycolysis (reviewed in ref. (50)). Interestingly, 
the effect of autophagy inhibition in EGFRvIII+ cells on survival and glucose consumption 
during hypoxia could not be rescued by glucose addition, but was rescued after py-
ruvate supplementation. This suggests that a) the glycolytic pathway is used to its fullest 
extent, and b) the high metabolic activity is not used to support ATP production, as 
pyruvate cannot further be degraded in the citric acid cycle due to the absence of oxy-
gen. In addition to being converted to ATP, pyruvate is able to prevent toxic effects of 
oxygen radicals and peroxides and indirectly prevents the depletion of glutathione dur-
ing hypoxia, (51) and may therefore decrease the toxic effects after reoxygenation. 
From a clinical perspective, the most important finding of this research is the rela-
tively large effect of CQ on tumours that express EGFRvIII compared to the non-
EGFRvIII-expressing tumours. In cell line-derived xenografts, we observed transition of 
the hypoxic into necrotic areas and a high degree of sensitization to radiotherapy. These 
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results were further confirmed in patient-derived xenografts. Furthermore, retrospec-
tive analysis of EGFRvIII expression in GBM patients treated with carmustine, radiother-
apy and surgery revealed a larger improvement in survival for patients with EGFRvIII-
positive GBM after concurrent CQ treatment compared to patients with EGFRvIII-
negative tumours. Although these initial clinical results are promising, larger cohorts of 
patients are required to fully understand the therapeutic potential of CQ administration 
in the treatment of GBM. Recently a phase I/II trial in newly diagnosed GBM has been 
reported where standard of care (temozolomide and radiotherapy) was combined with 
concurrent hydroxychloroquine (a derivative of CQ) (52). Due to unfavourable toxicity 
profiles and dose-limiting toxicity before consistent inhibition of autophagy was ob-
served, no changes, compared to historical data (EORTC trial), in overall survival were 
observed. Although hydroxychloroquine and chloroquine belong to the same class of 4-
aminoquinolines, their effective doses and toxicity profiles differ. Clinical trials to evalu-
ate toxicity and effectiveness (randomized phase II trial) of CQ in combination with 
temozolimide and radiotherapy are ongoing in our institute (clinicaltrials.gov identifier 
NCT02378532 and NCT02432417). Based on the findings described in this manuscript, 
in the phase II trial patients will be stratified based on expression of EGFRvIII. 
Interestingly, other mutation types in the RAS-RAF-MAPK/ERK pathway have also 
been associated with increased dependence on autophagy for survival. For example, 
HRASG12V or KRASG12V transformed cells upregulate their basal autophagy and depend on 
elevated autophagy for survival during starvation (53). Also the BRAFV600E mutation, 
which occurs in over 50% of childhood central nervous system tumours, results in ele-
vated autophagy and increased sensitivity to pharmacological or genetic autophagy 
inhibition in terms of cell viability.(54) Remarkable clinical responses have been ob-
served.  
These tumours are often also effectively treated using kinase inhibitors, such as 
vemurafenib. Unfortunately, development of resistance is often observed. Levy et al. 
reported that autophagy contributes to vemurafenib resistance. Hence, targeting au-
tophagy can overcome this resistance, and patients with resistant tumours display fa-
vourable clinical responses when chloroquine is combined with vemurafenib (55). Com-
bined with our data these results suggest that constitutive signalling through the RAS-
RAF-MAPK/ERK pathway creates autophagy dependence in tumour cells. This important 
information could be used for individualized treatment selection for patients with brain 
tumours.  
In conclusion, our results demonstrate that elevated autophagy activity contributes 
to the enhanced tolerance to metabolic stresses of EGFRvIII-expressing cells. Targeting 
this survival mechanism abrogates this advantage and results in enhanced tumour cell 
killing. Ultimately this downregulation of autophagy activity leads to reduced tumour 
growth, reduced tumour hypoxia, increased tumour necrosis and sensitization of tu-
mours to radiotherapy. In line with these pre-clinical findings, we observed that patients 
with EGFRvIII-expressing GBM benefit most from concurrent CQ treatment. Concurrent 
EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability 
87 
CQ treatment in combination with conventional therapy seems therefore a promising 
strategy to improve the outcome for EGFRvIII+ GBM patients. 
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Abstract 
Autophagy is best known as a lysosomal degradation and recycling pathway to maintain 
cellular homeostasis. During autophagy, cytoplasmic content is recognized and packed 
in autophagic vacuoles, or autophagosomes, and targeted for degradation. However, 
during the last years, it has become evident that the role of autophagy is not restricted 
to degradation alone but also mediates unconventional forms of secretion. Further-
more, cells with defects in autophagy apparently are able to reroute their cargo, like 
mitochondria, to the extracellular environment; effects that contribute to an array of 
pathologies. In this review we discuss the current knowledge of the physiological roles 
of autophagy-dependent secretion, i.e. the effect on inflammation and insulin/ hor-
mone secretion. Finally, we focus on the effects of autophagy-dependent secretion on 
the tumour microenvironment and tumour progression. The autophagy mediated se-
creted factors may stimulate cellular proliferation via auto- and paracrine signaling. The 
autophagy mediated release of immune modulating proteins change the immunosup-
pressive tumour microenvironment and may promote an invasive phenotype. These 
effects may be either direct or indirect through facilitating formation of the mobilized 
vesicle, aid in anterograde trafficking or alterations in homeostasis and/or autonomous 
cell signaling. 
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Autophagy 
Autophagy is a catabolic process required to maintain cellular homeostasis by lysosomal 
degradation of aged/damaged organelles (e.g. mitochondria), protein aggregates and 
pathogens. Autophagy commences with the formation of an initial cup-shaped mem-
brane (phagophore) that elongates while (non-) selectively capturing cytoplasmic con-
stituents into a double-membrane vesicle (autophagosome). Ultimately, the autophago-
some fuses with a hydrolase and protease containing lysosome for degradation of the 
content. The end-products are recycled into the cytosol and are reused in processes 
including protein synthesis and ATP production.  
During the last decade, extensive research revealed that at least 38 Autophagy re-
lated proteins (ATGs) comprise the core autophagy machinery that mediate initiation, 
elongation, cargo recruitment and fusion with lysosomes (1). Furthermore, the yeast 
atg8 orthologues of the LC3/GABARAP protein family fulfil specialized roles in the exe-
cution of autophagy (2). This family consists of 7 active members (LC3A (two splicing 
variants; LC3A-a and LC3A-b), LC3B, LC3C, GABARAP, GABARAPL1, and GABARAPL2) 
which share a high mutual homology, including a conserved C-terminal glycine residue 
for phosphatidylethanolamine (PE) conjugation to allow membrane association. Conju-
gation of the LC3/GABARAP protein family members to PE is required for expansion and 
closure of the phagophore. This process is controlled by 2 ubiquitin like conjugation 
systems, a process closely orchestrated the ATG4, -7, and -3 and the ATG12-ATG5-
ATG16L1 complex (9). 
Despite the high grade of homology, the protein family members harbour individual 
roles in autophagy but are associated with autophagy unrelated functions as well like 
receptor trafficking and (2). 
Autophagy (and related defects) is associated with several pathologies, including 
neuropathologies, Crohns disease and cancer. In cancer, autophagy is considered a 
double edged sword; i.e. in healthy tissue, autophagy plays a cytoprotective role by 
maintaining homeostasis through degradation of cytotoxic constituents, which other-
wise may trigger tumorigenic events. Nevertheless, once a tumour is formed, autopha-
gy contributes to survival of cancer cells in areas deprived of nutrients of oxygen (hy-
poxia)(3,4), a common feature of solid tumours that contributes to tumour progression, 
therapy resistance and metastases formation(5).  
Yet, accumulating research shows that the homeostatic role of autophagy and its re-
lated proteins is more elaborate than the degradation of cytoplasmic content alone. 
Autophagy not only contributes to intracellular homeostasis, but also seems to contrib-
ute to tissue homeostasis by mediating intercellular communication. Peptides, proteins 
and hormones that fail to enter the conventional secretory system due to the lack of a 
leader/secretion signal sequence can be secreted in an autophagy-dependent manner.  
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leader/secretion signal sequence can be secreted in an autophagy-dependent manner.  
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In this review we list the current knowledge on the role of the autophagy machinery 
in autophagy-dependent secretion and specifically focus on factors that may influence 
tumour progression.  
(Un) conventional protein secretion 
In eukaryotes, a classical route for proteins to be secreted is the endoplasmic reticulum 
(ER)-to-Golgi route. Herein, proteins are directed towards the ER by their amino termi-
nal signal peptide (leader peptide) and progress through vesicular flow to the Golgi. In 
brief, after ER translocation, proteins are oligomerized and packed into carrier vesicles 
that exit the ER at specialized regions. These vesicles assemble into vesiculo-tubular 
structure intermediates known as the ER-to-Golgi intermediate compartments (ERGIC) 
that, by lateral communication sorts proteins for further anterograde flow to the Golgi 
complex. In the Golgi, proteins are glycosylated to ensure proper protein structure, 
increase stability and to allow interactions with target proteins (6). In the trans-Golgi 
network, secretory proteins are sorted into secretory vesicles that deliver their content 
to the plasma membrane to result in secretion (7). An increasing number of secreted 
proteins that lack the leader peptide have been identified. These proteins require alter-
native pathways to be secreted in a regulated fashion. This implies differences in vesicle 
formation, sorting and transportation. Multiple alternate, non-classical pathways exist 
and are commonly referred to as unconventional protein secretion and include both 
non-vesicular and vesicular mechanisms (8). For example, cytosol-residing proteins, 
including ABC transporter mediated yeast a-factor (9) or mammalian fibroblast growth 
factor 2 (FGF-2) are directly transported across the plasma membrane. For FGF2 secre-
tion this is presumed to be mediated through PI(4,5)P2-induced oligomerization fol-
lowed by membrane insertion and translocation (10). Other proteins are sorted into 
vesicular intermediates that fuse with the plasma membrane to release their content 
into the extracellular space ((interleukin 1β (IL-1β) and IL-18 (11)), in part dependent on 
proteins required for autophagy execution (12,13). This suggests that autophagy-
proteins are required to produce secretory vesicles or that autophagosomes gain exo-
cytic features. These processes in autophagy-mediated secretion are distinct from its 
degradative compartment (as reviewed in more detail in (14)).In this context, the traf-
ficking, tethering, docking and plasma membrane fusion events would differ from ca-
nonical autophagy and resemble exocytic mechanisms. Herein, secretory vesicles are 
diverted from the endocytic system to be released from multivesicular bodies (MVB). 
These secretory vesicles are then transported to the plasma membrane for content 
release. For example, the interaction between autophagosomes and the endocytic/MVB 
pathway (reviewed in (15)) are required for acetyl-CoA-binding protein(Acb1)-secretion 
and requires the fusion of Acb1-containing autophagosomes with endosomes or MVBs 
before plasma membrane fusion (16).  
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The involvement of autophagy-related proteins, in protein secretion indicates that 
cells utilize these effectors in a surprising mechanism of unconventional secretion. 
Here, we will discuss the data that support a relation between autophagy and autopha-
gy-related proteins with secretory pathways (table 1). First, we will elaborate on the 
physiological roles of autophagy in secretory events. Second, cancer cells utilize secre-
tory mechanisms to communicate with stroma and surrounding cancer cells, thereby 
inducing alterations that influence tumour progression including immunoevasion, im-
munosuppression, auto- and paracrine signalling and angiogenesis. 
Table 1: Effects on the tumour microenvironment 
Protein(s) mechanism Effect ref 
I. Influencing immunogenic cell death to evade immune surveillance 
ATP ATG5 
knockdown 
After radiotherapy and MTX exposure “eat me signal” for 
immune cells. stimulus for DC recruitment, IFNγ-producing CD4 
and CD8 T cells 
(65)(63) 
(64) 
HMGB1 ATG5fl/fl Promote processing and presentation of tumour antigens by DCs, 
enhanced immuno surveillance.  
(11) 
II. Cytokine release and influence on the tumour microenvironment 
IL1-B, IL-6, IL2 GABARAP 
Knockout mice 
Increased secretion by macrophages 
 
(81) 
IFNγ GABARAP 
Knockout mice 
Increased secretion by lymphocytes (81) 
CXCL9, CXCL10 
and CXCL11 
FIP200 
conditional 
knockout 
Enhanced secretion, leading to improved immuno surveillance (49) 
III.a. Pro-metastatic: Driving an invasive behavior of cancer cells 
LIF, FAMC3, 
DKK3, IL-8 
ATG7 
knockdown 
These factor promote metastasis via MMP2 upregulation (IL-8), 
epithelial to mesenchymal transition (FAM3C, DKK3, LIF) and 
promotion of angiogenesis (IL-8 and DKK3) 
(83) 
 ATG7, 
ATG12,ATG3 
knockdown 
chloroquine or 
bafilomycin A1 
Autophagy deficient HRASV12 transformed breast cancer cell lines 
display reduced invasive protrusions. Conditioned medium of 
autophagy-proficient cells rescued the invasive phenotype 
(82) 
IL6, CCL-2, CCL-
20, VEGFA, 
MMP2 
3-MA, ATG5 
and ATG7 
knockdown 
TLR3 and TLR4 activation leads to autophagy –dependent 
secretion of these factors associated with a migratory and 
invasive phenotype of lung cancer cells.  
(85) 
IL6 ATG7 or beclin 
knockdown 
Autophagy deficiency lead to an in- or decrease in low or high 
autophagic breast cancer cells respectively. Autophagy-
dependent secretion of IL-6 are able to promote mammosphere 
formation and may be important in CSC maintenance 
(87) (86)  
III.b. Pro-metastatic: Proper Weibel-Palade body formation in vascular endothelium to facilitate metastasis 
WPB proteins  Autophagy is important to sustain secretion of WPBs containing 
proteins that influence tumour progression 
(88) 
IV. Chemoresistantance  
HMGB1  HMGB1 causes doxorubicin resistance in neighboring breast 
cancer cells.  
(91) 
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Physiological roles of autophagy mediated secretion  
The first evidence for the involvement of autophagy-related proteins in protein secre-
tion was obtained in yeast. Acyl coenzyme A-binding protein (Acbp) is secreted through 
an unconventional secretory pathway that depends on components of the autophagic 
process (Atg5, Atg7, Atg8, Atg12) (16). Importantly, this study also demonstrated that 
autophagy connects with compartments (multivesicular bodies) of endosomal traffick-
ing and SNARE-dependent membrane fusion events are both required for the Acbp 
secretion. Since the discovery of autophagy-dependent secretion in yeast, also several 
mammalian factors have been identified to be dependent on autophagy-related pro-
teins for their secretion. 
Phosphoinositides are membrane lipids with specific recognition domains for the re-
cruitment of cytosolic proteins and are involved in the regulation of membrane 
transport. So far, seven phosphoinositides have been described. They can be converted 
into each other by phosphoinositide kinases and phosphatases (17). PIKfyve is one of 
those converting kinases and has been implicated in membrane transport events. The 
substrate of PIKfyve, PI(3)P, plays a critical role in the initiation of autophagy and au-
tophagosome maturation (18). Inhibition or depletion of PIKfyve by apilimod or siRNA 
resulted in decreased autophagic flux, probably caused by an impaired autophago-
some/lysosome fusion. Interestingly, prostate cancer cells incubated with the PIKfyve 
inhibitor apilimod, secrete more autophagy associated proteins (NBR1, P62, OPTN and 
CACO2 and membrane-bound LC3B), however proteins involved in earlier stages of 
autophagy were not observed (ATG2A, ATG5, ATG16L). Analysis of density gradients 
reveal that these autophagy associated proteins are expressed on vesicles and appear 
as autophagosome subpopulations, suggesting induced secretory autophagy (19).  
I. Cytokines and inflammation 
Autophagy is able to suppress inflammasome activation through maintaining mitochon-
drial homeostasis (20). In line, Zhang et al observed increased inflammasome activation 
in macrophages after sepsis in Gamma (γ)-aminobutyric acid type A receptor (GABAAR)-
associated protein (GABARAP) knockout mice (20). Secretion of cytokines is central in 
inflammasome activity. Well-documented cytokines that are associated with unconven-
tional secretion in an autophagy-dependent manner are interleukin-1 beta (IL-1B) and 
IL-18. Dupont et al demonstrated in bone-marrow derived macrophages during condi-
tions of induced autophagy (starvation or Torkinib treatment) that secretion of IL-1B 
increased, which was reduced in the absence of ATG5. Consistent with data obtained 
from yeast Acbp, similar additional factors were required (as mammalian equivalents of 
yeast Golgi-associated protein (GRASP55) and small GTPase Rab8a), indicating a con-
served system or cooperation (11).  
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Interestingly, three dimensional STochastic Optical Reconstruction Microscopy 
(STORM) demonstrated that IL-1B was not only present in the inner vesicle of the au-
tophagosome, but was already recruited to the emerging phagophore. In this, IL-1B is 
actively translocated across the membrane and accumulated in the intermembrane 
space of the mature autophagosome (21). This, in contrast to the sequestration of de-
gradable autophagosomal content which is located in the inner vesicle as a result of 
cytoplasmic engulfment and closure of the phagophore, this novel mechanism indicates 
differences in cargo recruitment and indicates formation of different vesicles by the 
autophagy-related proteins that may guide the distinct fate of the produced vesicle.  
II. Role of autophagy-dependent secretion in establishing a barrier for infection 
Paneth cells are specialized epithelial cells present at the base of the crypts of 
Lieberkuhn. These cells control the intestinal microbiota through secretion of intracellu-
lar granules that contain antimicrobial peptides and lysozyme. Autophagy-proteins are 
essential for Paneth cell function. Knockdown of crucial autophagy genes (ATG16L1, 
ATG5 or ATG7 (22,23)) results in alterations in Paneth cell granules, as illustrated by 
fewer and aberrant granules with diffuse lysozyme patterns and decreased presence of 
lysozyme in mucus. Due to its relevance in establishing a microbial barrier, the ATG16L1 
gene was annotated as a Crohns disease (CD) risk allele (24) and the phenotype is simi-
lar to the abnormalities found in Paneth cells of CD patients.  
In contrast to CD where the ileum and colon are often affected, ulcerative colitis is 
restricted to the colon only. Conditional knockdown of ATG7 in the colon (GlcNAc6ST-2-
Cre) increased bacterial colonization in crypts. This phenotype was associated with a 
decreased release of mucin from goblet cells and reduced expression of antimicrobial 
and antiparasitic peptides (angiogenin 4, interlectin 1 and relmβ). Hence, colonic ATG7 
knockdown results in increased susceptibility to the development of UC-like colitis (25).  
In line with autophagy-dependent secretion by intestinal tissue, ATG5 and ATG16L1 
deficiency results in reduced secretion of mucins (MUC5AC) by human tracheal epithe-
lial cells (26).  
Together, autophagy-dependent secretion is required to maintain effective anti-
bacterial barriers by epithelial cells. In line, ATG16L1 conditional knockout mice (Villin-
Cre) are more susceptible to Salmonella typhimurium infection (27). Although, beyond 
the contribution of establishing a barrier function, autophagy is required for limiting 
bacterial proliferation through ATG16L1 and LC3C dependent degradation of cytosol-
residing Salmonella (xenophagy) (28). Evidently, autophagy is a prerequisite for differ-
ent cell types to maintain their function (e.g. mucus secretion) thereby and protection 
against inflammatory disorders.  
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III. Insulin secretion 
Pancreatic β-cells are specialized in secretion of insulin in response to high levels of 
blood glucose concentrations. Release of insulin is mediated by the fusion of insulin-
containing vesicles with the plasma membrane. These insulin-containing vesicles are 
transported towards the plasma membrane. Gamma (γ)-aminobutyric acid type A re-
ceptor (GABAAR)-associated protein (GABARAP), one of seven mammalian variants of 
yeast Atg8, which is already known to be implicated in multiple cellular functions includ-
ing fusion events in autophagy (29) and receptor trafficking (30) has recently been 
demonstrated to mediate insulin secretion. Herein, GABARAP binds insulin-containing 
vesicles in a PE conjugation-dependent mechanism (31)). Together with its microtu-
bules-binding feature (residue 10-22 (30)), GABARAP allows vesicle presentation to the 
motor protein KIF5B (located at microtubules) and facilitates vesicle mobility and insulin 
release (32).  
IV. NPY secretion 
In rat adrenal medullar pheochromocytoma derived cells, the neurites display ATG16L 
at dense-core vesicles. Although these vesicles do not co-localize with LC3, release of 
peptide hormone neuropeptide Y (NPY) is dependent on ATG16L1 functioning as a 
Rab33a (which regulates membrane trafficking events) effector. Interestingly, NPY se-
cretion was not altered in cells that were deficient in autophagy by overexpressing 
ATG4BC74A or knockdown of ATG13 or ULK1 and indicates a highly specialized role for 
ATG16L1 in hormone secretion that is independent of other canonical autophagy asso-
ciated proteins (33).  
V. Autophagy-mediated secretion of Weibel-Palade bodies in vascular 
endothelial cells 
Vascular injury stimulates endothelial cells to secrete factors to promote repair. Endo-
thelial secretory granules (Weibel-Palade bodies (WPBs)) contain active molecules in-
cluding von Willebrand factor (vWF), P-selectin, interleukin-8, angiopoietin-2 and endo-
thelin-1. The intracellular WPBs are characterized by striations parallel to its longitudinal 
axis and are delineated by a membrane. When secreted, the multimeric hemostatic 
vWF is tethered to the connective tissue to mediate platelet adhesion at sites of vascu-
lar injury. The processing of vWF to a mature form is important in the WPB formation. 
Treatment with chloroquine or bafilomycin A1, that both raise lysosomal pH, and 
knockdown of ATG7 or ATG5 reduce the number of endothelial WPBs due to incorrect 
processing of vWF. In line, endothelial specific deletion of Atg7 in mice led to reduced 
epinephrine-induced plasma vWF levels and increased bleeding time. Thus, autophagy 
in endothelial cells aids in hemostasis by proper maturation of WPBs (34). 
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VI. Osteoclastic bone resorption 
Bone remodeling is a lifelong process of bone degradation and formation important for 
bone healing after injury, bone restructuring and sustaining bone homeostasis. Osteo-
clasts cooperate with osteoblasts in bone remodeling in which osteoclasts are responsi-
ble for bone degradation and reabsorption of mineralized bone matrix. The osteoclasts 
are large multinucleated cells that are characterized by their ruffled border by which 
contact area with the bone is increased. Fusion of secretory lysosomes with the ruffled 
border causes release of matrix-degrading factors including cathepsin K which aids bone 
matrix degradation. ATG5 or ATG7 deficient osteoclasts lack a normal ruffled border, 
impaired localization of secretory factors including cathepsin K and eventually have 
impaired bone resorption. Importantly, development of osteoclasts was not aberrant 
indicating that the autophagy deficiency led to functional impairment independent of 
sustaining cellular homeostasis. Moreover, secretory lysosome formation was unaffect-
ed, whereas Rab7 (key factor for lysosome fusion events) localization to ruffled border 
was ATG5 dependent. Together, these data indicated that autophagy-related proteins 
aid in secretory events at the osteoclast ruffled border by directing fusion of the secre-
tory lysosome with the plasma membrane (35).  
In conclusion, autophagy is important for secretory functions of various cell types. 
Important to note is that autophagy can have either direct or indirect contribution to 
protein secretion. For example, autophagy related proteins directly facilitate protein 
secretion by mediating cargo sequestration (as IL-1B) or vesicle trafficking (as insulin), 
but autophagy also maintains cellular homeostasis that is important to preserve the 
specialized function (IL-1B and vWF) and primes the plasma membrane for proper re-
lease of autophagy-independent secretory vesicle (as in osteoclasts). Furthermore, for 
sustaining a microbial barrier, autophagy’s contribution is dual as both a canonical form 
of autophagy (xenophagy) and the regulation of important secretory factors as mucin 
contribute to prevent pathogen invasion.  
Secretory autophagy: waste disposal? 
Damaged and aggregated proteins and aged organelles are typically degraded by au-
tophagy. Substrates for autophagy are ubiquitylated and recognized by autophagy re-
ceptors and degraded. Recent work indicates that defective or saturated autophagy, i.e. 
by defective autophagosome/ lysosome fusion results in cargo secretion into the extra-
cellular environment.  
Lysosomal dysfunction is associated with the secretion of aggregation prone pro-
teins that are associated with neurodegenerative diseases as Parkinson’s and Alz-
heimer’s disease. α-Synuclein is a presynaptic neuronal protein that is genetically and 
neuropathologically linked to Parkinson's disease. Wild type α-synuclein is typically 
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knockdown of ATG7 or ATG5 reduce the number of endothelial WPBs due to incorrect 
processing of vWF. In line, endothelial specific deletion of Atg7 in mice led to reduced 
epinephrine-induced plasma vWF levels and increased bleeding time. Thus, autophagy 
in endothelial cells aids in hemostasis by proper maturation of WPBs (34). 
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VI. Osteoclastic bone resorption 
Bone remodeling is a lifelong process of bone degradation and formation important for 
bone healing after injury, bone restructuring and sustaining bone homeostasis. Osteo-
clasts cooperate with osteoblasts in bone remodeling in which osteoclasts are responsi-
ble for bone degradation and reabsorption of mineralized bone matrix. The osteoclasts 
are large multinucleated cells that are characterized by their ruffled border by which 
contact area with the bone is increased. Fusion of secretory lysosomes with the ruffled 
border causes release of matrix-degrading factors including cathepsin K which aids bone 
matrix degradation. ATG5 or ATG7 deficient osteoclasts lack a normal ruffled border, 
impaired localization of secretory factors including cathepsin K and eventually have 
impaired bone resorption. Importantly, development of osteoclasts was not aberrant 
indicating that the autophagy deficiency led to functional impairment independent of 
sustaining cellular homeostasis. Moreover, secretory lysosome formation was unaffect-
ed, whereas Rab7 (key factor for lysosome fusion events) localization to ruffled border 
was ATG5 dependent. Together, these data indicated that autophagy-related proteins 
aid in secretory events at the osteoclast ruffled border by directing fusion of the secre-
tory lysosome with the plasma membrane (35).  
In conclusion, autophagy is important for secretory functions of various cell types. 
Important to note is that autophagy can have either direct or indirect contribution to 
protein secretion. For example, autophagy related proteins directly facilitate protein 
secretion by mediating cargo sequestration (as IL-1B) or vesicle trafficking (as insulin), 
but autophagy also maintains cellular homeostasis that is important to preserve the 
specialized function (IL-1B and vWF) and primes the plasma membrane for proper re-
lease of autophagy-independent secretory vesicle (as in osteoclasts). Furthermore, for 
sustaining a microbial barrier, autophagy’s contribution is dual as both a canonical form 
of autophagy (xenophagy) and the regulation of important secretory factors as mucin 
contribute to prevent pathogen invasion.  
Secretory autophagy: waste disposal? 
Damaged and aggregated proteins and aged organelles are typically degraded by au-
tophagy. Substrates for autophagy are ubiquitylated and recognized by autophagy re-
ceptors and degraded. Recent work indicates that defective or saturated autophagy, i.e. 
by defective autophagosome/ lysosome fusion results in cargo secretion into the extra-
cellular environment.  
Lysosomal dysfunction is associated with the secretion of aggregation prone pro-
teins that are associated with neurodegenerative diseases as Parkinson’s and Alz-
heimer’s disease. α-Synuclein is a presynaptic neuronal protein that is genetically and 
neuropathologically linked to Parkinson's disease. Wild type α-synuclein is typically 
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degraded by the autophagy and the proteasome (36). Interestingly, tubulin polymeriza-
tion-promoting protein/p25a, expressed in the CNS, sorts α-synuclein into autophag-
somes but simultaneously prevents its degradation through inhibition of autophago-
some/lysosome fusion. Instead p25a controls α-synuclein clearance by its release in the 
extracellular environment in an autophagy-dependent manner (37). 
Alzheimers’ disease is characterized by the accumulation of intracellular Amyloid be-
ta (AB) peptide and tau aggregates and extracellular AB plaques. In normal conditions, 
intracellular proteins are cleared by autophagy and autophagosomes are resolved in the 
process. However, during Alzheimer disease, autophagosomes accumulate, indicative of 
impaired autophagy. Autophagy-deficiency (ATG7 knockout) in excitatory neurons re-
sults in intracellular AB accumulation, confirming its role in clearance of AB aggregates 
by autophagy. Although AB increased intracellularly, extracellular AB plaque formation 
was drastically reduced. Reconstitution of ATG7 expression by lentiviral transduction, 
rescued the secretory phenotype. In parallel, pharmacologic modulation by either in-
duction or inhibition of autophagy, by rapamycin or spautin-1, increased and reduced 
extracellular AB release respectively. Thus, autophagy influences intracellular transport 
and secretion of AB (38). 
Mitochondria, the energy producing centres of the cell, generate ROS as a by-
product of oxidative phosphorylation. In many cancers, ROS production is increased due 
to mutations in mitochondrial DNA, hypoxia and a disturbed metabolism, leading to 
cancer progression(39). The homeostasis of mitochondrial ROS plays an important role 
in the regulation of autophagy. Depolarized and ROS leaking mitochondria are typically 
degraded by a selective form of autophagy, mitophagy. In depolarized mitochondria, 
PINK recruits Parkin to mediate selective removal of the organelle in a degrative au-
tophagy-dependent manner. However, a recent report shows that there is an alterna-
tive way to maintain mitochondrial homeostasis in the cell. Mesenchymal stem cells 
(MSC) pack depolarized mitochondria in microvesicles and release them in the extracel-
lular environment to outsource mitophagy where they are recognized by and trans-
ferred to macrophages. These released microvesicles are highly enriched in LC3 and 
ATG12 compared to whole-cell extracts. This mitochondrial transfer probably serves to 
increase MSC survival. (40). Similarly, LPS stimulated rat hepatocytes secrete mitochon-
drial proteins CPS1 and COXIV, a component of the mitochondrial respiratory chain and 
associated with the inner mitochondrial membrane, and mitophagy related proteins 
PARK2 and PINK1 and LC3B-II. These effects are inhibited by the autophagy inhibitor 
3Metyladenine or after Atg5 knockout. Suggesting a role for autophagy in the secretion 
of mitochondria after LPS stimulation (41).  
Also endothelial cells are able to release vesicles with autophagosome characteris-
tics. During apoptosis, endothelial cells release in addition to apoptotic bodies, vesicles 
in an unconventional manner(42). Ultrastructural analysis by electron microscopy 
showed single membrane vesicles up to 10 um which contained structures of mito-
chondria, multivesicular bodies and autophagosomes. Further proteomic analysis re-
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vealed the release of autophagy associated proteins ATG16L1, LAMP2 and LC3B. The 
biological function is of this phenomenon remains to be elucidated (43).  
The previous section lists the evidence that cells are able to release autophagic vesi-
cles into the extracellular environment. Vesicle release during defects in the autophagic 
process, specifically during autophagosome/ lysosome fusion, suggests alternative 
mechanisms in waste removal.  
Effects on the tumour microenvironment  
Regardless of the clinical advances in the past decades that have improved cancer pa-
tient outcome, cancer is still one of the leading causes of death in the world. Important-
ly, the efficacy of treatment strategies is heavily influenced by cancer cell autonomous 
features but also by the tumour microenvironment. Solid tumours consist of a variety of 
cell types, including the cancer cells, endothelial cells, immune cells, fibroblasts and 
contain well- and poorly perfused areas that results in inefficient nutrient and oxygen 
supply (44,45). Normal (non-transformed) cells in the tumour microenvironment (TME) 
are reprogrammed by the cancer cells to their benefit. This is exemplified by growth 
supporting angiogenesis and the suppression of anti tumour immunity. Importantly, an 
existing connection between autophagy and tumorigenesis has already been estab-
lished. For example, deletion of a single BECN1 allele (Beclin1 protein important regula-
tor of autophagy (46)) predisposes mice to spontaneous tumour development (47,48). 
Further, depletion of FIP200 (important for autophagy initiation) in mammary cancer 
cells inhibits tumour initiation and progression including metastases (49). Autophagy in 
cancer cells supports their survival (by aiding the high energy demand) and abets re-
sistance to metabolic and oxidative stresses (e.g. hypoxia) (50-55). Although this role is 
well established, the contribution of autophagy related intercellular communication 
that influences tumour progression through evasion of immunosurveillance, immuno-
genic cell death, angiogenesis and an invasive phenotype is an emerging field with great 
interest. For example, in cancer the RAS genes HRAS and KRAS are frequently mutated. 
Although the exact role of autophagy in tumour progression of RAS mutated tumours is 
still under debate, autophagy seems to be dispensable for the growth and survival of 
KRAS mutated cancer cell lines derived from human tumours (56). However when non-
RAS mutated cells are transformed with oncogenic RAS, these cells are highly depend-
ent on autophagy for tumorigenic events (57). In addition, the invasive phenotype of 
HRASV12-transformed breast cancer cells is reduced in ATG7 knockdown cells. This 
invasive phenotype could be rescued by incubating these autophagy deficient cells with 
conditioned medium of autophagy proficient cells. This supports an autophagy-
dependent secretory system that supports tumour progression (58).  
In the next section, the current knowledge on proteins secreted through autophagy-
mediated processes that influence tumour progression is discussed (table 2).  
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showed single membrane vesicles up to 10 um which contained structures of mito-
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vealed the release of autophagy associated proteins ATG16L1, LAMP2 and LC3B. The 
biological function is of this phenomenon remains to be elucidated (43).  
The previous section lists the evidence that cells are able to release autophagic vesi-
cles into the extracellular environment. Vesicle release during defects in the autophagic 
process, specifically during autophagosome/ lysosome fusion, suggests alternative 
mechanisms in waste removal.  
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Regardless of the clinical advances in the past decades that have improved cancer pa-
tient outcome, cancer is still one of the leading causes of death in the world. Important-
ly, the efficacy of treatment strategies is heavily influenced by cancer cell autonomous 
features but also by the tumour microenvironment. Solid tumours consist of a variety of 
cell types, including the cancer cells, endothelial cells, immune cells, fibroblasts and 
contain well- and poorly perfused areas that results in inefficient nutrient and oxygen 
supply (44,45). Normal (non-transformed) cells in the tumour microenvironment (TME) 
are reprogrammed by the cancer cells to their benefit. This is exemplified by growth 
supporting angiogenesis and the suppression of anti tumour immunity. Importantly, an 
existing connection between autophagy and tumorigenesis has already been estab-
lished. For example, deletion of a single BECN1 allele (Beclin1 protein important regula-
tor of autophagy (46)) predisposes mice to spontaneous tumour development (47,48). 
Further, depletion of FIP200 (important for autophagy initiation) in mammary cancer 
cells inhibits tumour initiation and progression including metastases (49). Autophagy in 
cancer cells supports their survival (by aiding the high energy demand) and abets re-
sistance to metabolic and oxidative stresses (e.g. hypoxia) (50-55). Although this role is 
well established, the contribution of autophagy related intercellular communication 
that influences tumour progression through evasion of immunosurveillance, immuno-
genic cell death, angiogenesis and an invasive phenotype is an emerging field with great 
interest. For example, in cancer the RAS genes HRAS and KRAS are frequently mutated. 
Although the exact role of autophagy in tumour progression of RAS mutated tumours is 
still under debate, autophagy seems to be dispensable for the growth and survival of 
KRAS mutated cancer cell lines derived from human tumours (56). However when non-
RAS mutated cells are transformed with oncogenic RAS, these cells are highly depend-
ent on autophagy for tumorigenic events (57). In addition, the invasive phenotype of 
HRASV12-transformed breast cancer cells is reduced in ATG7 knockdown cells. This 
invasive phenotype could be rescued by incubating these autophagy deficient cells with 
conditioned medium of autophagy proficient cells. This supports an autophagy-
dependent secretory system that supports tumour progression (58).  
In the next section, the current knowledge on proteins secreted through autophagy-
mediated processes that influence tumour progression is discussed (table 2).  
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I. Influencing immunogenic cell death to evade immunosurveillance 
Under normal circumstances, immune cells (including dendritic cells (DCs), natural killer 
(NK) cells and T cells) recognize and eliminate newly formed neoplastic cells due to their 
high immunogenic nature as a result of their mutational burden (immunosurveillance). 
Cancer cells that have obtained an immune evasive phenotype are able to circumvent 
recognition and subsequent elimination by the cooperative immune cells. These cancer 
cells are then selected for characteristics that circumvent local immunosurveillance and 
contribute to the growth of the lesion. With recent advances, the immune evasive fea-
ture is a topic of interest for the development of therapeutic strategies. Ideally, the elic-
ited cancer therapy-induced cell death should provoke an immunogenic chain reaction 
that includes boosting the immune system to tilt the balance towards recognition rather 
than evasion, called immunogenic cell death (ICD). ICD invokes the release of immuno-
modulatory proteins (damage-associated molecular patterns (DAMPs) that incite anti 
tumour immunity (59). ICD can be induced by selective chemotherapeutics including 
mitoxantrone (MTX) and oxaliplatin (OXA) and radiotherapy (reviewed in (60)). Cancer 
cells undergoing ICD stimulate and activate the innate immune cells. Subsequently this 
can result in the cross-priming of the adaptive immune system for the antigens of dying 
cancer cells, thereby leading to an effective activation of anti tumour immunity. This can 
elicit a long-term therapeutic effect (even after therapy has stopped) and is fundamental 
to observed abscopal effects. In line, clinical studies have demonstrated that lymphope-
nia negatively affects chemotherapeutic response of solid tumours (61) and that ICD-
associated DAMPs can be used as predictive and prognostic biomarkers (62). 
Important immunogenic DAMPs that are displayed by cells undergoing ICD are se-
cretion of ATP, surface exposure of calreticulin (CRT), release of heat shock proteins and 
high mobility group box 1 (HMGB1). Interestingly, ATG5 knockdown in colon cancer 
cells reduces ATP release after radiotherapy (63) and MTX exposure (64), which was 
associated with a decreased effect on tumour growth inhibition. Interestingly, in au-
tophagy deficient cells no differences in CRT surface exposure or HMGB1 release were 
observed (64). The relevance of autophagy-dependent radiotherapy-induced ATP re-
lease was further supported by the observation that treatment with an inhibitor of 
ecto-ATPase only increased radiosensitivity in immunocompetent but not immunodefi-
cient mice. Here, a partial rescue of lymphocyte infiltration indicates that the autopha-
gy-dependent radiotherapy-induced ATP release enhances anti-tumour immunity (63). 
Similarly, for MTX treatment of osteosarcoma cells it was also shown that ATG5 is re-
quired for ATP secretion. Interestingly, on a more mechanistic level, Martins et al 
demonstrated that ATP (stored in lysosomes) is released upon MTX and OXA treatment 
and is associated with LAMP1 (lysosomal marker) translocation to the plasma mem-
brane. Nonetheless, a role for autophagy seems to be maintaining an intracellular ATP 
pool (may even be cargo sequestration) required for (LAMP1+) lysosome-dependent 
ATP release. Accordingly, the replenishment of ATP to lysosomes was reduced when 
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autophagy genes were knocked down (65). ATP release conveys an important “eat me” 
signal for immune cells. Once it is released, ATP may attract innate effector cells of the 
immune system into the tumour bed. Consistently, it was demonstrated that autopha-
gy-dependent ATP release from MTX treated colon cancers was a stimulus for DC re-
cruitment, IFNγ-producing CD4 and CD8 T cells that had favourable effects on MTX 
sensitivity (64). Correspondingly, ATG7 in a genetically-induced melanoma mouse mod-
el was required for MTX-dependent growth inhibition that was reliant on functional CD4 
and CD8 T cells (66). Further, caloric restriction or treatment with caloric restriction 
mimetics, that increase autophagy activity, enhance autophagy-dependent ATP release 
and improve MTX-induced tumour growth delay in a T cell dependent fashion (67). 
Oppositely, a different study using a different ICD inducer (photo-oxidative ER stress 
inducer hypericin) has demonstrated autophagy-independent ATP release, but ob-
served enhanced surface CRT exposure when autophagy was attenuated. The enhanced 
DC maturation and IL-6 secretion further promote IFNγ producing T lymphocytes (68). 
Interestingly, surface CRT exposure after MTX or hypericin treatment could be ablated 
in cells lacking lysosome associated LAMP2A, an essential gene for a chaperone-
mediated autophagy (69).Moreover, regarding ATP it was demonstrated that extracellu-
lar residing ATP does not relay an immunogenic response per se (70) and further illus-
trates the context dependence of effects resulting in immunogenicity. 
The involvement of autophagy-related proteins in the release of the DAMP HMGB1 
has been demonstrated using ATG5fl/fl Cre+ bone marrow-derived macrophages (11) and 
dying glioma cancer cells (in which HMGB1 was found in a subset of autophagosomes 
before release (71). The released HMGB1 by dying cancer cells can bind Toll-like recep-
tor (TLR-)4 and promotes the processing and presentation of tumour antigens by DCs. 
This leads to cross-priming of T-cells and enhances immunosurveillance (72). Further-
more, endothelial cell exposure to HMGB1 triggers pro-angiogenic effects (73) including 
endothelial cell migration, sprouting and induction of an autocrine signalling cascade 
that results in elevated expression of leukocyte adhesion molecules ICAM-1, VCAM-1 
and E-selectin. Moreover, HMGB1 induced expression of VEGF-A, VEGFR1, VEGFR2 and 
neuropilin-1 (74) and stimulation of angiogenesis (75).  
In conclusion, ICD is an important pillar of therapy-induced anti-tumour immunity as 
it relays important signalling to the immune system, including DCs. DC stimulation may 
be important to induce tumour cure as demonstrated by ICD-based DC-vaccines in high 
grade glioma bearing mice (76). Nevertheless, the influence of autophagy on the display 
of DAMPs may be ICD-inducer dependent and requires further understanding for effec-
tive use.  
II. Cytokine release and influence on the tumour microenvironment 
ATP can bind the P2RX7 receptor and activate the NOD-like receptor family, pyrin do-
main containing 3 (NLRP3) inflammasome in DCs and macrophages (77). This inflam-
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autophagy genes were knocked down (65). ATP release conveys an important “eat me” 
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gy-dependent ATP release from MTX treated colon cancers was a stimulus for DC re-
cruitment, IFNγ-producing CD4 and CD8 T cells that had favourable effects on MTX 
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in cells lacking lysosome associated LAMP2A, an essential gene for a chaperone-
mediated autophagy (69).Moreover, regarding ATP it was demonstrated that extracellu-
lar residing ATP does not relay an immunogenic response per se (70) and further illus-
trates the context dependence of effects resulting in immunogenicity. 
The involvement of autophagy-related proteins in the release of the DAMP HMGB1 
has been demonstrated using ATG5fl/fl Cre+ bone marrow-derived macrophages (11) and 
dying glioma cancer cells (in which HMGB1 was found in a subset of autophagosomes 
before release (71). The released HMGB1 by dying cancer cells can bind Toll-like recep-
tor (TLR-)4 and promotes the processing and presentation of tumour antigens by DCs. 
This leads to cross-priming of T-cells and enhances immunosurveillance (72). Further-
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In conclusion, ICD is an important pillar of therapy-induced anti-tumour immunity as 
it relays important signalling to the immune system, including DCs. DC stimulation may 
be important to induce tumour cure as demonstrated by ICD-based DC-vaccines in high 
grade glioma bearing mice (76). Nevertheless, the influence of autophagy on the display 
of DAMPs may be ICD-inducer dependent and requires further understanding for effec-
tive use.  
II. Cytokine release and influence on the tumour microenvironment 
ATP can bind the P2RX7 receptor and activate the NOD-like receptor family, pyrin do-
main containing 3 (NLRP3) inflammasome in DCs and macrophages (77). This inflam-
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masome activation can be suppressed by autophagy (20), which would be favorable as 
inflammasome activation and subsequent IL-1B release by e.g. macrophages have pro-
tumorigenic effects. However, the P2RX7 receptor impairs autophagy by blocking lyso-
somal function and stimulates release of vesicles with autophagolysosome characteris-
tics (78). This suggests that activation of the P2RX7 receptor leads to a secretory pheno-
type, via inhibition of autophagy. Depletion of IL-1B arrests growth in melanoma (79) 
and macrophage-derived IL-1B induced IL-17 expression from γδ T cells resulted in ex-
pansion of tumour associated neutrophils that suppress cytotoxic T cells in breast can-
cer, resulting in increased number of pulmonary and lymph node metastases (80). Al-
ternatively, in a murine colon carcinoma model autophagy-dependent ATP release after 
MTX treatment promoted recruitment of IFNγ-producing CD8+ T cells into the tumour 
in an IL-1B-mediated fashion (64).  
Lipopolysaccharide (LPS)/LPS+ATP stimulated GABARAP Knockout macrophages to 
secreted more IL-1B and IL-6. In addition, GABARAP knockout lymphocytes produced 
more IL-2 and interferon-γ. In this model, GABARAP KO was associated with reduced 
tumour incidence. These effects were validated on tumour control in a melanoma tu-
mour cell inoculated model (81) and indicate that GABARAP in non-cancerous cells is 
sufficient to sustain pro-tumorigenic effects potentially due to control of cytokine secre-
tion.  
A study using MMTV-PyMT mouse model of breast cancer-bearing a conditional de-
letion of autophagy gene FIP200 shows that these tumour cells have a different chemo-
kine secretion profile than FIP200 proficient cells. The TME polarizes towards an im-
proved immunosurveillance as enhanced secretion of chemokines including CXCL9, 
CXCL10 and CXCL11 lead to increased infiltration of IFNγ-producing CD8+ and CD4+ T 
cells (49). 
In conclusion, autophagy related secretion is important in controlling the cytokine 
profile of different cell types.  
III.a. Pro-metastatic: Driving an invasive behavior of cancer cells 
Oncogenic mutations in RAS are highly prevalent in cancers and drive different pro-
tumourigenic features including proliferation, survival and invasion. Autophagy deficient 
HRASV12 transformed breast cancer cell lines display reduced invasive protrusions in 
genetic knockdown models (including ATG7, ATG12 and ATG3) and after pharmacologi-
cal inhibition (chloroquine or bafilomycin A1). Addition of conditioned medium of au-
tophagy-proficient cells rescues the invasive phenotype, indicating a role for autophagy-
dependent secretion in triggering cellular migration. Correspondingly, the pulmonary 
metastatic potential of HRASV12 tumours is reduced in autophagy deficient cells, effects 
dependent on autophagy-related secretion (58). Despite these results in this model, the 
role of IL-6 in tumour progression is ambiguous in literature as both pro-tumorigenic 
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(metastasis, angiogenesis, immune suppression) and anti-tumorigenic (CD8+ T cell traf-
ficking to lymph nodes and tumours) effects on the TME are described (82).  
Kraya et al observed a cytokine profile that differed between melanoma cells with 
high and low autophagy activation that could be mimicked by introducing ATG7 knock-
down in an autophagy high cell line. The main secretory factors the authors focused on 
that were dependent on autophagy(-protein) are, leukemia inhibitory factor (LIF), family 
with sequence similarity 3 member C (FAM3C), dickkopf WNT signalling pathway inhibi-
tor 3 (DKK3) and IL-8. These factors are able to promote metastasis via mechanisms that 
include MMP2 upregulation (IL-8), epithelial to mesenchymal transition (FAM3C, DKK3, 
LIF) and promotion of angiogenesis (IL-8 and DKK3) (83). 
TLR3 and TLR4, that are expressed on immune cells including macrophages and DCs 
but also a variety of cancer cell, can activate the release of an array of cytokines (84). 
Recently, it has been demonstrated that TLR3 and TLR4 activation (in an LPS or poly(I:C) 
induced model) in lung cancer cell lines (A549 and H460) causes 1) Lys63 linked ubiqui-
tynation of TNF receptor associated factor 6 (TRAF6) and 2)induced autophagy. Herein, 
autophagy was required for TRAF6 ubiquitination that leads to downstream activation 
of NFkB and MAPK signalling and subsequent cytokine production. As a result, autopha-
gy deficiency in these lung cancer cells reduced release of IL-6, C-C motif chemokine 
ligand (CCL)-2, and CCL-20. CCL-2 secretion is associated with cell migration and CCL-20 
with a metastatic phenotype. Accordingly, autophagy deficiency impaired migratory 
capacity. IL-6 can induce VEGFA and MMP release that are associated with an invasive 
phenotype. Indeed, the invasive phenotype was dependent on autophagy and IL-6 and 
associated with VEGFA and MMP2 release (85).  
In breast cancer autophagy inhibition through ATG7 or Beclin1 knockdown altered 
IL-6 secretion. Interestingly, autophagy deficiency increased IL-6 secretion by MCF7 (low 
autophagy-dependent survival) and decreased IL-6 secretion by MDA-MB-468 (high 
autophagy-dependent survival) cells. IL-6 secretion is important for cancer stem cell 
(CSC) maintenance and is sufficient to induce CD44+:CD24low/- phenotype in breast 
cancer cells (86). In line, autophagy deficiency decreased mammosphere formation 
capacity of MDA-MB-468 cells. Rescue experiments illustrated that mammosphere 
formation was improved by IL-6 treatment and conditioned media from autophagy 
proficient MDA-MB-468 cells. Autophagy-dependent secretion of IL-6, but also other 
factors, are able to promote mammosphere formation and may be important in CSC 
maintenance (87).  
III.b. Pro-metastatic: Weibel-Palade body formation in vascular endothelium to 
facilitate metastasis 
Aberrant signaling in tumour-associated endothelial cells contributes to excessive neo-
vascularization that is a feature of solid tumours (reviewed in (75)). As discussed above, 
autophagy is important to sustain the secretion of protein-containing WPB by proper 
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vWF maturation. In tumour endothelial cells (TECs) these WPBs contain important se-
cretory factors that can influence tumour progression. In line, P-selectin is sorted into 
WPBs as a result of its ability to interact with vWF and is translocated to the cell mem-
brane upon stimulation (88). Once localized at the luminal side of the endothelial cell, it 
facilitates metastasis formation by promoting adhesion of circulating tumour cells (89). 
Impairment of autophagy may therefore reduce development of metastases. In addi-
tion to vWF and P-selectin, WPBs can contain other secretory proteins as angiopoietin 2 
which is positively associated with tumour progression (due to its angiogenic potential) 
and interleukin 8 which is important in tumour progression and metastasis (due to its 
angiogenic and immune response modulating potential). Collectively, autophagy-
dependent WPB formation may facilitate tumour progression, although these aspects 
require further investigation. 
IV. Therapy resistance  
Autophagy has been implicated in promoting chemo- and radioresistance. Although 
often presumed to be caused by its degradative feature, we demonstrated in irradiated 
cancer cells that knockdown of ATG7 or LC3B, but not treatment with lysosomal inhibi-
tor chloroquine, sensitizes cancer cells to radiation (90). This further supports a role of 
autophagy-related proteins to promote radioresistance through an alternative process 
such as secretion. For example, HMGB1 is secreted through autophagy-dependent 
mechanisms during ICD (11,71). Although this factor is an important DAMP that can 
increase immunogenic responses, HMGB1 increases Doxorubicin resistance in neighbor-
ing breast cancer cells (91). In line, the interaction of HMGB1 with the receptor for 
advanced glycation end products (RAGE) that is expressed on various cell lines in the 
tumour increases chemo resistance by inducing pro-survival autophagy (92).  
In addition to increasing angiogenesis and the pro-metastatic potential by DKK3 
DKK3 expression is associated with docetaxel chemo sensitivity in lung cancer cells 
through decreasing expression of the drug efflux pump P-glycoprotein (93). Further-
more, DKK3 overexpression in an esophageal adenocarcinoma cell line was associated 
with increased 5-FU and cisplatin resistance, invasion and activation of the TGF-B signal-
ing (94). 
In short, autophagy-dependent secretion is involved in anti-tumour effects through 
enhancing immunosurveillance, but is also important in tumour progression through 
stimulation of angiogenesis, changing drug resistance, triggering EMT and increasing 
metastases development. Manipulation of the secreted arsenal of proteins, and tilting 
the balance more towards an anti-tumour strategy may be an attractive novel approach 
in cancer treatment.  
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Table 2 autophagy dependent secreted factors 
Protein Mechanism REF 
Acbp Atg5, Atg7, Atg8, Atg12 (16) 
IL-1B ATG5 (11) 
NBR1, P62, OPTN and CACO2 LC3B-II Inhibition or depletion of PIKfyve by apilimod or siRNA (19) 
angiogenin 4, interlectin 1 and relmβ ATG16L1 ATG5 or ATG7 (25) 
MUC5AC ATG5 and ATG16L1  (26) 
Insulin GABARAP  
NPY ATG16L1 as RAB33a effector (33) 
von Willebrand factor (vWF), P-selectin, 
interleukin-8, angiopoietin-2 and endothelin-1 
ATG7,ATG5, chloroquine or bafilomycin A1 (34) 
matrix-degrading factors including cathepsin K ATG5 or ATG7 (35) 
Autophagy-dependent receptor trafficking in tumour progression 
Autophagy execution requires cargo recognition, packaging, vesicle transport, vesicle 
fusion and degradation. In addition to the catabolic function of autophagy, the autoph-
agy machinery is utilized for more purposes including intracellular trafficking and endo-
cytic signaling. In addition to these roles in secretion, autophagy mediates the retro- 
and anterograde trafficking of membrane bound receptors that may influence tumour 
progression. 
For example, the GABARAP protein family mediates membrane of cell- surface ex-
pression of receptors like the GABA (A) receptor (GABAAR (95), the human kappa opioid 
receptor (hKOPR) (96), transient receptor potential cation channel subfamily V member 
1 (TRPV1) (97),the angiotensin II receptors (AGTR) (98,99) and the epidermal growth 
factor receptor (EGFR) (100). 
EGFR controls cell proliferation, migration and differentiation and is frequently over 
activated in several cancer types due to amplification or mutation (101). EGFR express-
ing tumours depend on autophagy for their survival and proliferation. Inhibition of au-
tophagy by the administration of chloroquine abrogated the radioresistant phenotype 
of these tumours (55)(reviewed in (102)). Interestingly, during hypoxia translocation of 
EGFR to the plasma membrane is controlled by GABARAPL1 (100). Upon hypoxia expo-
sure, GABARAPL1 colocalizes with EGFR at the cytoplasmic site of the plasma mem-
brane. Moreover, knockdown of GABARAPL1 resulted in a decrease in EGFR membrane 
expression, but not in overall EGFR expression, suggesting a role for GABARAPL1 in 
anterograde transport of EGFR.  
The KOR and GABAAR are involved in neurological processes and play a role in a va-
riety of processes like pain sensation, consciousness, and mood.  
The GABA(A) receptor (GABAAR) is well known for its inhibitory role on active neu-
rons and is expressed on the postsynaptic throughout the whole body, although mainly 
expressed in the mammalian brain. Surprisingly, overexpression of the GABAAR leads to 
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brane. Moreover, knockdown of GABARAPL1 resulted in a decrease in EGFR membrane 
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anterograde transport of EGFR.  
The KOR and GABAAR are involved in neurological processes and play a role in a va-
riety of processes like pain sensation, consciousness, and mood.  
The GABA(A) receptor (GABAAR) is well known for its inhibitory role on active neu-
rons and is expressed on the postsynaptic throughout the whole body, although mainly 
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several types of cancer including breast, liver, lung and pancreatic cancers and contrib-
utes to migration of breast cancer cells through activation of extracellular-regulated 
kinase 1/2 (ERK1/2) (103-108). GABARAP and GABARAPL1 are both involved in GABAAR 
trafficking towards the plasma membrane. In this role, GABARAP probably serves as a 
cargo-receptor which mediates GABAAR incorporation in the transport vesicle by a 
direct interaction with the γ2 subunit of the receptor. GABARAP knockdown mice show 
no defects in GABAAR expression, suggesting that GABARAP is redundant and other 
molecules, like its homolog GABARAPL1, can take over its function (109).  
In contrast to the pro-tumorigenic effects of EGFR and GABAAR signalling, membrane 
expression mediated through autophagy-related proteins also results in the expression 
of receptors that may inhibit tumour progression, for example through KOR signalling. 
The KOR is well characterized for its analgesic role. However, the KOR also acts as a nega-
tive regulator of cell proliferation in breast, lung and prostate cancers (110,111). Opioid 
receptors belong to the GPCR family, and activation of the receptors modulates the 
MAPK pathway and inhibit pro survival PI3K/AKT signalling molecules and may antago-
nize EGFR signalling (110). Both GABARAP and GABARAPL1 are required for anterograde 
transport of the KOR receptor. Interestingly, because of its stronger interaction 
GABARAPL1 does not need C-terminal modification in contrast to GABARAP, which re-
quires membrane association to transport the KOR to the plasma membrane (96).  
Taken together, the GABARAP family proteins mediates trafficking and surface expres-
sion of receptors with both tumour promoting (EGFR, GABAAR) and tumour inhibitory 
characteristics (KOR). This suggests that the GABARAP family contributes to cancer pro-
gression in a context-dependent manner, being in a tumour promoting or inhibitory role. 
Concluding remarks 
Autophagy has been considered as an important tumour suppressive process for cellu-
lar homeostasis by effectuating lysosomal degradation of the cells’ toxic constituents. 
Importantly autophagy mediates an additional cellular feature, the trafficking and re-
lease of specific proteins. These effects are important during physiological conditions 
(e.g. maintaining a barrier for infection by mucus and lysozyme secretion and waste 
secretion), but also mediate important effects in tumour progression (figure 1). The 
autophagy mediated secreted factors may stimulate cellular proliferation via auto- and 
paracrine signaling and establish a communicative tool between cells that can either 
stimulate or limit tumour progression. The autophagy mediated release of DAMPs seem 
to be ICD inducer-dependent and polarize the tumour microenvironment towards a less 
immunosuppressive phenotype. Alternatively, tumours are characterized by promoting 
an immunosuppressed tumour microenvironment by cytokine signaling. Furthermore, 
autophagy mediated secretory signaling promotes an invasive phenotype. 
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Figure 1. Effects of autophagy dependent secretion on tumour progression. 
Schematic representation of autophagy mediated secretory events that either inhibit or support tumour 
progression displayed here on the left (‘Anti tumour’) and right side (‘Tumour supportive’) respectively. The 
different sources of autophagy dependent secretory factors (bold italic) establish multiple effects on the 
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tumour microenvironment (in blue boxes) by the designated factors. As such, factors that promote angiogen-
esis, invasion, a migratory phenotype, cancer stem cell (CSC) maintenance or chemoresistance support tu-
mour progression. Also, a reduced surface expression of calreticulin by cancer cells undergoing immunogenic 
cell death (ICD) hinders an immunogenic response. Oppositely, some factors have counteractive effects on 
tumour progression by improving immune cell adhesion or recruitment. Moreover, the ‘eat-me’ signal ATP 
together with HMGB1/TLR4 mediated improved processing and presentation of tumour antigens by dendritic 
cells (DCs) promote interferon gamma (IFNγ) producing T cells to aid antitumor immunity. The ATP/P2RX7-
mediated activation of the inflammasome in macrophages (mφ) and DCs can have an array of effects of which 
the final inhibition/support of tumour progression may be context-dependent.  
 
An important note is that autophagy may convey direct or indirect effects on secretory 
events through formation of the mobilized vesicle, facilitation of anterograde trafficking 
or alterations in homeostasis and/or autonomous cell signaling.  
In conclusion, autophagy (or autophagy-related proteins) is an important cellular 
process that is more elaborate than solemnly a degradative pathway. It facilitates mul-
tiple secretory events that can promote tumour progression by limiting immunosurveil-
lance and stimulating invasiveness and angiogenesis.  
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tumour microenvironment (in blue boxes) by the designated factors. As such, factors that promote angiogen-
esis, invasion, a migratory phenotype, cancer stem cell (CSC) maintenance or chemoresistance support tu-
mour progression. Also, a reduced surface expression of calreticulin by cancer cells undergoing immunogenic 
cell death (ICD) hinders an immunogenic response. Oppositely, some factors have counteractive effects on 
tumour progression by improving immune cell adhesion or recruitment. Moreover, the ‘eat-me’ signal ATP 
together with HMGB1/TLR4 mediated improved processing and presentation of tumour antigens by dendritic 
cells (DCs) promote interferon gamma (IFNγ) producing T cells to aid antitumor immunity. The ATP/P2RX7-
mediated activation of the inflammasome in macrophages (mφ) and DCs can have an array of effects of which 
the final inhibition/support of tumour progression may be context-dependent.  
 
An important note is that autophagy may convey direct or indirect effects on secretory 
events through formation of the mobilized vesicle, facilitation of anterograde trafficking 
or alterations in homeostasis and/or autonomous cell signaling.  
In conclusion, autophagy (or autophagy-related proteins) is an important cellular 
process that is more elaborate than solemnly a degradative pathway. It facilitates mul-
tiple secretory events that can promote tumour progression by limiting immunosurveil-
lance and stimulating invasiveness and angiogenesis.  
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Bioinformatic analysis 
Raw Data files were processed using MaxQuant software suite (version 1.5.2.8, Tyano-
va, S.; Temu, T.; Cox, J. The MaxQuant computational platform for mass spectrometry − 
based shotgun proteomics. Nature Protoc. 2016, 11 (12), 2301−2319) for identification 
and relative quantification of proteins. A false discovery rate (FDR) of 0.01 for proteins 
and peptides and a minimum peptide length of six amino acids were required. The An-
dromeda search engine was used to search the MS/MS spectra against the Human 
Uniprot database. A maximum of two missed cleavages were allowed. Q Exactive spec-
tra were analyzed using MaxQuant’s default settings for Orbitrap spectra, including a 
main search peptide and MS/MS match tolerance of 4.5 and 20 ppm, respectively. The 
maximum precursor ion charge state used for searching was 7, and the enzyme specific-
ity was set to trypsin. Further modifications were cysteine carbamidomethylation (fixed) 
as well as protein methionine oxidation. For demethylation labeled samples 28.031 Da 
on lysine and the peptide N-terminus (light) and 36.076 Da on lysine and the peptide N-
terminus (heavy) were added to the search parameters. The minimum number of razor 
and unique peptides was set to 1. Heavy-to-light (H/L) ratios were calculated using 
MaxQuant’s default settings. 
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Cancer is still causing great morbidity and mortality worldwide and as our population 
ages, the incidence rates are increasing. Cancer arises due to genetic changes that ac-
cumulate over cellular generations and cancer cells are selected to withstand the some-
times harsh conditions observed within the tumour. In addition, cancer cells use the 
same general mechanisms that normal cells utilize to adapt to (micro-) environmental 
changes.  
Tumours are characterized by the presence of immature and often chaotic vascula-
ture that results in insufficient blood supply to areas within the tumour. The high meta-
bolic rate of cancer cells in combination with insufficient oxygen delivery results in hy-
poxic tumour regions, a common feature of most solid tumours. Oxygenation in tu-
mours may vary from normal values (~5%) close to the vessel wall to complete anoxia 
(0% O2) close to perinecrotic regions. Hypoxic cells are more resistant to chemo- and 
radiotherapy and are associated with increased metastasis resulting in poor prognosis 
of patients. Although common in tumours, hypoxia (especially severe hypoxia) is not 
observed in the human body and therefore poses a therapeutic opportunity. Funda-
mental understanding of how cancer adapts to hypoxic episodes is therefore essential 
to develop novel therapeutic strategies. The work in this thesis addresses novel findings 
how cancer cells respond to hypoxia. One of the mechanisms that allows cells to survive 
hypoxia is autophagy, consequently autophagy inhibition increases therapy efficacy in 
pre-clinical studies and cancer patients (1,2) (+ chapter 4). Autophagy is a mechanism 
that allows the cell to recycle aged or obsolete subcellular compartments/ organelles 
and protein aggregates to maintain cellular homeostasis. During normal conditions the 
autophagic rate is relatively low, but can be rapidly upregulated during periods of (met-
abolic) stress. In cancer cells elevated autophagy-activity is frequently observed. Au-
tophagy is dependent on the formation of intracellular vesicles, the autophagosome. 
The cargo to be degraded is randomly or selectively sorted into these autophagosomes. 
The latter via specific adaptor proteins that recognize ubiquitylated substrates. These 
proteins act as an adaptor between the recognized cargo and members of the 
LC3/GABARAP protein family. This LC3/GABARAP protein family consists of 7 members 
including LC3A, -B and C, and GABARAP, GABARAPL1 and GABARAPL2, which share a 
high degree of homology in amino acid sequence and tertiary structure. The last decade 
most of autophagy research has been focused on LC3B. Yet, due to the high degree of 
homology and lack of unstructured overview the family members’ function, the current 
dogma is that all LC3B/GABARAP protein family members are redundant and functional-
ly involved in autophagy. In chapter 2, we systematically reviewed the current 
knowledge on the individual functional role of the LC3/ GABARAP protein family mem-
bers. In addition to overlapping functions, most LC3/ GABARAP protein family members 
mediate unique, autophagy (in)dependent functions. Proteins from the GABARAP sub-
family display several functions in intracellular trafficking. For example, GABARAP and 
GABARAPL1 are required for the trafficking and membrane expression of receptors, 
including the kappa opioid receptor, the angiotensin receptor II and the GABA receptor 
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(3-5), but also the transient receptor potential cation channel subfamily V member 
(TRPV). It is still unclear how these processes work exactly, but it is suggested that they 
might function as a scaffold protein between kinesin motor proteins and the transport 
vesicle (6). GABARAPL1 is also shown to interact with motor proteins, however the 
functional role is still under investigation. In addition, we identified a role for 
GABARAPL1 in membrane expression of the epidermal growth factor receptor (EGFR) 
during hypoxia (chapter 3). Interestingly, GABARAPL1 expression is induced during hy-
poxia, which suggests a specific function during these conditions. The upregulation is 
dependent on increased transcription orchestrated by the PERK-ATF4 arm of the un-
folded protein response (UPR), a cellular stress responsive pathway that senses unfold-
ed and misfolded proteins in the ER. Furthermore we observed that only GABARAPL1, 
and not GABARAPL2 mRNA expression was induced during hypoxia, indicating unique 
regulatory mechanisms that control expression and suggesting that both proteins are 
required to fulfill specific functions during these conditions.  
Tumour hypoxia is an independent prognostic marker for treatment outcome, irre-
spective of the treatment modality. Because GABARAPL1 expression is induced during 
hypoxia, we tested if GABARAPL1 expression could be linked to treatment outcome. In a 
panel of head and neck cancer patients GABARAPL1 expression correlated with reduced 
local and loco-regional control of these patients. In addition to the physical presence of 
hypoxia that contributes to resistance to therapies, GABARAPL1-dependent membrane 
expression of tumour growth stimulating receptors, such as the EGFR, and the secretion 
of pro-angiogenic factors (chapter 7) can contribute to decreased treatment outcome. 
In contrast to our studies, other groups reported tumour suppressive functions of 
GABARAPL1 and correlated GABARAPL1 expression to increased survival (7). However, 
these studies addressed different tumour sites, suggesting tumour specific mechanisms. 
Summarizing, this suggests that GABARAPL1 expression could be linked to treatment 
outcome and potentially could be used as a prognostic biomarker. 
In addition to their role in autophagy and intracellular trafficking of receptors, LC3/ 
GABARAP protein family members but also other proteins of the core autophagy ma-
chinery, have been associated to secretory mechanisms. In chapter 6 we summarized 
current knowledge about autophagy-dependent secretion and what the consequences 
are on tumour progression. In the classical ER-to-Golgi route, proteins are marked for 
secretion by a leader-peptide, which serves as a secretion signal. However, also proteins 
without this sequence can be secreted via alternative forms of unconventional secre-
tion in an autophagy-dependent manner (8-10). Autophagy-dependent secreted factors 
are actively released and have pro-metastatic properties can stimulate proliferation via 
auto- and paracrine signalling but also have immune modulating properties that can 
promote the invasive phenotype.  
Also defects in autophagy, such as defects in lysosome/ autophagosome fusion, can 
lead to secretion of the cargo in the extracellular environment. The concept autophagy-
dependent secretion is still in its infancy and is poorly understood. Many questions 
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Cancer is still causing great morbidity and mortality worldwide and as our population 
ages, the incidence rates are increasing. Cancer arises due to genetic changes that ac-
cumulate over cellular generations and cancer cells are selected to withstand the some-
times harsh conditions observed within the tumour. In addition, cancer cells use the 
same general mechanisms that normal cells utilize to adapt to (micro-) environmental 
changes.  
Tumours are characterized by the presence of immature and often chaotic vascula-
ture that results in insufficient blood supply to areas within the tumour. The high meta-
bolic rate of cancer cells in combination with insufficient oxygen delivery results in hy-
poxic tumour regions, a common feature of most solid tumours. Oxygenation in tu-
mours may vary from normal values (~5%) close to the vessel wall to complete anoxia 
(0% O2) close to perinecrotic regions. Hypoxic cells are more resistant to chemo- and 
radiotherapy and are associated with increased metastasis resulting in poor prognosis 
of patients. Although common in tumours, hypoxia (especially severe hypoxia) is not 
observed in the human body and therefore poses a therapeutic opportunity. Funda-
mental understanding of how cancer adapts to hypoxic episodes is therefore essential 
to develop novel therapeutic strategies. The work in this thesis addresses novel findings 
how cancer cells respond to hypoxia. One of the mechanisms that allows cells to survive 
hypoxia is autophagy, consequently autophagy inhibition increases therapy efficacy in 
pre-clinical studies and cancer patients (1,2) (+ chapter 4). Autophagy is a mechanism 
that allows the cell to recycle aged or obsolete subcellular compartments/ organelles 
and protein aggregates to maintain cellular homeostasis. During normal conditions the 
autophagic rate is relatively low, but can be rapidly upregulated during periods of (met-
abolic) stress. In cancer cells elevated autophagy-activity is frequently observed. Au-
tophagy is dependent on the formation of intracellular vesicles, the autophagosome. 
The cargo to be degraded is randomly or selectively sorted into these autophagosomes. 
The latter via specific adaptor proteins that recognize ubiquitylated substrates. These 
proteins act as an adaptor between the recognized cargo and members of the 
LC3/GABARAP protein family. This LC3/GABARAP protein family consists of 7 members 
including LC3A, -B and C, and GABARAP, GABARAPL1 and GABARAPL2, which share a 
high degree of homology in amino acid sequence and tertiary structure. The last decade 
most of autophagy research has been focused on LC3B. Yet, due to the high degree of 
homology and lack of unstructured overview the family members’ function, the current 
dogma is that all LC3B/GABARAP protein family members are redundant and functional-
ly involved in autophagy. In chapter 2, we systematically reviewed the current 
knowledge on the individual functional role of the LC3/ GABARAP protein family mem-
bers. In addition to overlapping functions, most LC3/ GABARAP protein family members 
mediate unique, autophagy (in)dependent functions. Proteins from the GABARAP sub-
family display several functions in intracellular trafficking. For example, GABARAP and 
GABARAPL1 are required for the trafficking and membrane expression of receptors, 
including the kappa opioid receptor, the angiotensin receptor II and the GABA receptor 
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(3-5), but also the transient receptor potential cation channel subfamily V member 
(TRPV). It is still unclear how these processes work exactly, but it is suggested that they 
might function as a scaffold protein between kinesin motor proteins and the transport 
vesicle (6). GABARAPL1 is also shown to interact with motor proteins, however the 
functional role is still under investigation. In addition, we identified a role for 
GABARAPL1 in membrane expression of the epidermal growth factor receptor (EGFR) 
during hypoxia (chapter 3). Interestingly, GABARAPL1 expression is induced during hy-
poxia, which suggests a specific function during these conditions. The upregulation is 
dependent on increased transcription orchestrated by the PERK-ATF4 arm of the un-
folded protein response (UPR), a cellular stress responsive pathway that senses unfold-
ed and misfolded proteins in the ER. Furthermore we observed that only GABARAPL1, 
and not GABARAPL2 mRNA expression was induced during hypoxia, indicating unique 
regulatory mechanisms that control expression and suggesting that both proteins are 
required to fulfill specific functions during these conditions.  
Tumour hypoxia is an independent prognostic marker for treatment outcome, irre-
spective of the treatment modality. Because GABARAPL1 expression is induced during 
hypoxia, we tested if GABARAPL1 expression could be linked to treatment outcome. In a 
panel of head and neck cancer patients GABARAPL1 expression correlated with reduced 
local and loco-regional control of these patients. In addition to the physical presence of 
hypoxia that contributes to resistance to therapies, GABARAPL1-dependent membrane 
expression of tumour growth stimulating receptors, such as the EGFR, and the secretion 
of pro-angiogenic factors (chapter 7) can contribute to decreased treatment outcome. 
In contrast to our studies, other groups reported tumour suppressive functions of 
GABARAPL1 and correlated GABARAPL1 expression to increased survival (7). However, 
these studies addressed different tumour sites, suggesting tumour specific mechanisms. 
Summarizing, this suggests that GABARAPL1 expression could be linked to treatment 
outcome and potentially could be used as a prognostic biomarker. 
In addition to their role in autophagy and intracellular trafficking of receptors, LC3/ 
GABARAP protein family members but also other proteins of the core autophagy ma-
chinery, have been associated to secretory mechanisms. In chapter 6 we summarized 
current knowledge about autophagy-dependent secretion and what the consequences 
are on tumour progression. In the classical ER-to-Golgi route, proteins are marked for 
secretion by a leader-peptide, which serves as a secretion signal. However, also proteins 
without this sequence can be secreted via alternative forms of unconventional secre-
tion in an autophagy-dependent manner (8-10). Autophagy-dependent secreted factors 
are actively released and have pro-metastatic properties can stimulate proliferation via 
auto- and paracrine signalling but also have immune modulating properties that can 
promote the invasive phenotype.  
Also defects in autophagy, such as defects in lysosome/ autophagosome fusion, can 
lead to secretion of the cargo in the extracellular environment. The concept autophagy-
dependent secretion is still in its infancy and is poorly understood. Many questions 
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remain unanswered: How is the autophagy machinery involved in the biogenesis of 
secretory vesicles/ exosomes? What differentiates secretory vesicles from degradative 
vesicles? Where do these machineries converge? What is the signal for secretion? 
After molecules have been internalized though several mechanisms of endocytosis, 
the internalized cargo are sorted in vesicular compartments referred to as endosomes 
after which they can have several different fates. Endosomes can be degraded though 
fusion with autophagosomes, or directly via fusion with lysosomes, but they can also be 
recycled back to the plasma membrane via formation of multivesicular bodies (MVB) 
which arise after intraluminal vesicles (ILV) formation by inward budding of the endo-
somal membrane. At this point, different sorting mechanisms, such as the ESCRT ma-
chinery are involved in fine-tuning the sorted cargo into these ILVs. Once MVBs fuse 
with the plasma membrane, ILVS are released in the extracellular environment as exo-
somes and are considered as extracellular vesicles.  
Extracellular vesicles are emerging as vehicles of intercellular communication and 
more is known about their role in physiological and pathological conditions such as 
cancer. EVs are small membranous particles which are secreted by most, if not all cells 
and contain biological information such as miRNAs and proteins. In general, EV content 
seems to reflect the status of the cell of origin, however, accumulating evidence shows 
that specific molecules are enriched in EV subpopulations. In chapter 7, we demonstrate 
that during severe hypoxia, cells secrete a subpopulation of EVs that are characterized 
by a difference in size. This subpopulation is secreted in a GABARAPL1 dependent man-
ner. These EVs, which are marked by GABARAPL1 expression on EV membrane, have 
pro-angiogenic properties that stimulate tumour growth. Depletion of GABARAPL1 
through the expression of shRNAs alters EV composition in a cell line dependent man-
ner. Xenografts of these GABARAPL1 knockdown cells displayed reduced growth, re-
duced vessel density and increased necrosis. However, the effect of GABARAPL1 deple-
tion on EV secretion and composition seems to be cell line dependent. In HT29, 
GABARAPL1 depletion leads to decreased marker expression and decreased total EV 
counts. In contrast, in U87, GABARAPL1 depletion leads to decreased expression of 
some makers, but an increase in the tetraspanin CD63. Also total secreted EV counts 
were not affected. GABARAPL1 deficient MDA-MB-231 cells (chapter 8) show an in-
crease in the tested markers CD81 and CD63 and differences in RNA loading. Currently, 
the mechanism how GABARAPL1 participates in EV secretion is under investigation. 
However, current data suggests that GABARAPL1 is involved in sorting of EV cargo ra-
ther than transport. This is supported by the observation that GABARAPL1 deficient cells 
have enlarged endosomal (CD63+) compartments (presumable late endosomes/ MVBs), 
which indicates defects in endosomal pathways. In HT29 cells, this sorting mechanism is 
probably disturbed to such an extensive degree, that also total EV secretion is de-
creased. 
LC3/ GABARAP subfamily members can be conjugated to phosphatidylethanolamine 
(PE) at the C-terminal site to associate with membranes. For LC3 subfamily members, 
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this conjugation is required for autophagy. GABARAPL1 also contains this C-terminal 
glycine, but this site is not required for GABARAPL1 mediated EV secretion (chapter 7). 
That GABARAPL1 is membrane bound, we demonstrated with cryo-transmission elec-
tron microscopy experiments, where we showed that after secretion, GABARAPL1 ex-
pression is retained at the EV surface. This might suggest that other post-translational 
mechanisms are at play to bind GABARAPL1 to the EV membrane. How this modification 
works and if this requires modification at the N or C terminal site, remains to be eluci-
dated.  
That GABARAPL1 expression is retained at the EV surface can be of therapeutic in-
terest. In a small group of patients with glioblastoma, colorectal cancer and small cell 
lung cancer we detected elevated levels of GABARAPL1+EVs in plasma compared to 
healthy volunteers. As we demonstrated that GABARAPL1+EVs are secreted by hypoxic 
cells and are functionally active by stimulating angiogenesis and potentially mediating 
metastasis formation, this means too they could be explored as a therapeutic target or 
as biomarkers to determine the hypoxic levels of a tumour. That inhibition of 
GABARAPL1+EVs works to inhibit blood vessel formation we showed in vitro by prevent-
ing GABARAPL1+EV function with blocking antibodies to inhibit tube formation. Current-
ly we are developing monoclonal antibodies to explore the therapeutical potential in 
vivo. In these studies we will explore tumour growth inhibition and prevention of me-
tastasis. Furthermore, we will explore to potential of GABARAPL1+EVs as a biomarker to 
determine the hypoxic fraction of a tumour. Additionally, methods to determine 
GABARAPL1+EVs in the blood of cancer patients are being developed.  
In addition to pro-angiogenic properties of GABARAPL1+EV, GABRAPL1+EVs are po-
tentially involved in metastasis formation (chapter 8). We observed a decrease of 80% in 
lung metastasis in GABARAPL1 deficient orthotopically implanted breast tumours in 
mice, indicating an important role for GABARAPL1 in mediating metastasis formation. 
Metastasis is complex mechanisms were the cell require survival of multiple stages in 
the cascade. To develop into a metastasis, cells need to detach from the tumour, enter 
and survive the circulation and infiltrate the tissue and outgrow to a metastasis. Previ-
ously, we showed that GABARAPL1+EV have growth stimulating properties at distant 
tumour sites, we were therefore prompted to investigate the role of GABARAPL1 in 
metastasis development. Although this remains work in progress to elucidate the role of 
GABARAPL1 in metastasis formation, several steps in the metastatic cascade were ad-
dressed. GABARAPL1 seems to contribute to metastasis formation by development of 
the pre-metastatic niche. During development of the pre-metatatic niche, the micro 
milieu of the distant tissue is prepared in such a way that circulating tumour cells can 
colonize. To show this, we implanted breast tumours orthotopically in the fat pad of 
mice, consisting of a mixed population of Green fluorescent protein (GFP) expressing 
control cells, and Red fluorescent protein (RFP) expressing GABARAPL1 knockdown 
cells. After the tumour reached the maximum size, lungs were removed and lungs were 
examined for green and red fluorescent metastases. If the decrease in metastasis would 
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remain unanswered: How is the autophagy machinery involved in the biogenesis of 
secretory vesicles/ exosomes? What differentiates secretory vesicles from degradative 
vesicles? Where do these machineries converge? What is the signal for secretion? 
After molecules have been internalized though several mechanisms of endocytosis, 
the internalized cargo are sorted in vesicular compartments referred to as endosomes 
after which they can have several different fates. Endosomes can be degraded though 
fusion with autophagosomes, or directly via fusion with lysosomes, but they can also be 
recycled back to the plasma membrane via formation of multivesicular bodies (MVB) 
which arise after intraluminal vesicles (ILV) formation by inward budding of the endo-
somal membrane. At this point, different sorting mechanisms, such as the ESCRT ma-
chinery are involved in fine-tuning the sorted cargo into these ILVs. Once MVBs fuse 
with the plasma membrane, ILVS are released in the extracellular environment as exo-
somes and are considered as extracellular vesicles.  
Extracellular vesicles are emerging as vehicles of intercellular communication and 
more is known about their role in physiological and pathological conditions such as 
cancer. EVs are small membranous particles which are secreted by most, if not all cells 
and contain biological information such as miRNAs and proteins. In general, EV content 
seems to reflect the status of the cell of origin, however, accumulating evidence shows 
that specific molecules are enriched in EV subpopulations. In chapter 7, we demonstrate 
that during severe hypoxia, cells secrete a subpopulation of EVs that are characterized 
by a difference in size. This subpopulation is secreted in a GABARAPL1 dependent man-
ner. These EVs, which are marked by GABARAPL1 expression on EV membrane, have 
pro-angiogenic properties that stimulate tumour growth. Depletion of GABARAPL1 
through the expression of shRNAs alters EV composition in a cell line dependent man-
ner. Xenografts of these GABARAPL1 knockdown cells displayed reduced growth, re-
duced vessel density and increased necrosis. However, the effect of GABARAPL1 deple-
tion on EV secretion and composition seems to be cell line dependent. In HT29, 
GABARAPL1 depletion leads to decreased marker expression and decreased total EV 
counts. In contrast, in U87, GABARAPL1 depletion leads to decreased expression of 
some makers, but an increase in the tetraspanin CD63. Also total secreted EV counts 
were not affected. GABARAPL1 deficient MDA-MB-231 cells (chapter 8) show an in-
crease in the tested markers CD81 and CD63 and differences in RNA loading. Currently, 
the mechanism how GABARAPL1 participates in EV secretion is under investigation. 
However, current data suggests that GABARAPL1 is involved in sorting of EV cargo ra-
ther than transport. This is supported by the observation that GABARAPL1 deficient cells 
have enlarged endosomal (CD63+) compartments (presumable late endosomes/ MVBs), 
which indicates defects in endosomal pathways. In HT29 cells, this sorting mechanism is 
probably disturbed to such an extensive degree, that also total EV secretion is de-
creased. 
LC3/ GABARAP subfamily members can be conjugated to phosphatidylethanolamine 
(PE) at the C-terminal site to associate with membranes. For LC3 subfamily members, 
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this conjugation is required for autophagy. GABARAPL1 also contains this C-terminal 
glycine, but this site is not required for GABARAPL1 mediated EV secretion (chapter 7). 
That GABARAPL1 is membrane bound, we demonstrated with cryo-transmission elec-
tron microscopy experiments, where we showed that after secretion, GABARAPL1 ex-
pression is retained at the EV surface. This might suggest that other post-translational 
mechanisms are at play to bind GABARAPL1 to the EV membrane. How this modification 
works and if this requires modification at the N or C terminal site, remains to be eluci-
dated.  
That GABARAPL1 expression is retained at the EV surface can be of therapeutic in-
terest. In a small group of patients with glioblastoma, colorectal cancer and small cell 
lung cancer we detected elevated levels of GABARAPL1+EVs in plasma compared to 
healthy volunteers. As we demonstrated that GABARAPL1+EVs are secreted by hypoxic 
cells and are functionally active by stimulating angiogenesis and potentially mediating 
metastasis formation, this means too they could be explored as a therapeutic target or 
as biomarkers to determine the hypoxic levels of a tumour. That inhibition of 
GABARAPL1+EVs works to inhibit blood vessel formation we showed in vitro by prevent-
ing GABARAPL1+EV function with blocking antibodies to inhibit tube formation. Current-
ly we are developing monoclonal antibodies to explore the therapeutical potential in 
vivo. In these studies we will explore tumour growth inhibition and prevention of me-
tastasis. Furthermore, we will explore to potential of GABARAPL1+EVs as a biomarker to 
determine the hypoxic fraction of a tumour. Additionally, methods to determine 
GABARAPL1+EVs in the blood of cancer patients are being developed.  
In addition to pro-angiogenic properties of GABARAPL1+EV, GABRAPL1+EVs are po-
tentially involved in metastasis formation (chapter 8). We observed a decrease of 80% in 
lung metastasis in GABARAPL1 deficient orthotopically implanted breast tumours in 
mice, indicating an important role for GABARAPL1 in mediating metastasis formation. 
Metastasis is complex mechanisms were the cell require survival of multiple stages in 
the cascade. To develop into a metastasis, cells need to detach from the tumour, enter 
and survive the circulation and infiltrate the tissue and outgrow to a metastasis. Previ-
ously, we showed that GABARAPL1+EV have growth stimulating properties at distant 
tumour sites, we were therefore prompted to investigate the role of GABARAPL1 in 
metastasis development. Although this remains work in progress to elucidate the role of 
GABARAPL1 in metastasis formation, several steps in the metastatic cascade were ad-
dressed. GABARAPL1 seems to contribute to metastasis formation by development of 
the pre-metastatic niche. During development of the pre-metatatic niche, the micro 
milieu of the distant tissue is prepared in such a way that circulating tumour cells can 
colonize. To show this, we implanted breast tumours orthotopically in the fat pad of 
mice, consisting of a mixed population of Green fluorescent protein (GFP) expressing 
control cells, and Red fluorescent protein (RFP) expressing GABARAPL1 knockdown 
cells. After the tumour reached the maximum size, lungs were removed and lungs were 
examined for green and red fluorescent metastases. If the decrease in metastasis would 
Dissertatie Tom Keulers Tab V.indd   189 02-01-19   16:07:51
Chapter 9 
190 
be caused by cell intrinsic changes caused by GABARAPL1 knock down, such as de-
creased membrane expression of certain receptors, we expect to identify GFP express-
ing metastases only. If the decrease in metastases was caused by a defect in tumour 
derived secreted factors, such as EVs, we expected to identify control and GABARAPL1 
deficient metastases in comparable numbers In the lungs we observed control cell-
derived metastases as well as GABARAPL1 knockdown derived metastases, which sup-
ports the hypothesis of a GABARAPL1 mediated pre-metastatic niche formation. Inter-
estingly, RFP expressing GABARAPL1 knockdown cells were always accompanied by GFP 
expressing control cells, which also could suggest a metastatic niche formation by the 
control cells, rather than a pre-metastatic niche. Taken together we can conclude that 
GABARAPL1 is important for metastasis formation, and that this is potentially mediated 
through GABARAPL1+EV. 
Epidermal growth factor receptor (EGFR) is a member of ErbB family of receptors 
and is expressed in normal tissues where it is involved in processes as proliferation and 
inhibition of apoptosis (11). Mutation or over expression of the receptor can lead to 
several pathologies such Alzheimer and cancer. EGFRvIII is a mutated form of EGFR 
characterized by a deletion of exon 2- 7 of the extracellular domain and is most preva-
lent in glioblastoma multiforme patients (GBM) who have a very poor prognosis (12,13). 
As a consequence of deletion of the extracellular domain the receptor is constitutively 
active, promoting pro-oncogenic effects and tumourigenicity (14,15).We demonstrated 
that EGFRvIII expressing tumours display increased activation and dependency on au-
tophagy during metabolic stress including hypoxia. Typically EGFRvIII+ tumours show an 
increased tolerance towards hypoxia resulting in an increased hypoxic fraction. Addi-
tionally, EGFRvIII+ tumours show increased growth and increased regrowth rates after 
radiotherapy, resulting in decreased treatment outcome. Tumour hypoxia is a major 
limiting factor in cancer treatment (16). Therefore, targeting hypoxia in these tumours 
may contribute to increased survival rates. We demonstrate that EGFRvIII+ cells are 
more dependent on autophagy during hypoxia than non-EGFRvIII expressing tumours. 
Pharmacological inhibition of autophagy with the lysosomotropic drug chloroquine 
sensitizes EGFRvIII+ cells to hypoxia and nutrient deprivation. As we have shown before, 
reducing the hypoxic fraction by targeting autophagy with chloroquine treatment sensi-
tizes xenografts to radiotherapy (17). This effect is more pronounced in EGFRvIII+ ex-
pressing tumours. In a retrospective study we showed that patients with EGFRvIII+ GBM 
benefit most from concurrent chloroquine treatment. These results suggest that EG-
FRvIII+ oncogene addiction in glioblastoma is a therapeutic vulnerability to chloroquine 
and could be a biomarker for patient stratification in clinical studies. 
Strikingly, EGFRvIII+ cells consume more glucose suggesting that autophagy supports 
metabolic processes in EGFRvIII+ cells. The effects of autophagy inhibition on EGFRvIII 
positive cells, such as decreased hypoxia tolerance, can be rescued by pyruvate but not 
by glucose supplementation in the cell culture medium. This suggests that the glycolysis 
is already used to its fullest extent, and that autophagy is required as an additional en-
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ergy source for these tumours. These data are in agreement with previous studies, 
showing that other mutations in the RAS/RAF/MEK/ERK pathway, such the BRAFV600E 
mutation (1), but also HRASG12V or KRASG12V transformed cells show an increased de-
pendency on autophagy (2). 
Taken together, this study indicates that EGFRvIII+ have an increased metabolism 
and are more dependent on autophagy for their survival than EGFRvIII negative cells 
during metabolic stress. Remarkable results have been observed of EGFRvIII+ GBM pa-
tients treated concurrently with chloroquine and Radio- and chemotherapy (1). Current-
ly 2 clinical trials (clinicaltrials.gov identifier NCT02378532 and NCT02432417) are initi-
ated to evaluate toxicity of chloroquine in combination with radiotherapy and temozo-
lamide, a chemotherapeutic commonly used for the treatment of GBM.  
Autophagy degrades cyto- and genotoxic components, such as excessive ROS pro-
ducing mitochondria, and is therefore considered a tumour suppressor mechanism. 
Several studies have demonstrated that defects in autophagy, due to deletions or muta-
tions of proteins of the core autophagy machinery such as BECLIN1, can contribute to 
oncogenic transformation or at least neoplastic growth (18) (19,20). The ATG12-ATG5 
complex acts as an E3-like ubiquitin ligase and functions in lipidation of LC3/GABARAP 
family proteins and is required for autophagy. In our study we observed that expression 
of the autophagy associated protein ATG12 is lost in ~40% of tumours in a cohort of 
head and neck cancer patients. Interestingly, patients with tumour with lost ATG12 
expression show improved survival and tumour control, especially in stage 3 and 4.  
Strikingly, patients with ATG12 negative tumours had almost no hypoxic fraction and 
responded betters to therapies. It is common knowledge that autophagy inhibition 
sensitizes cells to internal and external stresses like hypoxia and nutrient deprivation, 
stressors which are common in the tumour micro environment. Therefore we hypothe-
sized that defective autophagy (due to loss of ATG12 expression) sensitizes tumour cells 
to hypoxia leading to a decrease in tumour hypoxia, and since hypoxia is an important 
factor in therapy outcome, leading to improved therapy outcome. Indeed, in line with 
the observed effects in patients, xenografted ATG12 knockdown tumours do respond 
better to radiotherapy than their controls. However, this effect seems independent of 
the levels of hypoxia in these tumours as hypoxic fractions do not differ between con-
trol and knockdown groups. However, ATG12 deficient xenografts show a dramatically 
increase in tumour necrosis compared to control tumours, suggesting that these cells 
cannot survive in the tumour microenvironment due to stress exposure. Interestingly, 
ATG12 knockdown cells did not show an increased sensitization towards hypoxia alone, 
suggesting that a combination of stressors, such hypoxia and nutrient deprivation, is 
probably lethal. These combinations were not tested in the current study. The high 
fraction of ATG12 negative tumours prompted us to investigate if the loss of ATG12 
expressing contributes to the oncogenic transformation of healthy cells. To test this we 
developed a model to specifically knockout ATG12 in the head and neck region and 
follow up tumour formation over time. This model was adapted from a previously de-
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be caused by cell intrinsic changes caused by GABARAPL1 knock down, such as de-
creased membrane expression of certain receptors, we expect to identify GFP express-
ing metastases only. If the decrease in metastases was caused by a defect in tumour 
derived secreted factors, such as EVs, we expected to identify control and GABARAPL1 
deficient metastases in comparable numbers In the lungs we observed control cell-
derived metastases as well as GABARAPL1 knockdown derived metastases, which sup-
ports the hypothesis of a GABARAPL1 mediated pre-metastatic niche formation. Inter-
estingly, RFP expressing GABARAPL1 knockdown cells were always accompanied by GFP 
expressing control cells, which also could suggest a metastatic niche formation by the 
control cells, rather than a pre-metastatic niche. Taken together we can conclude that 
GABARAPL1 is important for metastasis formation, and that this is potentially mediated 
through GABARAPL1+EV. 
Epidermal growth factor receptor (EGFR) is a member of ErbB family of receptors 
and is expressed in normal tissues where it is involved in processes as proliferation and 
inhibition of apoptosis (11). Mutation or over expression of the receptor can lead to 
several pathologies such Alzheimer and cancer. EGFRvIII is a mutated form of EGFR 
characterized by a deletion of exon 2- 7 of the extracellular domain and is most preva-
lent in glioblastoma multiforme patients (GBM) who have a very poor prognosis (12,13). 
As a consequence of deletion of the extracellular domain the receptor is constitutively 
active, promoting pro-oncogenic effects and tumourigenicity (14,15).We demonstrated 
that EGFRvIII expressing tumours display increased activation and dependency on au-
tophagy during metabolic stress including hypoxia. Typically EGFRvIII+ tumours show an 
increased tolerance towards hypoxia resulting in an increased hypoxic fraction. Addi-
tionally, EGFRvIII+ tumours show increased growth and increased regrowth rates after 
radiotherapy, resulting in decreased treatment outcome. Tumour hypoxia is a major 
limiting factor in cancer treatment (16). Therefore, targeting hypoxia in these tumours 
may contribute to increased survival rates. We demonstrate that EGFRvIII+ cells are 
more dependent on autophagy during hypoxia than non-EGFRvIII expressing tumours. 
Pharmacological inhibition of autophagy with the lysosomotropic drug chloroquine 
sensitizes EGFRvIII+ cells to hypoxia and nutrient deprivation. As we have shown before, 
reducing the hypoxic fraction by targeting autophagy with chloroquine treatment sensi-
tizes xenografts to radiotherapy (17). This effect is more pronounced in EGFRvIII+ ex-
pressing tumours. In a retrospective study we showed that patients with EGFRvIII+ GBM 
benefit most from concurrent chloroquine treatment. These results suggest that EG-
FRvIII+ oncogene addiction in glioblastoma is a therapeutic vulnerability to chloroquine 
and could be a biomarker for patient stratification in clinical studies. 
Strikingly, EGFRvIII+ cells consume more glucose suggesting that autophagy supports 
metabolic processes in EGFRvIII+ cells. The effects of autophagy inhibition on EGFRvIII 
positive cells, such as decreased hypoxia tolerance, can be rescued by pyruvate but not 
by glucose supplementation in the cell culture medium. This suggests that the glycolysis 
is already used to its fullest extent, and that autophagy is required as an additional en-
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ergy source for these tumours. These data are in agreement with previous studies, 
showing that other mutations in the RAS/RAF/MEK/ERK pathway, such the BRAFV600E 
mutation (1), but also HRASG12V or KRASG12V transformed cells show an increased de-
pendency on autophagy (2). 
Taken together, this study indicates that EGFRvIII+ have an increased metabolism 
and are more dependent on autophagy for their survival than EGFRvIII negative cells 
during metabolic stress. Remarkable results have been observed of EGFRvIII+ GBM pa-
tients treated concurrently with chloroquine and Radio- and chemotherapy (1). Current-
ly 2 clinical trials (clinicaltrials.gov identifier NCT02378532 and NCT02432417) are initi-
ated to evaluate toxicity of chloroquine in combination with radiotherapy and temozo-
lamide, a chemotherapeutic commonly used for the treatment of GBM.  
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ducing mitochondria, and is therefore considered a tumour suppressor mechanism. 
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head and neck cancer patients. Interestingly, patients with tumour with lost ATG12 
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stressors which are common in the tumour micro environment. Therefore we hypothe-
sized that defective autophagy (due to loss of ATG12 expression) sensitizes tumour cells 
to hypoxia leading to a decrease in tumour hypoxia, and since hypoxia is an important 
factor in therapy outcome, leading to improved therapy outcome. Indeed, in line with 
the observed effects in patients, xenografted ATG12 knockdown tumours do respond 
better to radiotherapy than their controls. However, this effect seems independent of 
the levels of hypoxia in these tumours as hypoxic fractions do not differ between con-
trol and knockdown groups. However, ATG12 deficient xenografts show a dramatically 
increase in tumour necrosis compared to control tumours, suggesting that these cells 
cannot survive in the tumour microenvironment due to stress exposure. Interestingly, 
ATG12 knockdown cells did not show an increased sensitization towards hypoxia alone, 
suggesting that a combination of stressors, such hypoxia and nutrient deprivation, is 
probably lethal. These combinations were not tested in the current study. The high 
fraction of ATG12 negative tumours prompted us to investigate if the loss of ATG12 
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scribed study were 75% of mice with SMAD4-/- in the head and neck had developed 
tumours in the oral cavity after 80 weeks (21). Therefore, SMAD4-/- was taken as a posi-
tive control. In contrast to the original study, we did not observe excessive tumour 
growth in the head and neck area in any group, although we found an increase in 
anomalies in the ATG12-/- group compared to controls characterized by larger thymus, 
salivary glands and tongue. Although these observations still need to be confirmed by 
pathological examination, these findings support the hypothesis that loss of ATG12 
expression contributes to malignant transformation. Furthermore, ATG12 negative 
tumours are sensitized to stresses in the tumour microenvironment, probably due to 
defects in autophagy, what contributes to improved therapy outcome. Taken together, 
these findings imply the use of ATG12 as a biomarker to predict tumour hypoxia and 
treatment outcome. Tumour hypoxia is an important factor in treatment outcome, and 
is therefore important to determine. Currently, tumour hypoxia is not integrated in 
therapy treatments due to the lack of reliable detection methods.  
Other endogenous markers of hypoxia, such as HIF and its downstream targets 
GLUT-1 and CA9 are dependent on hypoxia for their expression and do not always re-
flect the spatio-temporal dynamics of hypoxia and are therefore not suitable for clinical 
applications (22,23). In contrast to endogenous markers which aim for determining 
levels of hypoxia, ATG12 expressions seems to predict if a tumour is hypoxic, infor-
mation which is relevant for treatment strategy. 
Understanding mechanisms at play that allow tumour cells to survive hypoxia and 
adapt to the harsh environment is likely to result in future intervention possibilities. In 
this thesis we have addressed the complexity and versatile role of autophagy and au-
tophagy-related proteins in tumorigenesis and tumour progression that based on our 
results may lead to novel prognostic tests and future treatment opportunities.  
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Kanker is een van de belangrijkste doodsoorzaken in de westerse samenleving. Kanker 
ontstaat door de accumulatie van mutaties in het DNA. De belangrijkste oorzaak van 
deze mutaties is blootstelling aan schadelijke stoffen van buitenaf, maar kunnen ook 
worden doorgegeven door overerving. Wanneer een cel genoeg mutaties heeft verwor-
ven in essentiële genen kunnen deze cellen niet meer reageren zoals het hoort en kan 
dit leiden tot ongecontroleerde celgroei waardoor een tumor ontstaat.  
De groei van bloedvaten in een tumor draagt in belangrijke mate bij aan de ontwikkeling 
en groei van een tumor. Echter de vaatgroei in een tumor is in tegenstelling tot het vas-
culair systeem in gezond weefsel minder gestructureerd en meer chaotisch van aard. 
Mede hierdoor, en ook door de snelle groei van tumoren, komen er in een tumor ge-
bieden voor die niet goed kunnen worden voorzien van zuurstof. Dit fenomeen heet 
hypoxie. Deze hypoxische gebieden zijn nadelig voor de prognose van een patiënt omdat 
deze gebieden in de tumor resistenter zijn tegen de meeste therapieën en dragen ze bij 
aan uitzaaiingen (metastasen). Omdat hypoxie elders in het lichaam niet voorkomt, lig-
gen er ook kansen voor therapieën die specifiek zijn gericht op deze gebieden. Het werk 
in dit proefschrift beschrijft nieuwe bevindingen over hoe cellen zich gedragen tijdens 
hypoxie. Een van de mechanismen die cellen gebruiken om het gebrek aan zuurstof te 
overleven is autofagie. Autofagie is afgeleid uit het Grieks, en betekent zichzelf (auto) 
eten (fagie). Tijdens autofagie worden organellen en eiwitten afgebroken tot de es-
sentiële bouwstenen zoals aminozuren, vetzuren en koolhydraten, waarna deze weer 
gebruikt kunnen worden voor de biogenese van onder andere nieuwe eiwitten die nodig 
zijn om de homeostase in de cel te bewaren. Autofagie is ook tijdens normale omstan-
digheden actief in de cel, maar wordt extra geactiveerd tijdens stress. Tijdens autofagie 
wordt het af te breken substraat ingepakt in een membraneus blaasje, het auto-
fagosoom. Deze autofagosomen fuseren met lysosomen die de enzymen bevatten om de 
inhoud af te breken tot de biologische bouwstenen. Het af te breken substraat wordt 
herkend door zogenaamde adaptereiwitten die het substraat koppelen aan het auto-
fagosoom via eiwitten van de LC3/GABARAP familie, die direct in het membraan van 
onder andere autofagosomen zijn verankerd. Tot nu toe zijn er zeven eiwitten van de 
LC3/GABARAP familie beschreven: LC3A (2 splicingvarianten), LC3B, LC3C, GABARAP, 
GABARAPL1 en GABARAPL2. Deze eiwitten van de LC3/GABARAP familie delen een hoge 
maten van homologie, echter zijn ze allen uniek in hun functie. Een uitgebreid litera-
tuuronderzoek is beschreven in hoofdstuk 2 waar specifiek wordt ingaan op de individu-
ele functies van elk van de eiwitten uit deze familie. Naast overeenkomsten, hebben LC3/ 
GABARAP eiwitten unieke autofagie afhankelijke en onafhankelijke functies. Zo is de 
GABARAP familie onder meer betrokken bij het transport van receptoren van en naar het 
plasmamembraan. Zo hebben wij aangetoond dat hypoxie specifiek de expressie van 
GABARAPL1, en geen andere eiwitten uit de LC3/GABARAP familie, induceert. Tijdens 
deze condities is GABARAPL1 nodig voor het tot expressie brengen van epidermale groei-
factor receptor (EGFR) op het plasmamembraan (hoofdstuk 3). De toegenomen expressie 
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van GABARAPL1 tijdens hypoxie wordt gereguleerd door de PERK-arm van de Unfolded 
protein response (UPR), een stressgereguleerde pathway die verkeerd- en ongevouwen 
eiwitten detecteert in het endoplasmatisch reticulum (ER) en daar op reageert.  
Tumorhypoxie is een onafhankelijke prognostische indicator (marker) ongeacht de 
toegepaste therapie. Omdat GABARAPL1 verhoogd tot expressie komt tijdens hypoxie 
hebben we onderzocht of GABARAPL1 mRNA expressie gelinkt kan worden aan uit-
komst van therapie. In een panel hoofd- halskankerpatiënten hebben we een correlatie 
aangetoond tussen GABARAPL1 expressie en verminderde tumorcontrole. Dit houdt in 
dat GABARAPL1 gebruikt zou kunnen worden als een biomarker om de uitkomst van 
therapie te voorspellen.  
Epidermale groei factor receptor (EGFR) is een lid van de ErbB receptorfamilie en komt 
tot expressie in normale weefsels waar het is betrokken bij proliferatie en inhibitie van 
apoptose. Mutaties of overexpressie van deze receptor kunnen leiden tot verschillende 
aandoeningen zoals Alzheimer en kanker. EGFRvIII is een gemuteerde vorm van EGFR 
waarbij exon 2-7 zijn gedeleteerd en komt veelvuldig voor in glioblastoma multiforme 
(GBM). Doorgaans hebben GBM patiënten een zeer slechte prognose. Doordat het 
extracellulaire deel van de EGFR receptor is gedeleteerd, is de receptor constant actief 
waardoor groeisignalen continu worden doorgegeven, dat de groei van tumorcellen 
bevordert. EGFRvIII+ cellen zijn doorgaans resistenter tegen hypoxie, wat resulteert in 
een grotere hypoxische fractie in een tumor. Verder groeien EGFRvIII+ tumoren door-
gaans sneller en vindt er snellere hergroei van de tumor plaats na bestraling.  
We hebben aangetoond dat tumoren met de EGFRvIII mutatie meer autofagie heb-
ben en hiervan ook meer afhankelijk zijn voor hun overleving (hoofdstuk 4). Omdat 
hypoxie bijdraagt een verminderde prognose, hebben we geprobeerd de hypoxische 
fractie van een tumor te verlagen door autofagie te remmen met de drug chloroquine. 
Chloroquine remt autofagie waardoor cellen gevoeliger worden voor stress zoals nutri-
entstarvatie en hypoxie. Verder hebben we aangetoond in muismodellen dat tumoren 
beter reageren op bestraling wanneer autofagie wordt geremd. Dit komt waarschijnlijk 
door het verlagen van de hypoxische fractie. Dit effect is het sterkst bij EGFRvIII+ tumo-
ren. In een retrospectieve studie hebben we aangetoond dat GBM patiënten die gelijk-
tijdig behandeld zijn met chloroquine meer voordeel halen uit de behandeling dan pati-
enten met EGFRvIII negatieve tumoren.  
Autofagie breekt cytotoxische componenten af, zoals reactieve zuurstofverbinding-
producerende (reactive oxigen species (ROS)) mitochondriën, en wordt daarom be-
schouwd als een tumorsupressormechanisme. Verschillende studies hebben aange-
toond dat autofagie-defecten, door bijvoorbeeld mutaties of deleties van eiwitten in de 
autofagiemachinerie zoals BECLIN1, bijdragen aan oncogene transformatie van cellen of 
minsten neoplastische groei. ATG12 is een essentieel eiwitten van de autofagie machi-
nerie en is betrokken bij de lipidatie van de LC3/GABARAP familie. Wij hebben aange-
toond dat ATG12 expressie is verloren in ongeveer 40% van de tumoren in een cohort 
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van GABARAPL1 tijdens hypoxie wordt gereguleerd door de PERK-arm van de Unfolded 
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producerende (reactive oxigen species (ROS)) mitochondriën, en wordt daarom be-
schouwd als een tumorsupressormechanisme. Verschillende studies hebben aange-
toond dat autofagie-defecten, door bijvoorbeeld mutaties of deleties van eiwitten in de 
autofagiemachinerie zoals BECLIN1, bijdragen aan oncogene transformatie van cellen of 
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toond dat ATG12 expressie is verloren in ongeveer 40% van de tumoren in een cohort 
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van 428 hoofd-halskanker patiënten (hoofdstuk 5). Uit een ander cohort waarvan de 
hypoxieachtergrond bekend is, bleek dat ATG12 negatieve tumoren een sterk verlaagde 
hypoxische fractie hebben. Patiënten met een ATG12 negatieve tumor hebben daar-
door een hogere kans op locale tumorcontrole en hogere overlevingskans in stadium 3 
en 4 van de ziekte. Opvallend genoeg lijkt deze verlaging van de hypoxische fractie niet 
te zijn veroorzaakt door een defect in autofagie alleen. Doordat ATG12 ook een positie-
ve regulator van apoptose is, gaan ATG12 negatieve cellen waarschijnlijk dood door 
andere mechanismen zoals necrose. Het niet naar behoren functioneren van autofagie 
en ongevoeligheid voor apoptose door het verlies van ATG12, leidt waarschijnlijk tot de 
vermeerderde necrose die we waarnemen in in vivo studies. Ook zou het zo kunnen zijn 
dat juist de combinatie van stressfactoren zoals hypoxie en nutriëntstarvatie zorgen 
voor celdood. Deze combinatie moet nog onderzocht worden. 
Naast de rol in degradatie van cellulaire componenten, lijkt autofagie ook betrokken bij 
vormen van secretie. In Hoofdstuk 6 hebben we uitgebreid literatuuronderzoek gedaan 
naar hoe autofagie-afhankelijke secretie bijdraagt aan tumorprogressie. Steeds meer 
onderzoeken laten zien dat autofagie betrokken is bij de secretie van tumorgroei stimu-
lerende factoren, zoals groeifactoren maar ook immuunmodulerende factoren die bij-
dragen aan het immunosuppressieve karakter van het tumormicromilieu.   
Tot deze factoren behoren ook de extracellulair vesicles (EVs). Dit zijn minuscule 
blaasjes die cellen onder andere gebruiken voor intercellulaire communicatie. Wij heb-
ben aangetoond dat hypoxische cellen een subpopulatie EVs uitscheiden, gekenmerkt 
door GABARAPL1 expressie op het membraan (GABARAPL1+EVs) (hoofdstuk7). Deze EVs 
hebben pro-angiogenetische eigenschappen, dat wil zeggen dat ze de vorming van 
bloedvaten stimuleren dat weer bijdraagt aan tumorgroei. Tevens hebben we aange-
toond dat deze GABARAPL1+EVs zijn te detecteren en verhoogd zijn in het bloed van 
kankerpatiënten. Doordat GABARAPL1 zich aan de buitenkant van deze EVs bevindt en 
in circulatie van de patiënt zijn, kunnen hier mogelijke therapieën op gericht worden. 
We hebben al aangetoond dat de functie van deze GABARAPL1+EVs geblokkeerd kan 
worden door middel van antilichamen die aan deze EVs binden. Momenteel zijn we 
bezig met de ontwikkeling van monoclonale antilichamen om de therapeutische wer-
king te onderzoeken in muismodellen.  
Naast pro-angiogenetische eigenschappen zijn GABARAPL1+EVs mogelijk betrokken 
bij de vorming van metastasen (Hoofdstuk 8). In metastaserende muismodellen zijn we 
in staat om het aantal longmetastasen met 80% te verminderen wanneer GABARAPL1 
wordt uitgeschakeld door middel van een hairpin. Om te bewijzen dat het GABA-
RAPL1+EVs zijn die een rol spelen bij de vorming van deze metastasen is nog verder 
onderzoek nodig. Wel zijn er aanwijzingen dat GABARAPL1+EVs een rol spelen bij de 
vorming van de zogenaamde “pre-metastatic niche”. Dat zijn gebiedjes elders in het 
lichaam die worden voorbereid op circulerende tumorcellen nog voordat deze hier 
kunnen nestelen en uitgroeien tot een metastase.   
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Despite great advanced in cancer research, cancer is one of the leading causes of death 
in western society. In solid tumours, areas deprived of oxygen (hypoxia) arise due to an 
aberrant and immature vasculature. Tumour hypoxia is a common characteristic of solid 
tumours and leads to expansion of tumour cells with a more invasive, metastatic and 
therapy resistant phenotype, and is therefore a major clinical challenge. The work in this 
thesis describes mechanisms that hypoxic cancer cells use to sustain their survival and 
thereby contribute to progression of the disease. Understanding of these mechanisms is 
important so that hypoxia can be detected and therapies can be directed to target 
these more resistant cells and improve treatment outcome. As a result of innovative 
research in the industry and academia, cancer survival rates have increased dramatically 
over the last decades and have a positive societal impact. 
Clinical relevance  
Tumour hypoxia is clinically important as hypoxic tumours show resistance to most 
cancer therapies and are therefore associated with decreased patient survival. Typically 
hypoxia reduces the effectiveness of radiotherapy. Depressed oxygen levels in tissue 
lead to a decrease of long-lived reactive oxygen radicals after X- or γ-irradiation that are 
required for fixed DNA damage of the tumour cell. Consequently, hypoxic cells are three 
times more resistant to irradiation than well oxygenized cells. Additionally, hypoxic cells 
are resistant to chemotherapeutic drugs. Typically, chemotherapeutic drugs target 
rapidly dividing cells. Hypoxia reduces cell proliferation and thereby limits the effects of 
chemotherapeutic agents.  Also the decreased drug delivery due to the aberrant vascu-
lature in the tumour contributes to resistance of chemotherapeutics due to delivery 
limitations. Also the propagation of metastasis and reduced the effectiveness of surgery 
are linked to hypoxia. Tumour metastasis is associated with high patient mortality and is 
responsible for more than 90% of cancer-related deaths.  
Taken together, hypoxia is one of the strongest contributors to patient’s poor 
treatment outcome. Therefore it is highly desired to develop methods to determine 
hypoxia in a tumour. Such a method can be used as a marker for treatment response 
but is also required to stratify patients for the right therapy plan and for the develop-
ment of therapies targeting hypoxia.  
Hypoxia cannot be determined anatomically, as hypoxia is independent of tumour 
size, grade and stage. Currently, there are no markers for tumour hypoxia used in the 
clinic for diagnostic or treatment purposes. Invasive polarographic electrodes are the 
‘gold standard’ for assessing tumour hypoxia.  However due to the heterogeneous and 
dynamic properties of hypoxia, multiple samples must been taken in the diseased tis-
sue, and are due to the high burden for the patient never used. Determining hypoxia by 
imaging markers, such as HX4 scanning or others have not shown adequate specificity 
or do not correlate with hypoxia at all. Other described methods are the use of deter-
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mining osteopontin in patient fluids. However due the low elevation of this marker in 
hypoxic tumours compared to healthy subjects, this method is of limited use when 
applied to a single patient. Taken together, methods to determine hypoxia in a tumour 
are limited and are not implemented in current treatment plans, but also to stratify 
patients for hypoxia-targeted therapies hypoxia markers are highly desired.  
Improvement for healthcare 
The work described in this thesis can be exploited to modify tumour hypoxia to 
improve therapy outcome, but also to develop targeted therapies and 
prognostic biomarkers.  
In chapter 5, findings are described that ATG12 could serve as a predictor for tumour 
hypoxia and a tumour control in head and neck cancer patients. We found that in 25-
40% of patients with head and neck cancer, tumours lack ATG12 expression. The loss of 
ATG12 expression correlates with a decreased hypoxic fraction in the tumour.  Striking-
ly, patients with ATG12 ‘negative’ tumours show improved local and loco-regional con-
trol. Therefore, ATG12 expression can be used as a hypoxia predictor and be imple-
mented in pathohistological analysis after biopsies. Such a marker can contribute to 
stratify patients for clinical trials investigating hypoxia targeted therapies. I.e. ATG12 
negative tumours are expected to be less sensitive to these therapies and should there-
fore be excluded from these trials. Because ATG12 expression is lost in a substantial 
group of head and neck cancer patients, institutes investigating the effectiveness of 
hypoxia targeting therapies in clinical trials should be aware of this phenomenon before 
including patients in their trials.  To investigate the effectiveness of hypoxia targeted 
therapies, stratification of patients with hypoxic tumours is required. The finding that 
ATG12 negative tumours have almost no hypoxic fraction could contribute to improved 
outcome of these trials.  
In chapter 7 we describe our findings that hypoxic cells secrete a subset of extracel-
lular vesicles that is marked by GABARAPL1 expression on their surface. This finding 
provides means for both diagnostic and therapeutic applications and marketable prod-
ucts: Since GABARAPL1+EVs are released by hypoxic cells and are detectable in circula-
tion of patients, GABARAPL1+EVs can be used as a hypoxia marker. We already showed 
that GABARAPL1+EVs are detectable and elevated in the blood of a small group (n=10) 
of colorectal, glioblastoma and small cell lung cancer patients. Currently our group is 
investigating if the number of circulating GABARAPL1+EVs correlate with the degree of 
hypoxia in a tumour to evaluate if we can determine the amount hypoxia. Enzyme-
linked immunosorbent assays (ELISA) are suitable assays to determine macromolecular 
species in fluids and are frequently used as a diagnostic tool. Currently our group is 
developing ELISA assays to detect GABARAPL1+EVs in the blood of cancer patients. Such 
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a GABARAPL1+EV ELISA can be translated in a marketable product and could be exploit-
ed as such.  A GABARAPL1+EV ELISA could provide information about the degree of 
hypoxia in a ‘bench test’ which is more desirable than invasive detection or expensive 
scanning methods which also require specialized personnel. Currently hypoxia activated 
pro-drugs (HAPs) are in development to specifically target hypoxic cells in a tumour. 
Tools to determine if a tumour is hypoxic are highly desired for patient stratification for 
these clinical trials.  
The finding that GABARAPL1 is expressed on EVs also has therapeutic applications. 
Since GABARAPL1 is expressed on the surface of hypoxic EVs, it is accessible for target-
ing, for instance with antibodies. We already showed in chapter 8 that inhibition of 
GABARAPL1 with hairpin RNA’s decreased metastasis formation by 80% in a metastatic 
breast cancer model in mice. Additionally, targeting GABARAPL1 resulted in decreased 
angiogenesis, tumour growth and tumour regrowth after irradiation and importantly, 
GABARAPL1+EVs are detectable and elevated in the circulation of cancer patients com-
pared to healthy controls (chapter 7).  
Therefore, we hypothesize that targeting GABARAPL1+EVs in the patient’s circulation 
by GABARAPL1 targeting antibodies can reduce the formation of metastasis, but also 
might affect growth of the primary tumour; two important goals to achieve in patients. 
In chapter 7 we showed in a proof of concept experiment that we are able to block 
GABARAPL1+EV with antibodies targeting GABARAPL1 in vitro and thereby inhibiting  
their pro-angiogenic properties. Extrapolated to patients, this could include that this 
approach might prevent the formation of a pre-metastatic niche, and thereby prevent 
the development of metastasis.  
These in vitro experiments were done with commercially available polyclonal anti-
bodies. For therapeutic applications, typically monoclonal antibodies are used. Most 
used antibody subtypes are IgG1, 2 or 4, due to their long half-life in circulation (up to 
21 days).  We already have developed GABARAPL1 targeting monoclonal antibodies to 
further explore and validate this approach in in vitro and in vivo studies. 
Since the use of the first monoclonal antibody in 1986, the market for these bio-
pharmaceutical drugs has grown significantly. At present, 47 antibodies have been ap-
proved in the US or Europe. Annually, 4 new antibodies achieve marked approval, lead-
ing to an estimated world-wide sale of nearly $125 billion in 2020 [1]. However, current-
ly there are no therapeutics on the marked or clinical trials investigating drugs targeting 
endogenous extracellular vesicles. In that perspective, this method could lead to the 
development of a novel and innovative anti-cancer therapy. The method to target EVs, 
and more specifically GABARAPL1+EVs, to prevent the formation of metastasis is de-
scribed in a patent in Europe and the US (Keulers & Rouschop, patent number 
WO2015121295A1). To further develop this approach and translate this into a possible 
treatment we are looking for research partners to support further (co-)-development 
and clinical proof of concept treatment. Such collaboration could lead to a university 
spin-off company to explore its clinical feasibility and efficacy. 
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GABARAPL1+EV targeting antibodies could be applied as a neoadjuvant therapy on 
patients with solid, and thus hypoxic, tumours. It needs to be empirically determined if 
GABARAPL1+EVs indeed are secreted by most solid tumours, but it is expected that 
most tumours release GABARAPL1+EVs. Most cancer related deaths are attributed the 
metastatic disease. Typically, distant metastases are frequently unresponsive to existing 
therapies and are treated systemically with palliative intent. Preventing the formation 
of metastasis could improve the life expectancy of many patients.  
Tumour hypoxia contributes to poor treatment outcome in several cancer types. 
Therefore, reducing the hypoxic fraction in a tumour is highly desired. Attempts to 
modulate the hypoxic fraction were primarily focussed on increasing oxygen supply to 
the tumour. A different approach is alleviating hypoxia by targeting cellular mechanisms 
that use cells for their survival, such as autophagy.  
Chloroquine is originally marketed as an anti-malaria drug, but is also used in the 
treatment of rheumatoid arthritis and lupus-associated arthritis. In addition to these 
properties, chloroquine is a potent autophagy inhibitor. Previously we showed that 
chloroquine sensitizes cells to hypoxia, reduces the hypoxic fraction and sensitizes xen-
ograft tumours to radiotherapy in mice [2]. 
In chapter 4 we show that EGFRvIII expression elevates the activation of autophagy 
during hypoxia. The mutant form of EGFR, EGFRvIII is frequently observed in glioblas-
toma (50-60% of patients with EGFR amplification) and is associated with increased 
therapy resistance and poor prognosis. A retrospective study indicated that patients 
with EGFRvIII positive tumours benefit most of concurrent chloroquine treatment (me-
dian survival form 3 to 15 months).  
Currently, a phase I clinical trial is ongoing in our institute (clinical trial 
NCT02378532) to determine the maximum tolerated dose of chloroquine with concur-
rent radiotherapy and temozolomid. So far, this trial shows promising results. To de-
termine if chloroquine can be repurposed as a drug in oncology and considered as an 
additional treatment for GBM patients, additional clinical trials are required to investi-
gate efficacy, effectiveness and safety.  
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and clinical proof of concept treatment. Such collaboration could lead to a university 
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GABARAPL1+EV targeting antibodies could be applied as a neoadjuvant therapy on 
patients with solid, and thus hypoxic, tumours. It needs to be empirically determined if 
GABARAPL1+EVs indeed are secreted by most solid tumours, but it is expected that 
most tumours release GABARAPL1+EVs. Most cancer related deaths are attributed the 
metastatic disease. Typically, distant metastases are frequently unresponsive to existing 
therapies and are treated systemically with palliative intent. Preventing the formation 
of metastasis could improve the life expectancy of many patients.  
Tumour hypoxia contributes to poor treatment outcome in several cancer types. 
Therefore, reducing the hypoxic fraction in a tumour is highly desired. Attempts to 
modulate the hypoxic fraction were primarily focussed on increasing oxygen supply to 
the tumour. A different approach is alleviating hypoxia by targeting cellular mechanisms 
that use cells for their survival, such as autophagy.  
Chloroquine is originally marketed as an anti-malaria drug, but is also used in the 
treatment of rheumatoid arthritis and lupus-associated arthritis. In addition to these 
properties, chloroquine is a potent autophagy inhibitor. Previously we showed that 
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ograft tumours to radiotherapy in mice [2]. 
In chapter 4 we show that EGFRvIII expression elevates the activation of autophagy 
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Currently, a phase I clinical trial is ongoing in our institute (clinical trial 
NCT02378532) to determine the maximum tolerated dose of chloroquine with concur-
rent radiotherapy and temozolomid. So far, this trial shows promising results. To de-
termine if chloroquine can be repurposed as a drug in oncology and considered as an 
additional treatment for GBM patients, additional clinical trials are required to investi-
gate efficacy, effectiveness and safety.  
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Leuk, zo’n baantje van 4 maanden! Even tijdens je master wat extra ervaring opdoen in 
het lab! In het lab bleek het echter veel leuker dan in de collegebanken, dus het was al 
snel duidelijk dat het niet bij die 4 maanden zou blijven. Een paar jaar als analist volg-
den, doorgestroomd naar promovendus, en nu ligt hier het resultaat! Dat doe je natuur-
lijk niet alleen, zo’n proefschrift. Er hebben door de jaren heen heel wat mensen, direct 
of indirect, aan bijgedragen die ik graag wil bedanken.  
Kasper, al heel wat jaren werken we nu samen. En dit is eindelijk eens een moment om 
je te bedanken voor alles wat je de afgelopen jaren voor me hebt gedaan. Ik wil je be-
danken voor het vertrouwen dat je van begin af aan in mij hebt gehad. Het heeft enorm 
bijgedragen aan wie ik nu ben en hoe ik onderzoek doe. Ik heb veel respect voor jou als 
persoon en als wetenschapper (ook al lijkt dat niet altijd zo ;)). Je vernieuwende ideeën 
en je eeuwige optimisme zijn altijd een inspiratie voor me. Je deur staat letterlijk altijd 
voor me open, wat vaak resulteert in lange brainstormsessies over waarom we in gods-
naam aan dat eiwit zijn gaan werken en hoe we de volgende experimenten gaan doen. 
Kasper, dankjewel!  
Kim, je was mijn steun en toeverlaat vanaf mijn eerste stage, lang geleden. Met jou in 
de buurt, wist ik dat het altijd allemaal wel goed kwam. Ik wil je bedanken voor je colle-
gialiteit, je kennis, je jaarlijkse carnavalsvibe en alle hulp die je hebt gegeven aan onze 
projecten, maar ook voor het in goede banen leiden van alles op en rondom het lab. 
Met jou in de buurt is het altijd een gezellige boel! 
Jan, bij jou is het allemaal begonnen. Ik weet nog goed dat ik bij een presentatie tijdens 
mijn studie direct was geboeid door je werk aan bacteriën die therapieën naar de tumor 
brengen. Een zeer interessante stage in je groep volgde, met als mededeling dat ik altijd 
terug mocht komen. Zo geschiedde. Jan, je bent altijd een inspirator voor me geweest. 
Als jij praat, luister ik. 
Marc, bedankt voor al je input en de leuke gesprekken naast het werk over fietsen, 
fietstochten, gitaren, muziek en sterke kraakverhalen! De verse koffie heeft me elke 
ochtend weer op de been geholpen!  
Graag wil ik de beoordelingscommissie, Frans Ramaekers, Esther Nolte-’t Hoen, Ray-
mond Schiffelers, Patrick Schrauwen en Lotte Wieten bedanken voor de tijd die jullie 
hebben genomen om mijn proefschrift te beoordelen! 
Marike, met jou als mijn roomie was het altijd gezellig en had ik altijd een opgeruimd 
bureau! Soms weet ik nog steeds niet of jij nou langs bent geweest of dat het toch de 
poetsvrouw was. Bedankt voor je collegialiteit, je vriendelijkheid en al die ommetjes 
naar de koffieautomaat!  
En dan is er Marijke, bekend om haar slechte muzieksmaak, maar voornamelijk om 
haar goede vragen op het goede moment. Een gewaardeerd lid van onze autofagieclub 
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en meer dan een collega alleen. Altijd in voor een feestje! Bedankt voor alle gezelligheid 
op het lab en daarbuiten!  
Ik wens jullie beiden heel veel succes! 
Hanneke, inmiddels onze club verlaten, maar de bijdrage die je hebt geleverd aan onze 
projecten zal ik niet vergeten! Honderden westernblotjes en heel wat uurtjes hebben 
we samen tumoren zitten meten in DM2. Bedankt voor je inzet! Barry, je was altijd een 
van de steunpilaren van het lab. Ik kon altijd bij je terecht met vragen en je was altijd 
bereid te helpen en mee te denken. Op de een of andere manier resulteerde het wel 
altijd in schunnige praat! Zelfs het Duits werd hierbij niet geschuwd! Bedankt voor alles 
Barry! Heel veel succes in de toekomst!  
En van schunnige praat is het een kleine stap naar Roger en Marco Uit het oog, maar 
niet uit het hart! Met jullie in de buurt was het altijd tijd voor ongein, op het lab, maar 
ook daarbuiten! Ik wens jullie veel succes met jullie carrière!  
Dan zijn er nog de PhD roomies, Damiënne & Alexander, Michael, Lorena, Judith, Jona-
than, Veronica, Eloy, Raymon en Venus. Een kantoor waar menig soapschrijver zijn hart 
aan op kan halen! Bedankt voor de leuke tijd, de ritjes naar de koffie de gezellige avon-
den en soms lange nachten! De tijd is gekomen dat jullie op zoek moeten naar een 
nieuw stamhoofd. Veel succes met het afronden van jullie PhDs! 
Nicolle, met jouw in de buurt was er altijd iets te beleven! De soepjes en de mid-
dagwandelingetjes waren altijd een fijn moment om even af te schakelen! Je wordt 
gemist! Arjan, Dr. Groß!, bedankt voor al je verhalen, je enthousiasme en je ideeën! 
Analisten zijn de ruggengraat van een lab! Bedankt Natasja, Rianne, Jolanda en Lydie, 
voor jullie inzet, hulp bij in vivo studies en het draaiend houden van het lab. Rianne, het 
recept van mijn geheime cocktail heb je nog tegoed ;)! Ook Nicole Bitsch bedankt voor 
alle hulp bij de in vivo experimenten! Ook Carla, die het toch maar altijd even regelt op 
de achtergrond, bedankt voor alles! 
Ook Ludwig, Ala en alle andere collega’s bij Maastro lab, bedankt voor jullie collegia-
liteit en input wanneer dat nodig was!  
Veel van dit werk was niet mogelijk geweest zonder de expertise in Utrecht! Marca, 
bedankt voor de fijne samenwerking en de introductie in de wereld van de EVs! Met 
Sten zijn er heel wat uurtjes, wat zeg ik, dagen, doorgebracht in het labje bij de Influx, 
maar het heeft heel wat mooie data en verhalen opgeleverd! Dank je Sten, en veel 
succes met je postdoc in Cambridge! 
Als we het over fijne samenwerkingen hebben, kom je al snel uit in Nijmegen waar ze 
het analyseren van tumoren tot in de fijnste puntjes beheersen, bedankt Paul Span, 
Johan Bussink en Hans Peters voor alle analyses en al het werk wat jullie voor ons ge-
daan hebben!  
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Als je hulp nodig hebt met welke vorm van microscopie dan ook, moet je bij Hans Dui-
mel, Helma Kuijpers, Marc van Zandvoort, en Carmen López Iglesias zijn! Ze leggen het 
je tot in het kleinste detail uit en zijn altijd bereid te helpen! 
Dan zijn er nog mijn stagestudenten Imke, Laura en Britta die naast hun gezelligheid en 
uitbundige treinritten ook nog een substantiële bijdrage hebben geleverd aan dit on-
derzoek. Succes met jullie PhDs en verdere carrière, ik heb er alle vertrouwen in! 
Veerle Melotte en Alexander Koch, bedankt voor jullie bijdrage aan het hoofdstuk over 
ATG12! 
Er moet ook genoeg afleiding zijn! Met mijn maatjes Roel-Germ, Ronald, Eric, Nils, Se-
bastiaan en Sander in de buurt is dat nooit een probleem! Bedankt voor alle lol, maffe 
avonden, alle biertjes en jullie vriendschap!   
Mijn lieve ouders, door jullie was mijn interesse in de biologie al vroeg gewekt; plantjes, 
vlindertjes en andere beestjes, alles werd thuis gekweekt en bestudeerd. Op mijn acht-
ste kreeg ik al mijn eigen microscoop en ik was trots op mijn trofeeën-rek vol samen 
uitgekookte dierenskeletjes en gevonden fossielen. Ook al was ik tijdens mijn studieja-
ren soms wat afgeleid, jullie hebben altijd vertrouwen in mij gehad. Zonder jullie grote 
hulp was het bovendien niet gelukt om ons huis te verbouwen en te promoveren tege-
lijk. Bedankt voor jullie onvoorwaardelijke steun en hulp en dat jullie me altijd in alles 
gestimuleerd hebben!  
Kiki en Josh, bedankt voor de gezelligheid, afleiding en alle ongein! Leuk he, broer en 
zus! 
Charles en Gerrie, bedankt voor jullie nimmer aflatende interesse in mijn werk en on-
derzoek, al jullie hulp en steun en vooral de gezellige tijd de afgelopen jaren! 
Lieve Anne, met jou in de buurt is het altijd het leukst! Dank je voor je onvoorwaardelij-
ke steun, je liefde en dat je me altijd weer op de been hielp wanneer het even tegenzat. 
Met ons huisje zo goed als klaar, jij op het punt om te beginnen met je opleiding tot 
huisarts, zie ik de toekomst met vertrouwen tegemoet  
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